Fortress Biotech (FBIO) 10-K 16 Mar 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 15, 2017	Jun. 30, 2016
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Entity Registrant Name	Fortress Biotech, Inc.
Entity Central Index Key	1,429,260
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 78,431,868
Trading Symbol	FBIO
Entity Common Stock, Shares Outstanding		50,319,919

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 88,294	$ 98,182
Accounts receivable	1,830	0
Cash deposits with clearing organizations	1,030	0
Receivables from broker-dealers and clearing organizations	3,357	0
Forgivable loans receivable	1,712	0
Securities owned, at fair value	2,357	0
Inventory	203	0
Other receivables - related party	1,790	156
Prepaid expenses and other current assets	9,061	1,599
Total current assets	109,634	99,937
Property and equipment, net	7,376	309
Restricted cash	15,860	14,586
Long-term investments, at fair value	1,414	2,485
Intangible asset - license	17,408	1,250
Goodwill	18,645	0
Other assets	394	43
Total assets	170,731	118,610
Current liabilities
Accounts payable and accrued expenses	24,295	10,438
Accrued commissions and payroll payable	11,940	0
Deferred clearing and marketing credits	995	0
Securities sold, not yet purchased, at fair value	298	0
Warrants issuable - National	14,359	0
Interest payable	88	27
Interest payable - related party	77	0
Notes payable, short-term	1,000	0
Subsidiary convertible note, short-term, at fair value	1,031	0
Contingently issuable liabilities	1,682	0
Derivative warrant liability	481	114
Other current liabilities	319	0
Total current liabilities	56,565	10,579
Notes payable, long-term (net of debt discount of $2,009 and $835 at December 31, 2016 and December 31, 2015, respectively)	22,528	23,174
Subsidiary convertible note, long-term, at fair value	3,656	0
Other long-term liabilities	5,014	584
Total liabilities	87,763	34,337
Commitments and contingencies
Stockholders' equity
Common Stock, $.001 par value, 100,000,000 shares authorized, 48,932,023 and 47,147,032 shares issued and outstanding as of December 31, 2016 and December 31, 2015, respectively	49	47
Additional paid-in-capital	283,697	246,955
Accumulated deficit	(245,251)	(190,156)
Total stockholders' equity attributed to the Company	38,495	56,846
Non-controlling interests	44,473	27,427
Total stockholders' equity	82,968	84,273
Total liabilities and stockholders' equity	170,731	118,610
Series C Convertible Preferred Stock [Member]
Stockholders' equity
Convertible Preferred stock, $.001 par value, 129,767 Series C shares authorized, 0 shares issued and outstanding as of December 31, 2016 and December 31, 2015, respectively	$ 0	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Debt Discount	$ 2,009	$ 835
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	48,932,023	47,147,032
Common Stock, shares outstanding	48,932,023	47,147,032
Series C Convertible Preferred Stock [Member]
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	129,767	129,767
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenue
Total National revenue	$ 16,480,000	$ 863,000
Net revenue	16,480,000	863,000	$ 0
Operating expenses
Cost of goods sold - product revenue	(790,000)	0
Research and development	(35,134,000)	(29,810,000)
Research and development - licenses acquired	5,532,000	11,408,000	0
General and administrative	(28,229,000)	(18,734,000)
Total operating expenses	82,190,000	51,394,000	20,652,000
Loss from operations	(65,710,000)	(50,531,000)	(20,652,000)
Other income (expenses)
Interest income	298,000	245,000	662,000
Interest expense and financing fee	(3,690,000)	(1,484,000)	(1,338,000)
Change in fair value of derivative liabilities	(1,039,000)	(438,000)	0
Change in fair value of subsidiary convertible note	(78,000)	0	0
Change in fair value of investments	(1,071,000)	(1,675,000)	942,000
Total other expenses	(5,580,000)	(3,352,000)	266,000
Net loss	(71,290,000)	(53,883,000)	(20,386,000)
Less: net loss attributable to non-controlling interests	16,195,000	5,455,000	0
Net loss attributable to common stockholders	$ (55,095,000)	$ (48,428,000)	$ (20,386,000)
Basic and diluted net loss per common share	$ (1.38)	$ (1.24)	$ (0.56)
Weighted average common shares outstanding—basic and diluted	39,962,657	39,146,589	36,323,596
Parent Company [Member]
Revenue
Product revenue, net	$ 3,587,000	$ 273,000	$ 0
Revenue - from a related party	2,570,000	590,000	0
Total National revenue	6,157,000	863,000	0
Operating expenses
Cost of goods sold - product revenue	790,000	0	0
Research and development	29,602,000	18,402,000	10,239,000
Research and development - licenses acquired	5,532,000	11,408,000	0
General and administrative	34,003,000	21,584,000	10,413,000
Total operating expenses	69,927,000	51,394,000	20,652,000
National Holdings Corporation [Member]
Revenue
Commissions	5,388,000	0	0
Net dealer inventory gains	253,000	0	0
Investment banking	2,829,000	0	0
Investment advisory	904,000	0	0
Interest and dividends	155,000	0	0
Transfer fees and clearing services	386,000	0	0
Tax preparation and accounting	338,000	0	0
Other	70,000	0	0
Total National revenue	10,323,000	0	0
Operating expenses
Commissions, compensation and fees	10,414,000	0	0
Clearing fees	144,000	0	0
Communications	177,000	0	0
Occupancy	193,000	0	0
Licenses and registration	147,000	0	0
Professional fees	327,000	0	0
Interest	1,000	0	0
Depreciation and amortization	545,000	0	0
Other administrative expenses	315,000	0	0
Total operating expenses	$ 12,263,000	$ 0	$ 0

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit	Non-Controlling Interests [Member]
Balance at Dec. 31, 2013	$ 81,278	$ 40	$ 202,580	$ (121,342)	$ 0
Balance (in shares) at Dec. 31, 2013		39,652,950
Exercise of stock options	596	$ 0	596	0	0
Exercise of stock options (in shares)		323,412
Issuance of Common Stock related to subscription	3,502	$ 2	3,500	0	0
Issuance of Common Stock related to subscription (in shares)		2,175,000
Stock-based compensation expense	5,546	$ 0	5,546	0	0
Issuance of restricted stock	0	$ 4	(4)	0	0
Issuance of restricted stock (in shares)		4,328,692
Issuance of Common Stock under ESPP	19	$ 0	19	0	0
Issuance of Common Stock under ESPP (in shares)		13,980
Common Stock issuance costs	(32)	$ 0	(32)	0	0
Net loss attributable to non-controlling interest	0
Net loss attributable to common stockholders	(20,386)	0	0	(20,386)	0
Balance at Dec. 31, 2014	70,523	$ 46	212,205	(141,728)	0
Balance (in shares) at Dec. 31, 2014		46,494,034
Exercise of stock options	216	$ 0	216	0	0
Exercise of stock options (in shares)		100,000
Stock-based compensation expense	14,291	$ 0	14,291	0	0
Issuance of restricted stock	0	$ 1	(1)	0	0
Issuance of restricted stock (in shares)		525,000
Subsidiary's offering, net	51,496	$ 0	51,496	0	0
Issuance of subsidiaries' common shares for license expenses	958	0	958
Issuance of Common Stock under ESPP	59	$ 0	59	0	0
Issuance of Common Stock under ESPP (in shares)		27,998
Issuance of warrants in conjunction with NSC debt	613	$ 0	613	0	0
Non-controlling interest in subsidiaries	0	0	(32,882)	0	32,882
Net loss attributable to non-controlling interest	(5,455)	0	0	0	(5,455)
Net loss attributable to common stockholders	(48,428)	0	0	(48,428)	0
Balance at Dec. 31, 2015	84,273	$ 47	246,955	(190,156)	27,427
Balance (in shares) at Dec. 31, 2015		47,147,032
Stock-based compensation expense	12,128	$ 0	12,128	0	0
Issuance of restricted stock	0	$ 2	(2)	0	0
Issuance of restricted stock (in shares)		1,568,408
Cashless exercise of warrants	0	$ 0	0	0	0
Cashless exercise of warrants (in shares)		12,633
Subsidiary's offering, net	36,818	$ 0	36,818	0	0
Issuance of subsidiaries' common shares for license expenses	53	0	53	0	0
Issuance of common stock for at-the-market offering	434	$ 0	434	0	0
Issuance of common stock for at-the-market offering (in shares)		150,556
At-the-market offering cost	(79)	$ 0	(79)	0	0
Issuance of Common Stock under ESPP	189	$ 0	189	0	0
Issuance of Common Stock under ESPP (in shares)		86,727
Cancellation of restricted stock	0	$ 0	0	0	0
Cancellation of restricted stock (in Shares)		(33,333)
Beneficial conversion feature of Opus Credit Facility	2,006	$ 0	2,006	0	0
Issuance of warrants in conjunction with NSC debt	793	0	793	0	0
Non-controlling interest in subsidiaries	0	0	(15,598)	0	15,598
Non-controlling interest in National Holdings Corp	17,643	0	0	0	17,643
Net loss attributable to non-controlling interest	(16,195)	0	0	0	(16,195)
Net loss attributable to common stockholders	(55,095)	0	0	(55,095)	0
Balance at Dec. 31, 2016	$ 82,968	$ 49	$ 283,697	$ (245,251)	$ 44,473
Balance (in shares) at Dec. 31, 2016		48,932,023

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash Flows from Operating Activities:
Net Loss	$ (71,290)	$ (53,883)	$ (20,386)
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization expense	944	26	23
Noncash interest expense	0	167	634
Amortization of debt discount	1,466	314	0
Amortization of product revenue license fee	183	0	0
Amortization of forgivable loans to registered representatives	176	0	0
Amortization of deferred clearing credit	(13)	0	0
Stock-based compensation expense	12,128	14,291	5,546
Recovery for doubtful accounts	(47)	0	0
Deferred tax benefit	(73)	0	0
Issuance of subsidiaries' common shares for license expenses	53	958	0
Common shares issuable for license expenses	1,682	0	0
Financing fees on subsidiaries' Convertible Note, at fair value	1,032	0	0
Change in fair value of investments	1,071	1,675	(942)
Change in fair value of derivative liabilities	1,039	438	0
Change in fair value of subsidiary convertible note	78	0	0
Change in fair value of contingent consideration payable - National	2	0	0
Research and development-licenses acquired, expense	3,785	10,448	0
Asset impairment loss	0	0	722
Increase (decrease) in cash and cash equivalents resulting from changes in operating assets and liabilities:
Accounts receivable	(1,830)	0	0
Receivables from broker-dealers and clearing organizations	(4,048)	0	0
Forgivable loans receivable	(84)	0	0
Securities owned, at fair value	(179)	0	0
Inventory	(203)	0	0
Other receivables - related party	(1,634)	(156)	(15)
Prepaid expenses and other current assets	(204)	(739)	(124)
Restricted cash	(1)	0	0
Other assets	(12)	0	0
Accounts payable and accrued expenses	5,395	5,889	(849)
Securities sold, but not yet purchased, at fair value	298	0	0
Interest payable	61	(1)	(81)
Interest payable - related party	66	0	0
End of term fee associated with Hercules Note	0	0	(398)
Other long-term liabilities	4,346	195	(464)
Net cash used in operating activities	(45,813)	(20,378)	(16,334)
Cash Flows from Investing Activities:
Purchase of marketable securities, at fair value	0	(79,947)	(20,002)
Sale of marketable securities	0	99,949	0
Purchase of short- term investment	0	0	(346)
Purchase of long-term investment	0	0	(2,925)
Purchase of research and development licenses	(3,785)	(10,448)	0
Purchase of property and equipment	(6,370)	(283)	0
Purchase of license	(350)	(1,250)	0
Security deposits paid	(6)	0	0
Security deposits refund	0	22	0
Net cash acquired in acquisition of National Holdings Corp.	4,626	0	0
Investment in Origo Acquisition Corp.	(175)	(158)	0
Net cash (used in) provided by investing activities	(6,060)	7,885	(23,273)
Cash Flows from Financing Activities:
Payment of Hercules Note	0	0	(13,654)
Proceeds from exercise of stock options	0	216	596
Proceeds from issuance of common stock under ESPP	189	59	19
Proceeds from issuance of common stock	0	0	3,502
Payment of costs related to the issuance of common stock	0	0	(32)
Proceeds from subsidiary's offering	39,662	57,817	0
Payment of costs related to subsidiary's offering	(2,844)	(6,321)	0
Proceeds from at-the-market offering	434	0	0
Payment of cost related to at-the-market offering	(79)	0	0
Payment of NSC note	(6,392)	0	0
Proceeds from NSC note	0	10,000	0
Payment of debt issuance costs associated with NSC Note	0	(855)	0
Proceeds from IDB note	920	0	14,009
Payments of Debt Issuance Costs	0	0	(9)
Proceeds from Opus Credit Facility	7,000	0	0
Transfer of restricted cash	(920)	0	(14,586)
Net cash provided by financing activities	41,985	60,916	(10,155)
Net (decrease) increase in cash and cash equivalents	(9,888)	48,423	(49,762)
Cash and cash equivalents at beginning of period	98,182	49,759	99,521
Cash and cash equivalents at end of period	88,294	98,182	49,759
Supplemental disclosure of cash flow information:
Cash paid for interest	349	80	785
Supplemental disclosure of non-cash financing and investing activities:
Issuance of restricted stock	2	1	4
Issuance of warrant liabilities in conjunction with NSC debt	634	114	0
Beneficial conversion feature related to Opus Credit Facility	2,006	0	0
Acquisition of National Holdings Corp.
Goodwill	(18,645)	0	0
Accounts receivable	(4,889)	0	0
Cash deposits with clearing organizations	(1,030)	0	0
Receivables from broker-dealers and clearing organizations	(1,607)	0	0
Securities owned, at fair value	(2,178)	0	0
Prepaid expenses and other current assets	(1,985)	0	0
Property and equipment, net	(1,132)	0	0
Restricted cash	(353)	0	0
Accounts payable and accrued expenses	6,079	0	0
Accrued commissions and payroll payable	14,029	0	0
Deferred clearing and marketing credits	1,007	0	0
Warrants issuable	13,406
Other current liabilities	707
Non-controlling interests	17,717	0	0
Net cash acquired in acquisition of National Holdings Corp.	4,626	0	0
Customer Lists [Member]
Acquisition of National Holdings Corp.
Intangible assets	(13,500)
Trademarks [Member]
Acquisition of National Holdings Corp.
Intangible assets	(3,000)
Helocyte [Member]
Cash Flows from Financing Activities:
Proceeds from Convertible Debt	4,409	0	0
Payments of Debt Issuance Costs	(535)	0	0
Avenue [Member]
Cash Flows from Financing Activities:
Proceeds from Convertible Debt	200	0	0
Payments of Debt Issuance Costs	(59)	0	0
Restricted Stock [Member]
Supplemental disclosure of non-cash financing and investing activities:
Issuance of warrants in conjunction with NSC debt	$ 793	$ 175	$ 0

Organization and Description of

Organization and Description of Business	12 Months Ended
	Dec. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Description of Business	1. Organization and Description of Business Fortress Biotech, Inc. (“ Fortress Company NHLD National As of December 31, 2016, in addition to NHLD, the Company has several consolidated Fortress Companies, some of which contain product licenses, including Avenue Therapeutics, Inc. (“ Avenue Cellvation Journey JMC Coronado SO Checkpoint Mustang Helocyte Escala Caelum Cyprium National On September 9, 2016, the Company, purchased approximately 56.6 0.02 3.25 22.9

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“ GAAP The accompanying consolidated financial statements include the accounts of the Company’s subsidiaries. For consolidated entities where the Company owns less than 100% of the subsidiary, the Company records net loss attributable to non-controlling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. The Company also consolidates subsidiaries in which it owns less than 50% of the subsidiary but maintains voting control. The National assets acquired and liabilities assumed and revenues and expenses are reported on a one quarter lag. Therefore, the National assets acquired and liabilities assumed included in these consolidated financial statements as of December 31, 2016 are actually the assets acquired and liabilities assumed as of September 30, 2016 and the revenues and expenses included in these consolidated financial statements for the year ended December 31, 2016 are actually the revenues and expenses for the period from September 10, 2016 through September 30, 2016. The Company’s consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Certain of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities. The carrying value of the amount owed to Ovamed GmbH (“ Ovamed Consistent with the increase in Journey’s operations as of April 1, 2016 and the investment in National as of September 9, 2016, the Company now operates in three operating and reportable segments, Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development and National. Intercompany revenue at National related to the Mustang raise of $ 1.3 The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at December 31, 2016 and at December 31, 2015 consisted of cash, money market funds and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities. Office equipment is recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset. Leasehold improvements are amortized over the shorter of the estimated useful lives or the term of the respective leases. The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. During the year ended December 31, 2014, in connection to the abandonment of its lease in Woburn, MA, the Company recorded an impairment loss of $ 0.4 The Company records cash held in trust or pledged to secure certain debt obligations as restricted cash. As of December 31, 2016 and 2015, the Company has $ 15.9 14.6 14.9 14.0 0.6 Inventories comprise finished goods, which are valued at the lower of cost or market, on a first-in, first-out basis. The Company evaluates the carrying value of inventories on a regular basis, taking into account anticipated future sales compared with quantities on hand, and the remaining shelf life of goods on hand. Accounts receivable consists of amounts due to the Company for product sales from JMC. The Company’s accounts receivable reflects discounts for estimated early payment and for product estimated returns. Accounts receivable are stated at amounts due from customers, net of an allowance for doubtful accounts. Accounts that are outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due and the customer’s current ability to pay its obligation to the Company. The Company writes off accounts receivable when they become uncollectible. Accounts receivable are net of allowance for doubtful accounts of nil and nil, at December 31, 2016 and December 31, 2015, respectively. The Company elects the fair value option for its long-term investments at fair value (see Note 7). The decision to elect the fair value option, which is irrevocable once elected, is determined on an instrument by instrument basis and applied to an entire instrument. The net gains or losses, if any, on an investment for which the fair value option has been elected are recognized as a change in fair value of investments on the Consolidated Statements of Operations. The Company has various processes and controls in place to ensure that fair value is reasonably estimated. While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. As permitted under the Financial Accounting Standards Board (“FASB”), Accounting Standards Codification (“ASC”) 825, Financial Instruments, The Company classifies as liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The fair value of warrants that include price protection reset provision features are deemed to be “down-round protection” and, therefore, do not meet the scope exception for treatment as a derivative under ASC 815, Derivatives and Hedging The Company assessed the classification of warrants issued, in connection with the Helocyte and Avenue convertible note financings in 2016 (the “ Helocyte and Avenue Warrants The Company accounts for the Opus Credit Facility with detachable warrants in accordance with ASC 470, Debt The Company recorded the related issue costs and value ascribed to the warrants as a debt discount of the Opus Credit Facility. The discount is amortized utilizing the effective interest method over the term of the Opus Credit Facility. The unamortized discount, if any, upon repayment of the Opus Credit Facility will be expensed to interest expense. In accordance with ASC Subtopic 470-20, the Company determined the weighted average effective interest rate of the debt was approximately 39 Derivatives and Hedging The Company issues complex financial instruments which include both equity and debt features. The Company analyzes each instrument under ASC 480, Distinguishing Liabilities from Equity, Derivatives and Hedging Debt In accordance with ASC 815, the Company classified the fair value of the warrants granted in connection with the NSC Note transferred to Avenue effective February 2015 (the “Contingently Issuable Warrants”) as a derivative liability. The Company valued these Contingently Issuable Warrants using an option pricing model and used estimates for an expected dividend yield, a risk-free interest rate, and expected volatility together with management’s estimate of the probability of issuance of the Contingently Issuable Warrants. At each reporting period, as long as the Contingently Issuable Warrants are potentially issuable and there is a potential for an insufficient number of authorized shares available to settle the Contingently Issuable Warrants, these Contingently Issuable Warrants will be revalued, and any difference from the previous valuation date will be recognized as a change in fair value of derivative liabilities in the Consolidated Statements of Operations. Acquired assets and assumed liabilities are recognized in a business combination on the basis of their fair values at the date of acquisition. The Company assesses fair value, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, using a variety of methods including income approaches such as present value techniques or cost approaches such as the estimation of current selling prices and replacement values. Fair value of the assets acquired and liabilities assumed, including intangible assets, are measured based on the assumptions and estimations with regards to the variable factors such as the amount and timing of future cash flows for the asset or liability being measured, appropriate risk-adjusted discount rates, nonperformance risk, or other factors that market participants would consider. Upon acquisition, the Company determines the estimated economic lives of the acquired intangible assets for amortization purposes, which are based on the underlying expected cash flows of such assets. Goodwill represents the excess acquisition cost over the fair value of net tangible and intangible assets acquired. Goodwill is not amortized and is subject to annual impairment testing on October 1st or between annual tests if an event or change in circumstance occurs that would more likely than not reduce the fair value of a reporting unit below its carrying value. In testing for goodwill impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances lead to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, the Company concludes that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is not required. If the Company concludes otherwise, it is required to perform the two-step impairment test. The goodwill impairment test is performed at the reporting unit level by comparing the estimated fair value of a reporting unit with its respective carrying value. If the estimated fair value exceeds the carrying value, goodwill at the reporting unit level is not impaired. If the estimated fair value is less than carrying value, further analysis is necessary to determine the amount of impairment, if any, by comparing the implied fair value of the reporting unit's goodwill to the carrying value of the reporting unit’s goodwill. The fair value of reporting units is based on widely accepted valuation techniques that the Company believes market participants would use, although the valuation process requires significant judgment and often involves the use of significant estimates and assumptions. The methodologies the Company utilizes in estimating the fair value of reporting units include market valuation methods that incorporate price-to-earnings and price-to-book multiples of comparable exchange traded companies and multiples of merger and acquisitions of similar businesses. The estimates and assumptions used in determining fair value could have a significant effect on whether or not an impairment charge is recorded and the magnitude of such a charge. Adverse market or economic events could result in impairment charges in future periods. Intangible assets deemed to have finite lives are amortized on a straight line basis over their estimated useful lives, where the useful life is the period over which the asset is expected to contribute directly, or indirectly, to its future cash flows. Intangible assets are reviewed for impairment on an interim basis when certain events or circumstances exist. For amortizable intangible assets, impairment exists when the carrying amount of the intangible asset exceeds its fair value. At least annually, the remaining useful life is evaluated. An intangible asset with an indefinite useful life is not amortized but assessed for impairment annually, or more frequently, when events or changes in circumstances occur indicating that it is more likely than not that the indefinite-lived asset is impaired. Impairment exists when the carrying amount exceeds its fair value. In testing for impairment, the Company has the option to first perform a qualitative assessment to determine whether it is more likely than not that an impairment exists. If it is determined that it is not more likely than not that an impairment exists, a quantitative impairment test is not necessary. If the Company concludes otherwise, it is required to perform a quantitative impairment test. To the extent an impairment loss is recognized, the loss establishes the new cost basis of the asset that is amortized over the remaining useful life of that asset, if any. Subsequent reversal of impairment losses is not permitted. Long-lived assets, primarily fixed assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value. Financing costs incurred in connection with the note in favor of National Securities Corporation’s NSC Biotech Venture Fund I LLC (the “NSC Note”) are recorded as a reduction of principal balance due to ASU No. 2015-3 and are amortized over the appropriate expected life based on the term of the NSC Note using the effective interest rate method. The Company recognizes revenue for the performance of services or the shipment of products when each of the following four criteria is met: (i) persuasive evidence of an arrangement exists; (ii) products are delivered or as services are rendered; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured. Collaborative Arrangements Checkpoint is paid by TGTX, a related party, a share of the cost of the license and future milestone payments that are payable to Dana-Farber Cancer Institute pursuant to the license agreement (see Note 8). Checkpoint is also paid by TGTX for the Sponsored Research Agreement between Checkpoint and NeuPharma (see Note 8). The gross amounts of these payments are reported as revenue in the accompanying Statements of Operations. Checkpoint acts as a principal, bears credit risk and may perform part of the services required in the transactions. Consistent with ASC 605-45-15 Revenue Recognition - Principal Agent Considerations The Company follows ASC 605-25, Revenue Recognition - Multiple-Element Arrangements ASC 605-25 Collaborative Arrangements ASC 605-25 provides guidance relating to the separability of deliverables included in an arrangement into different units of accounting and the allocation of arrangement consideration to the units of accounting. The evaluation of multiple-element arrangements requires management to make judgments about (i) the identification of deliverables, (ii) whether such deliverables are separable from the other aspects of the contractual relationship, (iii) the estimated selling price of each deliverable, and (iv) the expected period of performance for each deliverable. To determine the units of accounting under a multiple-element arrangement, management evaluates certain separation criteria, including whether the deliverables have stand-alone value, based on the relevant facts and circumstances for each arrangement. Management then estimates the selling price for each unit of accounting and allocates the arrangement consideration to each unit utilizing the relative selling price method. The allocated consideration for each unit of accounting is recognized over the related obligation period in accordance with the applicable revenue recognition criteria. If there are deliverables in an arrangement that are not separable from other aspects of the contractual relationship, they are treated as a combined unit of accounting, with the allocated revenue for the combined unit recognized in a manner consistent with the revenue recognition applicable to the final deliverable in the combined unit. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as deferred revenue in the Consolidated Balance Sheets and recognized as revenue in the Consolidated Statements of Operations when the related revenue recognition criteria are met. Revenue Recognition – Milestone Method The Company follows ASC 605-28, Revenue Recognition-Milestone Method JMC Product Revenue JMC sells its products directly to wholesalers and specialty pharmacies. JMC recognizes product sales revenue when delivery has occurred, collectability is reasonably assured, and the price to the buyer is fixed or determinable, (in accordance with the specific contractual terms). Delivery occurs when title has transferred to the customer, and the customer has assumed the risks and rewards of ownership. Revenue from product sales is recognized net of provisions for estimated cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to certain of JMC’s wholesale customers. JMC establishes these provisions concurrently with the recognition of product sales revenue. JMC offers cash discounts for prompt payment and allowances are recorded at the time of sale. JMC allows customers to return product within a specified period of time before and after its expiration date. Provisions for returns are estimated based on historical levels for like products from external data sources, taking into account additional available information such as historical return and exchange levels, and inventory levels in the wholesale distribution channel through its partners. Although the company has limited history with these product sales, the Company believes based on its current level of sales that it can make reasonable estimates of returns based upon external data sources. JMC reviews its methodology and adequacy of the provision for returns on a quarterly basis, adjusting for changes in assumptions, historical internal and external results and business practices, as necessary. JMC’s co-promotion revenue for Dermasorb HC is based upon prescription volume over an established baseline. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company’s behalf will be expensed as services are rendered or when the milestone is achieved. Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations for preclinical and clinical studies, investigative sites for clinical trials, consultants, the cost of acquiring and manufacturing clinical trial materials, and costs associated with regulatory filings, laboratory costs and other supplies. In accordance with ASC 730-10-25-1, Research and Development The Company records accruals for contingencies and legal proceedings expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated. If a loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates. For stock-based compensation awards to non-employees, the Company remeasures the fair value of the non-employee awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of these non-employee awards are recognized as compensation expense in the period of change. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model or 409A valuations, as applicable. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if management believes it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50 Non-controlling interests in consolidated entities represent the component of equity in consolidated entities held by third parties. Any change in ownership of a subsidiary while the controlling financial interest is retained is accounted for as an equity transaction between the controlling and non-controlling interests. The Company’s comprehensive loss is equal to its net loss for all periods presented. Certain prior period amounts may have been reclassified to conform to the current year presentation. National's Summary of Significant Accounting Policies The consolidated financial statements include the accounts of National and its wholly owned and majority owned subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation. In addition, National may consolidate entities which meet the definition of a variable interest entity for which National is the primary beneficiary. The primary beneficiary is the party who has the power to direct the activities of a variable interest entity that most significantly impact the entity’s economic performance and who has an obligation to absorb losses of the entity or a right to receive benefits from the entity that could potentially be significant to the entity. As of December 31, 2016 and 2015, National did not consolidate any variable interest entities . The preparation of these financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Commission revenue represents commissions generated by National's financial advisors for their clients' purchases and sales of mutual funds, variable annuities, general securities and other financial products, most of which is paid to the advisors as commissions for initiating the transactions. Commission revenue is generated from front-end sales commissions that occur at the point of sale, as well as trailing commissions. National recognizes front-end sales commission revenue and related clearing and other expenses on transactions introduced to its clearing brokers on a trade date basis. National also recognizes front-end sales commissions and related expenses on transactions initiated directly between the financial advisors and product sponsors upon receipt of notification from sponsors of the commission earned. Commission revenue also includes 12b-1 fees, and variable product trailing fees, collectively considered as trailing fees, which are recurring in nature. These trailing fees are earned by National based on a percentage of the current market value of clients' investment holdings in trail eligible assets. Because trail commission revenues are generally paid in arrears, management estimates commission revenues earned during each period. These estimates are based on a number of factors including investment holdings and the applicable commission rate and the amount of trail commission revenue received in prior periods. Estimates are subsequently adjusted to actual based on notification from the sponsors of trail commissions earned. Net dealer inventory gains, which are recorded on a trade-date basis, include realized and unrealized net gains and losses resulting from the National's principal trading activities. Investment banking revenues consist of underwriting revenues, advisory revenues and private placement fees. Underwriting revenues arise from securities offerings in which National acts as an underwriter and include management fees, selling concessions and underwriting fees, net of related syndicate expenses. Underwriting revenues are recorded at the time the underwriting is completed and the income is reasonably determined. Management estimates National’s share of the transaction-related expenses incurred by the syndicate, and recognizes revenues net of such expense. On final settlement, typically within 90 days from the trade date of the transaction, these amounts are adjusted to reflect the actual transaction-related expenses and the resulting underwriting fee. Investment advisory fees are derived from account management and investment advisory services. These fees are determined based on a percentage of the customers assets under management, may be billed monthly or quarterly and are recognized when earned. Interest is recorded on an accrual basis and dividends are recorded on the ex-dividend date. Transfer fees and fees for clearing services, which are recorded on a trade date basis, are principally charged to the broker on customer security transactions. Tax preparation and accounting fees are recognized upon completion of the services. Securities owned and securities sold, but not yet purchased, are recorded at fair value. Authoritative accounting guidance defines fair value, establishes a framework for measuring fair value, and establishes a fair value hierarchy which prioritizes the inputs to valuation techniques. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A fair value measurement assumes that the transaction to sell the asset or transfer the liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market. Valuation techniques that are consistent with the market, income or cost approach are used to measure fair value. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three categories: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 Inputs other than quoted market prices that are observable, either directly or indirectly, and reasonably available. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of National. Level 3 Unobservable inputs which reflect the assumptions that National develops based on available information about what market participants would use in valuing the asset or liability. Deferred clearing credit represents a clearing fee rebate from National Financial Services (“NFS”), one of National’s clearing brokers, which is being recognized pro rata as a reduction of clearing charges over the term of the clearing agreement which expires in 2022. At September 30, 2016, the deferred clearing credit amounted to approximately $ 0.7 Deferred marketing credit represents a marketing rebate from NFS, which is being recognized pro rata as a reduction of marketing expenses over the term of the clearing agreement which expires in 2022. At September 30, 2016, the deferred marketing credit amounted to approximately $ 0.3 The Company incurs certain costs on behalf of its financial advisors including those for insurance, professional registration, technology and information services a

National Holdings Corporation

National Holdings Corporation	12 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
National Holdings Corporation	3. National Holdings Corporation On September 9, 2016, the Company, purchased approximately 56.6 0.02 3.25 On April 27, 2016, the Company entered into an Agreement and Plan of Merger with National and a wholly owned subsidiary of the Company, providing for the acquisition of National (the “Merger Agreement”). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions described therein, the Company agreed to cause its wholly owned subsidiary to commence a tender offer for all the issued and outstanding shares of National’s common stock, par value $ 0.02 3.25 7 56 22.9 Assets Cash and cash equivalents $ 27,498 Accounts receivable 4,889 Cash deposits with clearing organizations 1,030 Receivable from brokers, dealers and clearing agencies 1,607 Securities owned, at fair value 2,178 Prepaid expenses and other current assets 1,985 Property and equipment 1,132 Restricted cash 353 Intangible assets - trademark 3,000 Intangible assets - customer list 13,500 Goodwill 18,645 Total assets 75,817 Liabilities Accrued compensation payable $ 14,029 Accounts payable and accrued expenses 6,079 Deferred clearing and marketing credits 1,007 Warrants issuable 13,406 Other current liabilities 707 Total liabilities assumed 35,228 Non-controlling interests 17,717 Net assets acquired $ 22,872 Cash and cash equivalents from National $ 27,498 Cash to NHLD Shareholders (Tender Offer) 22,872 Net cash acquired in acquisition of National $ 4,626 The preliminary estimated fair values of the assets acquired and liabilities assumed will be finalized as further information is received regarding these items and analysis of this information is completed. The Company preliminarily recognized $ 18.6 Intangible assets consist of trademark and customer lists acquired in the merger under the purchase method of accounting are recorded at preliminary fair value net of accumulated amortization since the purchase date. Useful life Trademark 10 years Customer lists 10 years Intangible assets at September 9, 2016 $ 16,500 Amortization expense (509) Intangible assets at December 31, 2016 $ 15,991 Trademark Customer List Total Year Ended December 31, 2017 $ 300 $ 1,350 $ 1,650 Year Ended December 31, 2018 300 1,349 1,649 Year Ended December 31, 2019 300 1,349 1,649 Year Ended December 31, 2020 301 1,353 1,654 Year Ended December 31, 2021 300 1,349 1,649 Thereafter 1,407 6,333 7,740 Total $ 2,908 $ 13,083 $ 15,991 The Company reviews its finite-lived intangible assets for impairment when events or changes in circumstances indicate that the carrying amount of finite-lived intangible asset may not be recoverable. Recoverability of a finite-lived intangible asset is measured by a comparison of its carrying amount to the undiscounted future cash flows expected to be generated by the asset. If the asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were no indicators of impairment during the period ended September 30, 2016. National’s results of operations have not been included in the consolidated financial statements prospectively from the date of acquisition, because we have elected to record National’s financial results in operations under a three-month lag. The following unaudited pro forma financial data assumes the acquisition had occurred at the beginning of January 1, 2015. Pro forma results have been prepared by adjusting the Company’s historical results to include National's results of operations. The unaudited pro forma results presented do not necessarily reflect the results of operations that would have resulted had the acquisition been completed at the beginning of January 1, 2015, nor do they indicate the results of operations in future periods. Additionally, the unaudited pro forma results do not include the impact of possible business model changes, nor do they consider any potential impacts of current market conditions or revenues, reduction of expenses, asset dispositions, or other factors. The impact of these items could alter the following pro forma results ($ in thousands): Year Ended December 31, 2016 2015 (Unaudited) (Unaudited) Total revenues $ 190,556 $ 163,909 Net loss attributable to common stockholders $ (59,027) $ (47,310) Los per share: Basic $ (1.48) $ (1.21) Diluted $ (1.48) $ (1.21)

Broker-Dealers and Clearing Org

Broker-Dealers and Clearing Organizations and Other Receivables	12 Months Ended
	Dec. 31, 2016
Brokers and Dealers [Abstract]
Broker-Dealers and Clearing Organizations and Other Receivables	4. Broker-Dealers and Clearing Organizations and Other Receivables At September 30, 2016, National’s receivables of $ 3.4 5.4 0.7

Forgivable Loans Receivable

Forgivable Loans Receivable	12 Months Ended
	Dec. 31, 2016
Forgivable Loans Receivable [Abstract]
Forgivable Loans Receivable	5. Forgivable Loans Receivable From time to time, National's operating subsidiaries may make loans, evidenced by promissory notes, primarily to newly recruited independent financial advisors as an incentive for their affiliation. The notes receivable balance is comprised of unsecured non-interest-bearing and interest-bearing loans (interest ranging up to 9 National provides an allowance for doubtful accounts on the notes based on historical collection experience and continually evaluates the receivables for collectability and possible write-offs where a loss is deemed probable. As of September 30, 2016, no allowance for doubtful accounts was required. There were no unamortized forgivable loans outstanding at September 30, 2016 attributable to registered representatives who ended their affiliation with National’s subsidiaries prior to the fulfillment of their obligation.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2016
Property Plant And Equipment [Abstract]
Property and Equipment	6. Property and Equipment As of December 31, ($ in thousands) Useful Life (Years) 2016 2015 Computer equipment 3 $ 440 $ 13 Furniture and fixtures 5 821 69 Leasehold improvements 5 - 15 5,396 21 Construction in progress (1) NA – 274 Total property and equipment 6,657 377 Less: Accumulated depreciation (445) (68) Property and equipment, net $ 6,212 $ 309 (1) For build-out of the Company's new office in New York, NY. Depreciation expenses of Fortress' s property and equipment for the years ended December 31, 2016, 2015, and 2014 was $ 0.4 26,000 23,000 September 30, Estimated Useful 2016 Lives (in years) Equipment $ 600 5 Furniture and fixtures 65 5 Leasehold improvements 259 Lesser of useful life or term of lease Capital Leases (Primarily composed of computer equipment) 276 5 Total property and equipment 1,200 Less: Accumulated depreciation (36) Property and equipment, net $ 1,164 Depreciation expense of National's property and equipment for the period from September 10, 2016 through September 30, 2016 was $ 36,000

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	Certain of the Company’s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities. Laser Device for Treatment of Migraine Headaches On March 17, 2014, the Company invested $ 250,000 35 13,409,962 83 16,091,954 0.3 Origo Acquisition Corporation (formerly CB Pharma Acquisition Corporation) On June 10, 2016, CB Pharma Acquisition Corp (“ CB Pharma Meeting Charter Extension Origo 1,050,000 265,000 On December 19, 2016, Origo announced the execution of a Merger Agreement with Aina Le’a Inc., a residential and commercial real estate developer in Hawaii, pursuant to which Origo will merge with and into Aina Le’a Merger Sub, a wholly-owned subsidiary of Aina Le’a Inc. (the “ Merger Under the Merger, shareholders and warrant holders in Origo will receive 0.6 shares or warrants of Aina’s common stock, respectively, for each share or warrant of Origo they hold. As of December 31, 2016, the Company valued its investment in Origo, a publicly traded company, utilizing the following assumptions: probability of a successful business combination of 51.53 8.16 25.6 0.85 11.50 0.82 0.58 51.53 4.20 0.42 0.30 1.1 25,000 1.0 1.2 0.3 Uracil Topical Cream In April 2014, the Company paid $ 243,000 50,000 0.3 0.3 Contingently Issuable Warrant Pursuant to the Amended NSC Note (see Note 11), if a Fortress Company has the proceeds of the NSC Note transferred to it, such Fortress Company will issue a note to NSC and NSC will also receive a warrant to purchase a number of shares of the Fortress Company’s stock equal to 25 10 Derivatives and Hedging. Avenue classified the fair value of the Contingently Issuable Warrants that may have been granted in connection with Avenue’s $ 3.0 December 31, December 31, 2016 2015 Risk-free interest rate 2.45 % 2.27 % Expected dividend yield - - Expected term in years 10.00 9.84 Expected volatility 87 % 83 % Probability of issuance of the warrant 50 % 25 % Avenue’s Contingently Issuable ($ in thousands) Warrants Beginning balance at January 1, 2016 $ 114 Additions - Change in fair value 188 Ending balance at December 31, 2016 $ 302 Mustang classified the fair value of the Contingently Issuable Warrants that may have been granted in connection with Mustang’s $ 3.6 138,462 0.8 Issuance Dates Risk-free interest rate 1.37 % Expected dividend yield - Expected term in years 10.00 Expected volatility 76.70 % Probability of issuance of the warrant 100 % Mustang’s Contingently Issuable ($ in thousands) Warrants Beginning balance at January 1, 2016 $ - Additions 634 Change in fair value 159 Issuance of Warrants (October 25, 2016) (793) Ending balance at December 31, 2016 $ - On October 30, 2015, Checkpoint issued 139,592 Checkpoint’s Contingently Issuable ($ in thousands) Warrants Beginning balance at January 1, 2015 $ - Additions 175 Change in fair value 438 Issuance of Warrants (October 30, 2015) (613) Ending balance at December 31, 2015 $ - Issuance Dates 0.2 0.6 October 30, Issuance Dates 2015 Risk-free interest rate 2.26 % 2.16 % Expected dividend yield - - Expected term in years 10.00 10.00 Expected volatility 83 % 100.86 % Probability of issuance of the warrant 25 % 100 % Avenue Warrant Liabilities On December 30, 2016, Avenue held a closing of the sale of convertible promissory notes. In the closing, WestPark Capital, Inc., (“ WestPark WestPark Warrant 10,000 December 31, 2016 Risk-free interest rate 2.45 % Expected dividend yield - Expected term in years 10.00 Expected volatility 87 % Fair Value of Derivative Warrant ($ in thousands) Liability Beginning balance at January 1, 2016 $ - Additions 12 Change in fair value of derivative liabilities - Ending balance at December 31, 2016 $ 12 Helocyte Warrant Liabilities The fair value of Helocyte’s warrant liability was measured at fair value using a Monte Carlo simulation valuation methodology. December 31, 2016 Risk-free interest rate 1.82% - 1.91 % Expected dividend yield -% Expected term in years 4.50 – 4.92 Expected volatility 70.0% Strike price $0.44 ($ in thousands) Fair Value of Beginning balance at January 1, 2016 $ - Additions 428 Change in fair value of derivative liabilities (261) Ending balance at December 31, 2016 $ 167 Helocyte’s convertible debt is measured at fair value using the Monte Carlo simulation valuation methodology. December 31, 2016 Risk-free interest rate 0.74% - 1.17 % Expected dividend yield -% Expected term in years 0.75 – 1.91 Expected volatility 61.7% Avenue’s convertible debt is measured at fair value using the Monte Carlo simulation valuation methodology. December 31, 2016 Risk-free interest rate 0.62% - 1.20 % Expected dividend yield -% Expected term in years 0.50 – 2.00 Expected volatility 63.1% Fair Value Measurement as of December 31, 2016 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Long-term investments, at fair value $ - $ - $ 1,414 $ 1,414 Total $ - $ - $ 1,414 $ 1,414 Liabilities Contingently Issuable Warrants $ - $ - $ 302 $ 302 Warrant liabilities - - 179 179 Helocyte Convertible Note, at fair value - - 4,487 4,487 Avenue Convertible Note, at fair value - - 200 200 Total $ - $ - $ 5,168 $ 5,168 Fair Value Measurement as of December 31, 2015 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Long-term investments, at fair value $ - $ - $ 2,485 $ 2,485 Liabilities Derivative warrant liability $ - $ - $ 114 $ 114 Fair Value Measurement as of September 30, 2016 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Corporate stock 101 — 101 Municipal bonds — 2,111 — 2,111 Restricted stock — 145 — 145 Total $ 101 $ 2,256 $ — $ 2,357 Liabilities Corporate stock 298 — — 298 Warrants issuable 14,359 14,359 Total $ 298 $ — $ 14,359 $ 14,657 In accordance with the Merger Agreement, since less than 80 five 3.25 5.4 44 September 30, 2016 Dividend yield 0.00 % Expected volatility 118.85 % Risk-free interest rate 1.14 % Life (in years) 5 In the Merger Agreement, National agreed to set a record date within ninety (90) days following the Acceptance Time (as defined therein) with respect to the distribution to its stockholders of warrants to purchase one share of its common stock for every share of its common stock owned at an exercise price of $ 3.25 As a result of “due bill” trading procedures, those persons who held shares of National’s common stock as of the record date, or who acquire shares of National's common stock in the market following the record date, and in each case who continue to hold such shares at the close of trading the date before the ex-dividend date to be established by The Nasdaq Stock Market with respect to the Warrants Issuable, will be entitled to receive a Warrants Issuable with respect to each share of National's common stock owned by such person as of the ex-dividend date. Conversely, those persons who held shares of National's common stock as of the record date, or who acquire shares of National's common stock in the market following the record date, but in each case who do not hold such shares of National's common stock at the close of trading on the date before the ex-dividend date, will not be entitled to receive any Warrants Issuable with respect to such shares. Therefore, a shareholder selling their shares of National’s common stock prior to the ex-dividend date would not receive any Warrants Issuable with respect to the shares that are sold by such person even if such person held the shares on the record date, since the shares of National's common stock sold would be accompanied by a “due-bill” entitling the buyer of those shares to receive the Warrants Issuable with respect to such shares. The actual right to receive the Warrants Issuable with respect to any shares of National’s common stock requires still holding such shares until the ex-dividend date. Helocyte Contingently Convertible Avenue Investment in Investment in Issuable Note, at fair Convertible Note, Warrant ($ in thousands) Origo laser device Warrants value at fair value liabilities Total Balance at December 31, 2015 $ 2,235 $ 250 $ 114 $ - $ - $ - $ 2,599 Additions during the period - - 14,040 4,409 200 440 19,089 Issuance of warrants - - (793) - - - (793) Change in fair value of investments (1,071) - - - - - (1,071) Change in fair value of convertible notes - - - 78 - 78 Change in fair value of derivative liabilities - - 1,300 - (261) 1,039 Balance at December 31, 2016 $ 1,164 $ 250 $ 14,661 $ 4,487 $ 200 $ 179 $ 20,942 Contingently Investment in Investment in Issuable Warrant ($ in thousands) Origo laser device Warrants liabilities Total Balance at December 31, 2014 $ 3,910 $ 250 $ - $ - $ 4,160 Additions during the period - - 175 114 289 Change in fair value of investments (1,675) - - - (1,675) Change in fair value of derivative liabilities - - 438 - 438 Issuance of warrants (613) (613) Balance at December 31, 2015 $ 2,235 $ 250 $ - $ 114 $ 2,599

Licenses Acquired

Licenses Acquired	12 Months Ended
	Dec. 31, 2016
Licenses Acquired [Abstract]
Licenses Acquired	8. Licenses Acquired 2016 and 2015 Activities In accordance with ASC 730-10-25-1, Research and Development 5.5 For the Years Ended December 31, ($ in thousands) 2016 2015 2014 Fortress $ 325 $ - $ - Fortress Companies: Avenue - 3,000 - Checkpoint 3,160 3,159 - Coronado SO - 1,607 - Helocyte 53 200 - Mustang 1,682 2,147 - Escala - 1,295 - Cellvation 312 - - Total $ 5,532 $ 11,408 $ - Fortress Biotech, Inc. In July 2016, Fortress entered into a License Agreement with GeneMedicine, Inc. (“ GeneMedicine 0.3 0.1 19.3 In September 2016, Fortress entered into a Development and License Agreement with Effcon Laboratories, Inc. (“ Effcon 0.2 million 5.3 1.6 Avenue Therapeutics, Inc. License Agreement with Revogenex Ireland Ltd In February 2015, the Company purchased an exclusive license to IV Tramadol for the U.S. market from Revogenex, a privately held company in Dublin, Ireland. Fortress made an upfront payment of $ 2.0 1.0 The Company transferred the Revogenex license and all other rights and obligations of Fortress under the License Agreement to Avenue pursuant to the Avenue Founders Agreement effective as of February 17, 2015. Per the terms of the agreement, Avenue assumed $ 3.0 During the year ended December 31, 2016, Avenue completed a pharmacokinetics or PK study for IV Tramadol in healthy volunteers and completed an End-of-Phase 2 (EOP) meeting with the FDA. Initiation of the Phase 3 study is anticipated to begin in 2017. Cellvation, Inc. In October 2016, Cellvation entered into a license agreement with the University of Texas Health Science Center at Houston (“ University of Texas Initial TBI License 0.3 500,000 5 6.2 6.0 50,000 0.2 Second TBI License 50,000 0.1 0.3 500,000 The Company valued the stock grant to the University of Texas utilizing a discounted cash flow model to determine the weighted market value of invested capital, discounted by a lack of marketability of 40.2 30 0.024 12,000 12,000 Checkpoint Therapeutics, Inc. Dana-Farber Cancer Institute In March 2015, Checkpoint entered into an exclusive license agreement with Dana-Farber Cancer Institute (“ Dana-Farber 1.0 500,000 32,500 0.065 5 10.0 136,830 0.6 21.5 60.0 In connection with the license agreement with Dana-Farber, Checkpoint entered into a collaboration agreement with TGTX, a related party, to develop and commercialize the anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies, while Checkpoint retains the right to develop and commercialize these antibodies in the field of solid tumors. Michael Weiss, Chairman of the Board of Directors of Checkpoint is also the Executive Chairman, President and Chief Executive Officer and a stockholder of TGTX. Under the terms of the agreement, TGTX paid Checkpoint $ 0.5 21.5 7.0 14.5 60.0 42,000 0.6 NeuPharma, Inc. In March, 2015, the Company entered into an exclusive license agreement with NeuPharma, Inc. (“ NeuPharma 1.0 40.0 22.5 40.0 In connection with the license agreement with NeuPharma, in March 2015, the Company entered into an option agreement with TGTX, a related party, which agreement was assigned to Checkpoint on the same date, for a global collaboration of certain compounds licensed. The option agreement will expire on December 31, 2017 unless both parties agree to extend the option period. Also in connection with the license agreement with NeuPharma, Checkpoint entered into a Sponsored Research Agreement with NeuPharma for certain research and development activities. Effective January 11, 2016, TGTX, a related party, agreed to assume all costs associated with this agreement and paid Checkpoint for all amounts previously paid by Checkpoint. The company recognized approximately $ 1.0 Teva Pharmaceutical Industries Ltd. (through its subsidiary, Cephalon, Inc.) In December 2015, the Company entered into a license agreement with Teva Pharmaceutical Industries Ltd. through its subsidiary, Cephalon, Inc. (“ Cephalon 0.5 220.0 206.5 Jubilant Biosys Limited In May 2016, Checkpoint entered into a license agreement with Jubilant Biosys Limited (“ Jubilant Jubilant License 2.0 89.0 59.5 89.0 2.0 research and development-licenses acquired In connection with the Jubilant License, Checkpoint entered into a sublicense agreement with TGTX (the “Sublicense Agreement”), a related party, to develop and commercialize the compounds licensed in the field of hematological malignancies, with Checkpoint retaining the right to develop and commercialize these compounds in the field of solid tumors. Michael Weiss, Chairman of the Board of Directors of Checkpoint and the Company’s Executive Vice Chairman, Strategic Development, is also the Executive Chairman, President and Chief Executive Officer and a stockholder of TGTX. Under the terms of the Sublicense Agreement, TGTX paid Checkpoint $ 1.0 87.5 0.3 25.5 61.7 89.0 50 1.5 Coronado SO Co. License Agreement In February 2015, Coronado SO entered into an exclusive license agreement with a third party for a topical product used in the treatment of hand-foot syndrome, a common painful side effect of chemotherapeutics. Coronado SO paid $ 0.9 150,000 0.5 10.7 26.2 The Company valued the stock grant to the third party utilizing a discounted cash flow model to determine the weighted market value of invested capital, discounted by a lack of marketability of 44.8 30 1.19 0.2 Helocyte, Inc. License Agreement with the City of Hope In March 2016, Helocyte entered into amended and restated license agreements for each of its PepVax and Triplex immunotherapies programs with its licensor City of Hope National Medical Center (“COH”). The amended and restated licenses expand the intellectual property and other rights granted to Helocyte by COH in the original license agreement. The financial terms of the original license have not been modified, and if Helocyte successfully develops and commercializes PepVax and Triplex, COH will receive milestones, royalties and other payments. Helocyte entered into the original license agreement with COH on March 31, 2015, to secure: (i) an exclusive worldwide license for two immunotherapies for CMV control in the post-transplant setting (known as Triplex and PepVax); and (ii) an option for an exclusive worldwide license to an immunotherapy for the prevention of congenital CMV (known as Pentamer). In consideration for the license and option, Helocyte made an upfront payment of $ 150,000 45,000 1.5 13.0 0.2 9.0 26.0 0.75 5.5 26.0 0.75 As further consideration for the licenses, in March and May 2016, Helocyte granted COH 500,000 8,333 44.5 30 0.097 48,500 Mustang Bio, Inc. License Agreement with the City of Hope In March 2015, Mustang entered into an exclusive license agreement with COH to acquire intellectual property rights pertaining to CAR-T (the “ COH License 2.0 research and development-licenses acquired expenses 1.0 10 2.0 14.5 1.0 The Company valued the stock grant to COH utilizing a discounted cash flow model to determine the weighted market value of invested capital, discounted by a lack of marketability of 44.8 30 0.147 0.1 Effective October 2016, Mustang closed on gross proceeds of $ 10.0 293,588 COH Anti-Dilution Shares 5.73 1.7 1.0 Escala Therapeutics, Inc. On July 16, 2015, Escala acquired from New Zealand Pharmaceuticals Limited (“NZP”) a license from the NIH and cooperative research and development agreements for the development of oral ManNAc, a key compound in the sialic biosynthetic pathway, for the treatment of hyposialylation disorders, including GNE myopathy and various forms of nephropathy. As part of this agreement, Escala provided NZP and NIH an upfront payment of approximately $ 1.3 0.7 0.6 1.3 Seven milestones totaling approximately $ 22.0 7.0

Milestones and Sponsored Resear

Milestones and Sponsored Research Agreements	12 Months Ended
	Dec. 31, 2016
Research and Development [Abstract]
Research, Development, and Computer Software Disclosure	9. Milestones and Sponsored Research Agreements Fortress Biotech, Inc. The Company has a license agreement with the University College London Business PLC (“ UCLB 0.1 22.0 0.4 3 5 Cellvation, Inc. In October 2016, Cellvation entered research funding agreement with the University of Texas in connection with the license for a method and apparatus for conditioning cell populations for cell therapies. In connection with this agreement Cellvation agreed to fund $ 0.7 0.2 Helocyte, Inc. In March 2016, Helocyte entered into an Investigator-Initiated Clinical Research Support Agreement, as amended, with the COH, to support a Phase 2 clinical study of its PepVax immunotherapy for CMV control in allogeneic stem cell transplant recipients (“ PepVax Research Agreement NCI 1.0 2.0 In February 2016, Helocyte entered into an Investigator-Initiated Clinical Research Support Agreement, as amended, with the COH, to support a Phase 2 clinical study of its Triplex immunotherapy for CMV control in allogeneic stem cell transplant recipients (“ Triplex Research Agreement 1.0 3.4 In August 2016, Helocyte made a payment of $ 2.0 1.0 1.0 4.4 2.4 2.0 Mustang Bio, Inc. In March 2015, in connection with Mustang’s license with COH for the development of CAR-T, Mustang entered into a Sponsored Research Agreement in which Mustang will fund continued research in the amount of $ 2.0 of $ 2.0 1.5

Intangibles

Intangibles	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangibles	10. Intangibles Journey Medical Corporation In January 2016, JMC entered into a licensing agreement with a third party to distribute its prescription wound cream Luxamend TM 50,000 TM 0.3 0.2 In March 2015, JMC entered into a license and supply agreement to acquire the rights to distribute Targadox TM 1.3

Debt and Interest

Debt and Interest	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Debt and Interest	11. Debt and Interest Debt December 31, ($ in thousands) 2016 2015 Interest rate Maturity IDB Note $ 14,929 $ 14,009 2.25% Feb - 2018 NSC Note 3,608 10,000 8.00% Sep - 2018 Opus Credit Facility 7,000 - 12.00% Sep - 2018 Helocyte Convertible Note, at fair value 1,031 - 5.00% - 8.00% Dec - 2017 Helocyte Convertible Note, at fair value 2,051 - 5.00% - 8.00% March - 2018 Helocyte Convertible Note, at fair value 1,405 - 5.00% - 8.00% May - 2018 Avenue Convertible Note, at fair value 200 - 5.00% - 8.00% June - 2018 Total notes payable 30,224 24,009 Less: Discount on notes payable 2,009 835 Total notes payable, long-term $ 28,215 $ 23,174 IDB Note On February 13, 2014, the Company executed a promissory note in favor of IDB in the amount of $ 15.0 14.0 0.1 million 2.25 The obligations of the Company under the IDB Note are collateralized by a security interest in, a general lien upon, and a right of set-off against the Company’s money market account of $ 15.0 The Company will default on the IDB Note if, among other things, it fails to pay outstanding principal or interest when due. Following the occurrence of an event of default under the IDB Note, the Bank may: (i) declare the entire outstanding principal balance of the IDB Note, together with all accrued interest and other sums due under the IDB Note, to be immediately due and payable; (ii) exercise its right of setoff against any money, funds, credits or other property of any nature in possession of, under control or custody of, or on deposit with IDB; (iii) terminate the commitments of IDB; and (iv) liquidate the money market account to reduce the Company’s obligations to IDB. During 2016, the Company and IDB extended the maturity date of the IDB Note to February 27, 2018. At December 31, 2016 and 2015, the Company had approximately $ 14.9 14.0 The Company applied the 10 NSC Note In March 2015, the Company closed a private placement of a promissory note for $ 10.0 NSC Note 8 0.9 17.83 14.0 The NSC Note was amended and restated on July 29, 2015 to provide that any time a Fortress subsidiary receives from the Company any proceeds from the NSC Note, the Company may, in its sole discretion, cause the Fortress Company to issue to NSC Biotech Venture Fund I LLC a new promissory note (the “ Amended NSC Note 2.8 3.0 3.6 In connection with the transfer of NSC Note proceeds to a Fortress Company, NSC will receive a warrant to purchase the Fortress Company’s common stock equal to 25 10 On October 30, 2015, Checkpoint granted 139,592 0.0001 0.6 0.2 0.4 On October 31, 2015, Avenue recorded approximately $ 0.1 In February 2016, Checkpoint repaid its NSC Debt of $ 2.8 0.3 0.2 In July 2016, Fortress transferred $ 3.6 25 0.6 On October 25, 2016, Mustang issued 138,462 0.0001 0.8 As of December 31, 2016, Avenue recorded approximately $ 0.4 0.1 In January 2017, the Company and Avenue notified NSC of their intention to extend the maturity date of the NSC Notes by six months, to September 2018. Hercules Debt Agreement In August 2012, the Company entered into a Loan and Security Agreement (the “ Loan Agreement Hercules 15.0 14.7 The loan bore interest at a rate per annum equal to the greater of (i) 9.25% or (ii) 9.25% plus the sum of the prevailing prime rate minus 3.25%. March 1, 2016 The loan required interest-only payments for the initial 12 months and thereafter requires repayment of the principal balance with interest in 30 monthly installments. 2.0 Warrant 73,009 5.65 The fair value of the Warrant was calculated using the Black-Scholes option-pricing model with the following assumptions: volatility of 87.2 1.1 0.3 2.65 0.4 0.2 0.9 12.3 On February 13, 2014, the Company repaid the Hercules Note in full. Early Payment of the Hercules Note was $ 14.0 13.2 0.4 0.3 0.1 Helocyte Convertible Notes During 2016 Helocyte entered into an agreement with Aegis Capital Corp. (“ Aegis 5.0 18 5 8 (a) the lowest price per share at which equity securities of Helocyte are sold in such sale less a 33% discount and (b) a per share price based on a pre-offering valuation of $50.0 million divided by the number of common shares outstanding on a fully-diluted basis. 10.0 (a) a discount to the price per share being paid in the Sale of Helocyte equal to 33% or (b) a conversion price per share based on a pre-sale valuation of $50.0 million divided by the fully-diluted common stock of Helocyte immediately prior to the Sale of Helocyte (excluding the notes). As of December 31, 2016, Helocyte realized net proceeds in its four separate closings of $3.9 million after paying Aegis, its placement fee of $0.4 million, or approximately 10% of the net proceeds, and legal fees of approximately $ 0.1 Helocyte Warrants 0.4 110 Due to the complexity and number of embedded features within each convertible note, and as permitted under accounting guidance, the Company elected to account for the convertible notes and all the embedded features under the fair value option (see note 7). Opus Credit Facility Agreement On September 14, 2016, Fortress entered into a Credit Facility Agreement (the “Opus Credit Facility”) with Opus Point Healthcare Innovations Fund, LP (“OPHIF”). Since Fortress’s Chairman, President and Chief Executive Officer (Lindsay A. Rosenwald) and Fortress’s Executive Vice President, Strategic Development (Michael S. Weiss), are Co-Portfolio Managers and Partners of Opus Point Partners Management, LLC (“Opus”), an affiliate of OPHIF, all of the disinterested directors of Fortress’s board of directors approved the terms of the Credit Facility Agreement and accompanying Pledge and Security Agreement and forms of Note and Warrant (collectively, the “Financing Documents”). Pursuant to the Opus Credit Facility, Fortress may borrow up to a maximum aggregate amount of $ 25.0 September 14, 2018 Pursuant to the Opus Credit Facility and form of Note, each Note will bear interest at 12 Fortress may terminate the Opus Credit Facility upon notice to the Lenders and payment of all outstanding obligations under the Credit Facility Agreement. Notwithstanding any early termination of the Credit Facility Agreement, within 15 days after termination of the Commitment Period, Fortress will issue each Lender warrants (each a “Warrant”) pursuant to the terms of the Credit Facility Agreement and form of Warrant to purchase their pro rata share of (a) 1,500,000 3.00 As of December 31, 2016, $ 7.0 2.0 Avenue Convertible Notes On December 31, 2016, Avenue held the first closing of the sale of convertible promissory notes (the “ Avenue Notes 18 5 8 10.0 (a) the lowest price per share at which equity securities of Avenue are sold in such sale less a 33% discount and (b) a per share price based on a pre-offering valuation of $30.0 million divided by the number of common shares outstanding on a fully-diluted basis. Gross proceeds from this offering totaled $ 0.2 0.1 58,000 10,000 10 44,000 4,000 Avenue Warrants 10,000 Due to the complexity and number of embedded features within each convertible note, and as permitted under accounting guidance, the Company elected to account for the convertible notes and all the embedded features (collectively, the “ hybrid instrument At December 31, 2016 Avenue had $ 0.2 IDB Letters of Credit The Company has several letters of credit (“ LOC 1.5 2 Interest Expense For the Years Ended December 31, ($ in thousands) 2016 2015 2014 IDB Note Interest $ 328 $ 314 $ 292 Amortization of fees 1 5 4 Total IDB Note 329 319 296 NSC Debt Interest 599 690 - Amortization of fees 1,270 309 - Total NSC Debt 1,869 999 - Opus Credit Facility Interest 192 - - Amortization of fees 195 - - Total Opus Note 387 - - Ovamed Interest - 166 154 Total Ovamed - 166 154 LOC Fees Interest 11 - - Total LOC 11 - - Helocyte Convertible Note Interest 61 - - Financing fee 962 - - Total Helocyte Convertible Note 1,023 - - Avenue Convertible Note Financing fee 70 - - Total Avenue Convertible Note 70 - - Hercules Debt Interest (1) - - 845 Amortization of fees - - 43 Total Hercules Debt - - 888 D&O Insurance Interest 1 - - Total D&O Insurance 1 - - Total Interest Expense and Financing Fee $ 3,690 $ 1,484 $ 1,338 (1) Interest expense related to the Company’s loan with Hercules was $ 0.8 0.4

Accrued Liabilities and other L

Accrued Liabilities and other Long-Term Liabilities	12 Months Ended
	Dec. 31, 2016
Payables and Accruals [Abstract]
Accrued Liabilities and other Long-Term Liabilities	12. Accrued Liabilities and other Long-Term Liabilities In December 2012, the Company acquired certain manufacturing rights from Ovamed and agreed to pay an aggregate of $ 1.5 0.5 1.1 0.9 0.2 0.2 The Company also had a collaboration agreement with Dr. Falk Pharma (“Falk”) in connection with the development of TSO. Under this agreement, Falk was to provide the Company with the Final Clinical Study Report (“CSR”). On August 3, 2015, Falk notified the Company that the CSR was complete and that access to the CSR was available. While the Company disputes the adequacy of the CSR and does not believe any payment is due to Falk, upon receipt of access to the CSR, the Company recorded a liability of € 2.5 2.6 December 31, ($ in thousands) 2016 2015 Accrued expenses: Professional fees $ 1,253 $ 382 Salaries, bonuses and related benefits 2,846 2,492 Accrued Severance 53 Ovamed manufacturing rights - short term component 900 2,007 Research and development 394 303 Dr. Falk Pharma milestone 2,634 2,717 JMC accrued cost of goods sold 726 - Lease impairment 128 146 Other 1,148 523 Total accrued expenses $ 10,082 $ 8,570 Other long-term liabilities: Deferred rent and long-term lease abandonment charge 5,014 584 Total other long-term liabilities $ 5,014 $ 584 September 30, 2016 Legal $ 1,346 Audit 198 Telecommunications 209 Data Services 425 Regulatory 444 Settlements 832 Deferred rent 65 Contingent consideration payable 424 Other 3,223 Total $ 7,166

Non-Controlling Interests

Non-Controlling Interests	12 Months Ended
	Dec. 31, 2016
Noncontrolling Interest [Abstract]
Non-Controlling Interests	13. Non-Controlling Interests As of December 31, 2016 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Helocyte Cellvation National Holdings Total NCI equity share $ (494) $ (217) $ 12,376 $ 32,160 $ (192) $ (612) $ 4 $ 17,643 $ 60,668 Net loss attributed to non-controlling interests (349) (19) (1,805) (11,733) (355) (1,155) (158) (621) (16,195) Non-controlling interests in consolidated entities $ (843) $ (236) $ 10,571 $ 20,427 $ (547) $ (1,767) $ (154) $ 17,022 $ 44,473 ($ in thousands) As of December 31, 2015 Avenue Coronado SO Mustang Checkpoint JMC Total NCI equity share $ 6 $ 23 $ 14 $ 32,760 $ 79 $ 32,882 Net loss attributed to non-controlling interests (567) (240) (373) (3,855) (420) (5,455) Non-controlling in interests consolidated entities $ (561) $ (217) $ (359) $ 28,905 $ (341) $ 27,427 For the year ended December 31, 2016 ($ in thousands) Avenue Coronado SO Mustang Checkpoint (1) JMC Helocyte Cellvation National Holdings Total Non-controlling interests in loss of consolidated entities $ (349) $ (19) $ (1,805) $ (11,733) $ (355) $ (1,155) $ (158) $ (621) $ (16,195) Non-controlling ownership 10.2 % 13.0 % 26.7 % 62.9 % 7.0 % 20.5 % 22.0 % 43.4 % (1) Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights. ($ in thousands) For the year ended December 31, 2015 Avenue Coronado SO Mustang Checkpoint JMC Total Non-controlling interests in loss of consolidated entities $ (567) $ (240) $ (373) $ (3,855) $ (420) $ (5,455) Non-controlling ownership 11.5 % 13 % 10 % 62.3 %(1) 8.8 %

Net Loss per Common Share

Net Loss per Common Share	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Net Loss Per Common Share	14. Net Loss per Common Share The Company calculates loss per share using the two-class method, which is an earnings allocation formula that determines earnings per share for Common Stock and participating securities, if any, according to dividends declared and non-forfeitable participation rights in undistributed earnings. Under this method, all earnings (distributed and undistributed) are allocated to Common Stock and participating securities, if any, based on their respective rights to receive dividends. Holders of restricted Common Stock were entitled to all cash dividends, when and if declared, and such dividends are non-forfeitable. The participating securities do not have a contractual obligation to share in any losses of the Company. As a result, net losses are not allocated to the participating securities for any periods presented. Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of Common Stock outstanding during the period, without consideration for Common Stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of Common Stock and Common Stock equivalents outstanding for the period. Included in Common Stock issued and outstanding as of December 31, 2016, 2015 and 2014 were 8,749,052 6,816,321 6,087,717 The Company’s potential dilutive securities which consist of unvested restricted stock, unvested restricted stock units, options, and warrants have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average Common Stock outstanding used to calculate both basic and diluted net loss per share is the same. For the Years Ended December 31, 2016 2015 2014 Warrants to purchase Common Stock 456,150 685,061 693,636 Opus warrants to purchase Common Stock 1,780,000 - - Options to purchase Common Stock 1,604,214 1,960,443 2,276,813 Unvested Restricted Stock 8,749,052 6,816,321 6,087,717 Unvested Restricted Stock Units 1,087,563 427,627 - Total 13,676,979 9,889,452 9,058,166

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Stockholders’ Equity	15. Stockholders' Equity Common Stock The Company’s Certificate of Incorporation, as amended, authorizes the Company to issue 15,000,000 0.001 100,000,000 0.001 The terms, rights, preference and privileges of the Common Stock are as follows: Voting Rights Each holder of Common Stock is entitled to one vote per share of Common Stock held on all matters submitted to a vote of the stockholders, including the election of directors. The Company’s certificate of incorporation and bylaws do not provide for cumulative voting rights. Dividends Subject to preferences that may be applicable to any then outstanding preferred stock, the holders of the Company’s outstanding shares of Common Stock are entitled to receive dividends, if any, as may be declared from time to time by the Company’s Board of Directors out of legally available funds. Liquidation In the event of the Company’s liquidation, dissolution or winding up, holders of Common Stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of the Company’s debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any outstanding shares of Preferred Stock. Rights and Preference Holders of the Company’s Common Stock have no preemptive, conversion or subscription rights, and there is no redemption or sinking fund provisions applicable to our Common Stock. The rights, preferences and privileges of the holders of Common Stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of the Company’s preferred stock that are or may be issued. Fully Paid and Nonassessable All of the Company’s outstanding shares of Common Stock are fully paid and nonassessable. Stock-Based Compensation including National As of December 31, 2016, the Company had four equity compensation plans: the Fortress Biotech, Inc. 2007 Stock Incentive Plan (the “ 2007 Plan 2013 Plan ESPP LTIP 6,000,000 7,700,000 10,000,000 The purpose of the Company’s equity compensation plans is to provide for equity awards as part of an overall compensation package of performance-based rewards to attract and retain qualified personnel. Such awards include, without limitation, options, stock appreciation rights, sales or bonuses of restricted stock, restricted stock units or dividend equivalent rights, and an award may consist of one such security or benefit, or two or more of them in any combination or alternative. Vesting of awards may be based upon the passage of time, the occurrence of one or more events, or the satisfaction of performance criteria or other conditions. An aggregate of 9,978,201 6,021,799 Incentive and nonstatutory stock options are granted pursuant to option agreements adopted by the plan administrator. Options generally have 10 The Company estimates the fair value of stock option grants using a Black-Scholes option pricing model. In applying this model, the Company uses the following assumptions: • Risk-Free Interest Rate: • Volatility: • Expected Term: • Expected Dividend Rate: The fair value of each option award was estimated on the grant date using the Black-Scholes option-pricing model and expensed under the straight line method. Journey issued stock options during the years ended December 31, 2016 and 2015. The fair value for non-employee stock based awards are marked-to-market on each valuation date until vested using the Black-Scholes pricing model. For the Years Ended December 31, ($ in thousands) 2016 2015 2014 Employee awards $ 7,386 $ 8,130 $ 5,492 Executive awards of Fortress Companies' stock - 2,228 - Non-employee awards 33 33 54 Fortress Companies (1), (2) 4,709 3,900 - Total stock-based compensation expense $ 12,128 $ 14,291 $ 5,546 (1) Consists of approximately $ 28,000 3.9 0.5 0.3 7,000 42,000 (2) Consists of approximately $ 50,400 3.3 0.6 In February 2016, the Company modified the vesting schedule on the 1.9 3.9 0.4 For the years ended December 31, 2016, 2015 and 2014, $ 4.7 5.8 1.1 7.4 8.5 4.4 Options Total weighted Weighted average Weighted average average intrinsic remaining contractual Number of shares exercise price value life (years) Options vested and expected to vest at December 31, 2015 1,779,365 $ 4.37 $ 666,396 6.32 Forfeited (648,864) 0.51 - - Options vested and expected to vest at December 31, 2016 1,130,501 $ 3.73 $ 602,451 4.93 Exercisable as of December 31, 2016 1,105,501 $ 3.71 $ 602,451 4.91 During the years ended December 31, 2016 and 2015, exercises of stock options resulted in total proceeds of approximately nil and $ 0.2 Restricted Stock Stock-based compensation expense from restricted stock awards and restricted stock units for the years ended December 31, 2016, 2015, 2014 was $ 9.9 6.9 4.0 During 2014, the Company granted 4,343,692 11.6 Senior Vice President (“SVP”) Grant On July 15, 2015, the Company’s SVP, Biologics Operations, was granted 1.0 50 200,000 3.3 0.4 3.7 150,000 300,000 1.9 Acceleration of Grants to Former Director On July 15, 2015, the Board of Directors accelerated the vesting of 133,000 0.4 Restricted Stock Unit Grant to a Current Director During 2016, the Company granted 1,240,868 641,000 3.4 1.8 On July 15, 2015, a Director joined the Board of Directors. In connection therewith, Fortress granted the Director 50,000 25 40,000 Weighted average Number of shares grant price Unvested balance at December 31, 2015 8,757,935 $ 2.47 Restricted stock granted 1,240,868 2.77 Restricted stock cancelled (33,333) 2.69 Restricted stock vested (173,333) 2.73 Restricted stock units granted 641,000 2.93 Restricted stock units cancelled (111,750) 3.58 Restricted stock units vested (227,292) 3.56 Unvested balance at December 31, 2016 10,094,095 $ 2.49 As of December 31, 2016, the Company had unrecognized stock-based compensation expense related to all unvested restricted stock and restricted stock unit awards of $ 4.1 2.2 2.0 Deferred Compensation Plan On March 12, 2015, the Company’s Compensation Committee approved the Deferred Compensation Plan allowing all non-employee directors the opportunity to defer all or a portion of their fees or compensation, including restricted stock and restricted stock units. During the year ended December 31, 2016, certain non-employee directors elected to defer an aggregate of 230,000 Employee Stock Purchase Plan Eligible employees can purchase the Company’s Common Stock at the end of a predetermined offering period at 85 On June 2, 2014, the Company issued 7,139 1.45 85 1.71 6,841 1.80 85 2.12 On June 1, 2015, the Company issued 14,681 1.80 85 2.12 13,317 2.41 85 2.84 On June 1, 2016, the Company issued 33,958 2.40 85 2.82 52,769 2.03 85 2.39 As of December 31, 2016, 177,919 22,081 0.1 45,000 25,000 Warrants Total weighted Weighted average Weighted average average intrinsic remaining contractual Number of shares exercise price value life (years) Outstanding as of December 31, 2015 569,835 $ 6.31 $ 120,700 1.84 Granted 1,880,000 3.00 - 5.65 Expired (161,382) 6.30 - - Exercised (*) (25,000) 1.37 33,250 - Outstanding as of December 31, 2016 2,263,453 $ 3.62 $ 79,800 4.74 Exercisable as of December 31, 2016 483,453 $ 5.88 $ 79,800 2.13 (*) - cashless All stock-based expense in connection with these warrants has been recognized prior to January 1, 2016. Long-Term Incentive Program (“LTIP”) On July 15, 2015, the stockholders approved the LTIP for the Company’s Chairman, President and Chief Executive Officer, Dr. Rosenwald, and Executive Vice Chairman, Strategic Development, Mr. Weiss. The LTIP consists of a program to grant equity interests in the Company and in the Company’s subsidiaries, and a performance-based bonus program that is designed to result in performance-based compensation that is deductible without limit under Section 162(m) of the Internal Revenue Code of 1986, as amended. 500,000 Exercise 2015 Warrant Shares Risk Free Rate Volatilty Life price Fair Value Mustang 1,000,000 2.36 % 106.11 % 10 $ 0.147 $ 135 Checkpoint 1,000,000 2.36 % 106.11 % 10 $ 0.129 $ 118 Avenue 1,000,000 2.36 % 106.11 % 10 $ 0.146 $ 134 CNDO SO 1,000,000 2.36 % 106.11 % 10 $ 1.190 $ 1,091 Helocyte 1,000,000 2.36 % 106.11 % 10 $ 0.097 $ 89 JMC 1,000,000 2.36 % 106.11 % 10 $ 0.650 $ 596 Escala 1,000,000 2.36 % 106.11 % 10 $ 0.071 $ 65 2016 Cellvation 1,000,000 2.86 % 70 % 9 $ 0.024 $ 18,075 The exercise price, which approximates the fair value, was determined by the Company utilizing a discounted cash flow model to determine the weighted market value of invested capital, discounted by a lack of marketability of 44.8 30 On January 1, 2016, the Compensation Committee granted 510,434 1 100.0 , Compensation - Stock Compensation, 2.8 0.3 Fortress Companies Checkpoint Therapeutics, Inc. Checkpoint has a long term incentive plan. In March 2015, Checkpoint issued a restricted stock grant to Dr. Marasco for services in connection with its Scientific Advisory Board. Dr. Marasco was issued a grant for 1.5 25 48 44.8 30 0.065 4.39 83 1.5 5.43 80 2.10 2.5 3.0 Certain Checkpoint employees and directors have been awarded restricted stock under Checkpoint’s 2015 Incentive Plan. Checkpoint recorded stock-based compensation expense of $ 1.4 0.3 During 2016, 60,000 5.43 100.65 2.6 10 5,500 Avenue Therapeutics, Inc. Avenue has a long term incentive program. During 2015, Avenue granted 150,000 1.0 100,000 0.176 17,600 44.8 30 0.146 50 12.5 50 14,000 29,000 14,000 21,000 Journey Medical Corporation During the year ended December 31, 2016, JMC granted 440,000 44.2 25.1 0.53 42.7 21.1 0.68 0 For the year ended December 31, 2016 Risk-free interest rate 1.14% - 2.25 % Expected dividend yield - Expected term in years 5.05 - 6.95 Expected volatility 96.89% - 105.48 % On July 28, 2015, JMC granted 1,950,000 44.5 30 0.65 On October 19, 2015, JMC repurchased 1,250,000 0.8 Fair Value RSU Grant Vesting Term Vested Forfeited Unvested per Share President 1,500,000 4 250,000 (1,250,000) - $ 0.650 Sales Operations Staff 450,000 4 116,666 - 333,334 $ 0.650 1,950,000 366,666 (1,250,000) 333,334 During the year ended December 31, 2016, stock-based compensation associated with the amortization of stock option expense was approximately $ 0.4 85,000 0.6 Helocyte, Inc. On March 30, 2016, Helocyte granted 150,000 508,333 127,084 0.46 68 1.3 70 1.47 0.59 0.2 On March 30, 2016, Helocyte granted 1.0 0.097 55,000 There were no stock-based compensation expenses recorded in 2015. Cellvation, Inc. On October 31, 2016, Cellvation granted 700,000 0.024 70 1.1 2,500 On October 31, 2016, Cellvation granted 1,000,000 4,000 There were no stock-based compensation expenses recorded in 2015. Capital Raise Checkpoint Therapeutics, Inc. On September 18, 2015, Checkpoint entered into a placement agency agreement with National Securities Corporation (the “Placement Agent”) relating to Checkpoint’s offering, issuance and sale (the “Offering”) to select institutional investors (the “Investors”) of units consisting of 10,000 0.0001 2,500 7.00 50,000 10.0 57.8 51.5 10,000 2,500 7.00 50,000 Following this capital raise, the Company’s ownership in Checkpoint decreased to 37.7 On February 23, 2016, Checkpoint closed on gross proceeds of $ 0.6 10,000 3,500 7.00 45,000 126,640 44,324 As of December 31, 2016, the Company determined that the warrants still did not meet the definition of a derivative and continued to qualify for equity recognition. Mustang Bio, Inc. In third and fourth quarter of 2016, Mustang closed on gross proceeds of $ 39.1 3.9 10 10,000 2,500 8.50 65,000 6.0 1.5 601,486 As of December 31, 2016, the Company determined that the warrants still did not meet the definition of a derivative and continued to qualify for equity recognition. At Market Offerings In May 2016, the Company issued 150,556 2.89 0.4 79,000 On August 17, 2016, the Company entered into an Amended and Restated At Market Issuance Sales Agreement, or Sales Agreement, with MLV & Co. LLC, or MLV, and FBR Capital Markets & Co., or FBR. On August 18, 2016, the Company filed a Registration Statement on Form S-3, which became effective on December 1, 2016 and permits the Company to issue and sell shares of its common stock having an aggregate offering price of up to $ 53.0

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	16. Commitments and Contingencies Operating Lease Obligations - Fortress (excluding National) In July 2016, Journey extended its lease for one year for $ 2,295 53,000 In October 2015, the Company entered into a 5 6,100 0.2 15 2.7 10 45 0.3 1.1 1.3 In December 2012, we assumed a lease from TSO Laboratories, Inc., a wholly owned subsidiary of Ovamed GmbH, for approximately 8,700 February 28, 2018 0.1 In April 2013, the Company entered into a three-year lease for approximately 1,500 0.1 Pursuant to the Second Amendment and Agreement, dated as of December 21, 2012, by and between the Company and Ovamed (the “Manufacturing Agreement”), in December 2012, the Company entered into an Assignment and Assumption of Lease (“Assignment”) with TSO Laboratories, Inc., a wholly owned subsidiary of Ovamed, for approximately 8,700 0.6 0.1 0.4 Total future minimum lease payments under these leases are: ($ in thousands) 2017 $ 2,806 2018 2,692 2019 2,713 2020 2,754 2021 2,622 Beyond 27,261 Total minimum lease payments $ 40,848 The Company recognizes rent expense on a straight-line basis over the non-cancellable lease term. Rent expense for the years ended December 31, 2016, 2015 and 2014 was $ 1.8 0.4 0.3 Operating Lease Obligations - National Fiscal Year Ending Rental Expense Less, Sublease Income Net 2017 $ 2,774 $ 84 $ 2,690 2018 2,196 — 2,196 2019 1,524 — 1,524 2020 1,390 — 1,390 2021 1,092 — 1,092 Thereafter 2,232 — 2,232 Total $ 11,208 $ 84 $ 11,124 Rental expense under all operating leases for the period from September 9, 2016 through September 30, 2016 was approximately $ 0.2 8,200 As of September 30, 2016, National had outstanding three letters of credit, which have been issued in the maximum amount of $ 0.4 Indemnification In accordance with its certificate of incorporation, bylaws and indemnification agreements, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company’s request in such capacity. There have been no claims to date, and the Company has director and officer insurance to address such claims. Pursuant to agreements with clinical trial sites, the Company provides indemnification to such sites in certain conditions. Legal Proceedings Fortress In the ordinary course of business, the Company and its subsidiaries may be subject to both insured and uninsured litigation. Suits and claims may be brought against the Company by customers, suppliers, partners and/or third parties (including tort claims for personal injury arising from clinical trials of the Company’s product candidates and property damage) alleging deficiencies in performance, breach of contract, etc., and seeking resulting alleged damages. On August 1, 2016, the Company entered into a Settlement and Forbearance Agreement with Ovamed to settle contractual obligations of approximately $ 1.9 1.1 0.8 Mustang and Fortress On January 15, 2016, Dr. Winson Tang (“ Plaintiff 15 As of December 31, 2016, neither Fortress nor Mustang has accrued any losses in connection with this litigation as both believe that Plaintiff’s claims are without merit and intend to vigorously defend this lawsuit. Even in the event of an adverse determination, Fortress and Mustang intend to satisfy any judgment from sources other than newly issued shares of the Company or Mustang, in order to prevent dilution. Litigation and Regulatory Matters - National National is a defendant or respondent in various pending and threatened arbitrations, administrative proceedings and lawsuits seeking compensatory damages. Several cases have no stated alleged damages. Claim amounts are infrequently indicative of the actual amounts National will be liable for, if any. Further, National has a history of collecting amounts awarded in these types of matters from its brokers that are still affiliated, as well as from those that are no longer affiliated. Many of these claimants also seek, in addition to compensatory damages, punitive or treble damages, and all seek interest, costs and fees. These matters arise in the normal course of business. National intends to vigorously defend itself in these actions, and the ultimate outcome of these matters cannot be determined at this time. Liabilities for potential losses from complaints, legal actions, government investigations and proceedings are established where management believes that it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. In making these decisions, management bases its judgments on its knowledge of the situations, consultations with legal counsel and its historical experience in resolving similar matters. In many lawsuits, arbitrations and regulatory proceedings, it is not possible to determine whether a liability has been incurred or to estimate the amount of that liability until the matter is close to resolution. However, accruals are reviewed regularly and are adjusted to reflect management’s estimates of the impact of developments, rulings, advice of counsel and any other information pertinent to a particular matter. Because of the inherent difficulty in predicting the ultimate outcome of legal and regulatory actions, management cannot predict with certainty the eventual loss or range of loss related to such matters. These amounts are included in accounts payable and other accrued expenses in the statements of financial condition. Awards ultimately paid, if any, may be covered by our errors and omissions insurance policy. While National will vigorously defend itself in these matters, and will assert insurance coverage and indemnification to the maximum extent possible, there can be no assurance that such matters will not have a material adverse impact on our financial position, results of operations or cash flows. National has included in "Professional fees" litigation and FINRA related expenses of $ 0.2

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2016
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Employee Benefit Plans	17. Employee Benefit Plan Fortress Biotech, Inc. On January 1, 4 0.2 0.1 83,000 National Holdings Corporation In September 2011, National created a new defined contribution 401(k) plan (the “Plan”) merging the two plans originally formed prior to the merger of National and vFinance effective October 1, 2011. Under the Plan, employees can elect to defer up to 75

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Note	18. Related Party Transactions Other Related Parties The Company’s Chairman, President and Chief Executive Officer, individually and through certain trusts over which he has voting and dispositive control, beneficially owned approximately 12.3 12.2 12.4 14.5 14.8 14.9 Service Agreement with Opus Point Management Partners, LLC On April 3, 2014, the Company entered into a Shared Services Agreement with OPPM in which the parties agreed to share a rented facility as well as costs for certain services, which they individually require for the operation of their respective entities. The Company’s Chairman, President and Chief Executive Officer and the Company’s Executive Vice President, Strategic Development, are both Co-Portfolio Managers and Partners of OPPM. The Company incurred expense of approximately $ 84,000 24,000 0.1 Shared Services Agreement with TGTX In July 2015, TGTX and the Company entered into an arrangement to share the cost of certain research and development employees. The Company’s Executive Vice Chairman, Strategic Development, is Executive Chairman and Interim Chief Executive Officer of TGTX. Under the terms of the Agreement, TGTX will reimburse the Company for the salary and benefit costs associated with these employees based upon actual hours worked on TGTX related projects. For the year ended December 31, 2016, the Company invoiced TGTX $ 0.8 71,800 Desk Share Agreements with TGTX and OPPM In September 2014, the Company entered into Desk Share Agreements with OPPM and TGTX to occupy 20 40 0.5 1.1 45 10 Each initial Desk Share Agreement has a term of five years. The Company took possession of the New York, NY office space in December 2015, commenced build out of the space shortly thereafter and took occupancy of the space in April 2016. The Company expects the total build out costs to approximate $ 5.1 1.0 95 0.4 4.8 2.1 0.5 Checkpoint Collaborative Agreements with TGTX Checkpoint has entered into various agreements with TGTX to develop and commercialize certain assets in connection with its licenses, including a collaboration agreement for some of the Dana Farber licensed antibodies, an option agreement and sponsored research agreement for compounds licensed from NeuPharma, and a sublicense agreement for the Jubilant family of patents. Checkpoint believes that by partnering with TGTX to develop these compounds in therapeutic areas outside of its business focus, it may substantially offset its preclinical costs and milestone costs related to the development and marketing of these compounds in solid tumor indications. Opus Credit Facility On September 14, 2016, Fortress entered the Opus Credit Facility with OPHIF. Since Fortress’s Chairman, President and Chief Executive Officer and Fortress’s Executive Vice President, Strategic Development, are Co-Portfolio Managers and Partners of Opus, an affiliate of OPHIF, all of the disinterested directors of Fortress’s board of directors approved the terms of the Credit Facility Agreement and accompanying Pledge and Security Agreement and forms of Note and Warrant. Founders Agreement and Management Services Agreement with Checkpoint Effective March 17, 2015, the Company entered into a Founders Agreement with Checkpoint, which was amended and restated on July 11, 2016 (the “ Checkpoint Founders Agreement 2.8 Effective March 17, 2015, the Company entered into a Management Services Agreement (the “ Checkpoint MSA Services 0.5 Annual Consulting Fee 1.0 100.0 Founders Agreement and Management Services Agreement with Avenue Effective as of February 17, 2015, the Company entered into a Founders Agreement with Avenue, which was amended and restated on September 13, 2016 (the “ Avenue Founders Agreement PIK Dividend Payment Date PIK Dividends Effective as of February 17, 2015, the Company entered into a Management Services Agreement (the “ Avenue MSA 0.5 1.0 100.0 Founders Agreement and Management Services Agreement with Helocyte Effective March 20, 2015, the Company entered into a Founders Agreement with Helocyte, which was amended and restated as of September 14, 2016 (the “ Helocyte Founders Agreement NSC Note Effective March 20, 2015, the Company entered into a Management Services Agreement (the “ Helocyte MSA Founders Agreement and Management Services Agreement with Mustang Effective March 13, 2015, the Company entered a Founders Agreement with Mustang, which was amended and restated on May 17, 2016 and again on July 26, 2016 (the “ Mustang Founders Agreement PIK Dividend Payment Date PIK Dividends As additional consideration under the Mustang Founders Agreement, Mustang will also: (i) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Mustang or any of its respective subsidiaries that occurs after the effective date of the Mustang Founders Agreement and ending on the date when the Company no longer has majority voting control in Mustang’s voting equity, equal to two and one-half (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one-half percent (4.5%) of Mustang’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a Change in Control, Mustang will pay a one-time change in control fee equal to five (5x) times the product of (A) net sales for the twelve (12) months immediately preceding the change in control and (B) four and one-half percent (4.5%). Effective as of March 13, 2015, the Company entered into a Management Services Agreement (the “ Mustang MSA 0.5 Annual Consulting Fee 1.0 100.0 As consideration for the Mustang Founders Agreement, Mustang assumed $ 3.6 Founders Agreement and Management Services Agreement with Cellvation Effective October 31, 2016, the Company entered into a Founders Agreement with Cellvation (the “ Cellvation Founders Agreement PIK Dividend Payment Date PIK Dividends As additional consideration under the Cellvation Founders Agreement, Cellvation will also: (i) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Cellvation or any of its respective subsidiaries that occurs after the effective date of the Cellvation Founders Agreement and ending on the date when the Company no longer has majority voting control in Cellvation’s voting equity, equal to two and one-half (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one-half percent (4.5%) of Cellvation’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a Change in Control, Cellvation will pay a one-time change in control fee equal to five (5x) times the product of (A) net sales for the twelve (12) months immediately preceding the change in control and (B) four and one-half percent (4.5%). Effective October 31, 2016, the Company entered into a Management Services Agreement (the “ Cellvation MSA Services 0.5 Annual Consulting Fee 1.0 100.0 Fees and Stock Grants Received by Fortress Fees recorded in connection with the Company’s agreements with its subsidiaries are eliminated in consolidation. These include management services fees, issuance of common shares of Fortress Companies in connection with third party raises and annual stock dividend or issuances on the anniversary date of respective Founders Agreements. Chord Advisors, LLC In May 2015, we entered into a full service consulting agreement with Chord Advisors, LLC (“ Chord 10,000 5,000 7,500 National In September 2016, pursuant to the terms of the Merger Agreement between National and Fortress, the Company acquired 56.1 22.9 1.3 Additionally, the Company’s Chairman, President and Chief Executive Officer and the Company’s Executive Vice Chairman, Strategic Development are both Co-Portfolio Managers and Partners of OPPM which owns approximately 4.6

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	19. Income Taxes Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards. The significant components of the Company’s deferred taxes consist of the following: As of December 31, 2016 2015 Deferred tax assets: Net operating loss carryforwards $ 76,486 $ 54,249 Amortization of up-front fees 7,277 4,442 Amortization of in-process R&D 742 599 Stock compensation 10,899 8,158 Accruals and reserves 4,025 210 Tax Credits 6,305 4,583 Start Up Costs 98 - Unrealized loss on investments 1,095 358 Total deferred tax assets 106,927 72,599 Less valuation allowance (94,688) (66,730) Net deferred tax assets $ 12,239 $ 5,869 Deferred tax liabilities: Intangibles $ (4,449) $ - Basis in subsidiary (7,790) (5,869) Total deferred tax assets, net $ - $ - For the Year Ended December 31, 2016 2015 2014 Percentage of pre-tax income: U.S. federal statutory income tax rate 35 % 35 % 35 % State taxes, net of federal benefit 3 % 5 % 5 % Credits 2 % 1 % 6 % Non-deductible items (4) % - % (1) % Provision to return 2 % - % - % Stock based compensation shortfall (2) % (1) % - % Other - % 1 % - % Change in valuation allowance (33) % (44) % (45) % Change in subsidiary basis (3) % 3 % - % Effective income tax rate - % - % - % ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of all positive and negative evidence, it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. Realization of the deferred tax assets is substantially dependent on the Company’s ability to generate sufficient taxable income within certain future periods. Management has considered the Company’s history of cumulative tax and book losses incurred since inception, and the other positive and negative evidence, and has concluded that it is more likely than not that the Company will not realize the benefits of the net deferred tax assets as of December 31, 2015 and December 31, 2016. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December 31, 2015 and December 31, 2016. The valuation allowance increased by a net $ 28.0 The Company has incurred net operating losses (“NOLs”) since inception. At December 31, 2016, the Company had federal NOLs of $ 197.5 189.5 6.3 As of December 31, 2016, the Company had no unrecognized tax benefits and does not anticipate any significant change to the unrecognized tax benefit balance. The Company would classify interest and penalties related to uncertain tax positions as income tax expense, if applicable. There was no interest expense or penalties related to unrecognized tax benefits recorded through December 31, 2016. The NOLs from tax years 2006 through 2016 remain open to examination (and adjustment) by the Internal Revenue Service and state taxing authorities. In 2016, as a result of the acquisition of National, the Company acquired $ 0.4 8.8 8.8 3.2 Checkpoint is not consolidated with the Company for federal income tax purposes; therefore, its federal NOLs (and other federal tax attributes) are not available to offset the federal taxable income or federal tax liability of the Company or other members of the Company’s consolidated group. In December 2015, Checkpoint experienced an ownership change as a result of an issuance of its common stock and its NOLs (and other tax attributes) are subject to applicable 382 Limitations (and similar state provisions).

Net Capital Requirements of Bro

Net Capital Requirements of Broker-Dealer Subsidiaries	12 Months Ended
	Dec. 31, 2016
Brokers and Dealers [Abstract]
Net Capital Requirements of Broker-Dealer Subsidiaries	20 . Net Capital Requirements of Broker-Dealer Subsidiaries National Securities is subject to the SEC’s Uniform Net Capital Rule (Rule 15c3-1), which, among other things, requires the maintenance of minimum net capital. In February 2015, pursuant to a directive form FINRA, National Securities reverted back to using the alternative method of computing net capital from the aggregate indebtedness method. At September 30, 2016, National Securities had net capital of $ 6.2 6.0 250,000 vFinance Investments is also subject to the SEC’s Uniform Net Capital Rule (Rule 15c3-1), which, among other things, requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. At December 31, 2016, vFinance Investments had net capital of $ 2.2 1.2 1.0 0.8 1 Advances, dividend payments and other equity withdrawals from its Broker-Dealer Subsidiaries are restricted by the regulations of the SEC, and other regulatory agencies. These regulatory restrictions may limit the amounts that a subsidiary may dividend or advance to the Company.

Off Balance Sheet Risk and Conc

Off Balance Sheet Risk and Concentrations of Credit Risk	12 Months Ended
	Dec. 31, 2016
Risks and Uncertainties [Abstract]
Off Balance Sheet Risk and Concentrations of Credit Risk	21. Off Balance Sheet Risk and Concentrations of Credit Risk National is engaged in trading and providing a broad range of securities brokerage and investment services to a diverse group of retail and institutional clientele, as well as corporate finance and investment banking services to corporations and businesses. Counterparties to National’s business activities include broker-dealers and clearing organizations, banks and other financial institutions. National uses clearing brokers to process transactions and maintain customer accounts for National on a fee basis. National permits the clearing firms to extend credit to its clientele secured by cash and securities in the client’s account. National’s exposure to credit risk associated with the non-performance by its customers and counterparties in fulfilling their contractual obligations can be directly impacted by volatile or illiquid trading markets, which may impair the ability of customers and counterparties to satisfy their obligations to National. National has agreed to indemnify the clearing brokers for losses they incur while extending credit to National’s clients. It is National’s policy to review, as necessary, the credit standing of its customers and counterparties. Amounts due from customers that are considered uncollectible by the clearing broker are charged back to National by the clearing broker when such amounts become determinable. Upon notification of a charge back, such amounts, in total or in part, are then either (i) collected from the customers, (ii) charged to the broker initiating the transaction and/or (iii) charged to operations, based on the particular facts and circumstances. National maintains cash in bank deposits, which, at times, may exceed federally insured limits. National has not experienced and does not expect to experience losses on such accounts. A short sale involves the sale of a security that is not owned in the expectation of purchasing the same security (or a security exchangeable) at a later date at a lower price. A short sale involves the risk of a theoretically unlimited increase in the market price of the security that would result in a theoretically unlimited loss.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Segment Information	22. Segment Information The Company operates in three reportable segments, Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development and National. The accounting policies of the Company’s segments are the same as those described in Note 2. Dermatology Pharmaceutical and Products Biotechnology Year Ended December 31, 2016 Sales Product Development National Consolidated Net Revenue $ 3,587 $ 2,570 $ 10,323 $ 16,480 Direct cost of goods (790) - - (790) Sales and marketing costs (5,774) - - (5,774) Research and development - (35,134) - (35,134) General and administrative (1,474) (26,755) - (28,229) National expenses (11,754) (11,754) Segment loss from operations $ (4,451) $ (59,319) $ (1,431) $ (65,201) Segment assets $ 4,469 $ 115,145 $ 38,220 $ 157,834 Dermatology Pharmaceutical and Products Biotechnology Year Ended December 31, 2015 Sales Product Development National Consolidated Net Revenue $ 273 $ 590 $ - $ 863 Direct cost of goods - ) - - - ) Sales and marketing costs (2,850) - - (2,850) Research and development - (29,810) - (29,810) General and administrative (1,682) (17,052) - (18,734) Segment loss from operations $ (4,259) $ (46,272) $ - $ (50,531) Segment assets $ 1,965 $ 116,542 $ - $ 118,610 Corporate pre-tax loss consists of certain expenses that have not been allocated to reportable segments. Significant Customers For the year ended December 31, 2016, three of the Company’s customers accounted for more than 10.0% of its total gross revenue in the amount of $ 1.9 $ 1.1 $ 0.7 At December 31, 2016, two of the Company’s customers accounted for more than 10.0% of its total accounts receivable balance in the amount of $ 1.1 0.5 Net Revenue from Pharmaceutical and Biotechnology Product Development represents collaboration revenue from TGTX in connection with Checkpoint, which is classified as related party revenue.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	23. Subsequent Events Fortress Opus Credit Facility Agreement Since December 31, 2016 through March 16, 2017, the Company requested additional advances totaling $ 2.0 Mustang City of Hope Amended & Restated License Agreements In March 2015, Mustang entered into an Exclusive License Agreement with COH (the “ Original COH License IV/ICV Agreement On February 17, 2017, Mustang entered into an exclusive license agreement (the “ IV/ICV Agreement 0.1 0.1 Private Placement Financing On January 31, 2017, Mustang completed the final closing of its private placement raising gross proceeds of $ 55.5 5.5 10 853,667 10 10,000 2,500 8.50 65,000 8,536,774 2,134,193 40 COH Issuance of Shares In February 2017, Mustang issued 293,588 5.73 1.7 Advisory Agreement with Caribe BioAdvisors, LLC, a Related Party On December 30, 2016, Mustang’s board of directors unanimously approved and authorized the execution of an advisory agreement dated January 1, 2017 (the “ Advisory Agreement Advisor 60,000 Cyprium Effective March 10, 2017, the Company and Cyprium entered into a Founders Agreement and a Management Services Agreement. On March 13, 2017, Cyprium entered into a Cooperative Research and Development Agreement (CRADA) with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (“ NICHD Caelum Effective January 1, 2017, the Company and Caelum entered into a Founders Agreement and a Management Services Agreement. On January 1, 2017, Caelum also entered into an Exclusive License Agreement with Columbia University to secure worldwide license rights to CAEL-101 (11-1F4), a chimeric fibril-reactive monoclonal antibody (mAb) being evaluated in a Phase 1a/1b study for the treatment of amyloid light chain amyloidosis. Checkpoint On December 30, 2016, Checkpoint’s board of directors unanimously approved and authorized the execution of an advisory agreement dated January 1, 2017 (the “Advisory Agreement”) with Caribe BioAdvisors, LLC (the “Advisor”), owned by Michael S. Weiss, the Chairman of the Board of Checkpoint, to provide the board advisory services of Mr. Weiss as Chairman of the Board. Pursuant to the Advisory Agreement, the Advisor will be paid an annual cash fee of $60,000, in addition to any and all annual equity incentive grants paid to members of the Board of Checkpoint.

Selected Quarterly Financial Da

Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information	24. Selected Quarterly Financial Data (Unaudited) (in thousands, except per share data) First Quarter Second Quarter Third Quarter Fourth Quarter 2016 Total Revenue $ 660 $ 2,230 $ 975 $ 14,405 Operating expenses $ (15,571) $ (17,042) $ (17,180) $ (32,217) Other income/(expense) $ (1,552) $ (1,253) $ (710) $ (2,065) Non-controlling interests $ 4,438 $ 3,911 $ 3,975 $ 3,871 Net loss attributable to common stockholders $ (12,205) $ (12,478) $ (12,981) $ (17,431) Basic and diluted net loss per common share $ (0.31) $ (0.31) $ (0.32) $ (0.43) 2015 Total Revenue $ 500 $ - $ 25 $ 338 Operating expenses $ (12,571) $ (7,762) $ (18,097) $ (12,964) Other income/(expense) $ (464) $ 1,344 $ (1,783) $ (2,449) Non-controlling interests $ 479 $ 243 $ 1,694 $ 3,039 Net loss attributable to common stockholders $ (12,056) $ (6,175) $ (18,161) $ (12,036) Basic and diluted net loss per common share $ (0.31) $ (0.16) $ (0.46) $ (0.30)

Summary of Significant Accoun31

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“ GAAP The accompanying consolidated financial statements include the accounts of the Company’s subsidiaries. For consolidated entities where the Company owns less than 100% of the subsidiary, the Company records net loss attributable to non-controlling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. The Company also consolidates subsidiaries in which it owns less than 50% of the subsidiary but maintains voting control. The National assets acquired and liabilities assumed and revenues and expenses are reported on a one quarter lag. Therefore, the National assets acquired and liabilities assumed included in these consolidated financial statements as of December 31, 2016 are actually the assets acquired and liabilities assumed as of September 30, 2016 and the revenues and expenses included in these consolidated financial statements for the year ended December 31, 2016 are actually the revenues and expenses for the period from September 10, 2016 through September 30, 2016.
Use of Estimates	Use of Estimates The Company’s consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.
Fair Value Measurement	Fair Value Measurement The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Certain of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities. The carrying value of the amount owed to Ovamed GmbH (“ Ovamed
Segment Reporting	Segment Reporting Consistent with the increase in Journey’s operations as of April 1, 2016 and the investment in National as of September 9, 2016, the Company now operates in three operating and reportable segments, Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development and National. Intercompany revenue at National related to the Mustang raise of $ 1.3
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at December 31, 2016 and at December 31, 2015 consisted of cash, money market funds and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities.
Property and Equipment	Property and Equipment Office equipment is recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset. Leasehold improvements are amortized over the shorter of the estimated useful lives or the term of the respective leases.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. During the year ended December 31, 2014, in connection to the abandonment of its lease in Woburn, MA, the Company recorded an impairment loss of $ 0.4
Restricted Cash	Restricted Cash The Company records cash held in trust or pledged to secure certain debt obligations as restricted cash. As of December 31, 2016 and 2015, the Company has $ 15.9 14.6 14.9 14.0 0.6
Inventories	Inventories Inventories comprise finished goods, which are valued at the lower of cost or market, on a first-in, first-out basis. The Company evaluates the carrying value of inventories on a regular basis, taking into account anticipated future sales compared with quantities on hand, and the remaining shelf life of goods on hand.
Accounts Receivable	Accounts Receivable Accounts receivable consists of amounts due to the Company for product sales from JMC. The Company’s accounts receivable reflects discounts for estimated early payment and for product estimated returns. Accounts receivable are stated at amounts due from customers, net of an allowance for doubtful accounts. Accounts that are outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due and the customer’s current ability to pay its obligation to the Company. The Company writes off accounts receivable when they become uncollectible. Accounts receivable are net of allowance for doubtful accounts of nil and nil, at December 31, 2016 and December 31, 2015, respectively.
Investments at Fair Value	Investments at Fair Value The Company elects the fair value option for its long-term investments at fair value (see Note 7). The decision to elect the fair value option, which is irrevocable once elected, is determined on an instrument by instrument basis and applied to an entire instrument. The net gains or losses, if any, on an investment for which the fair value option has been elected are recognized as a change in fair value of investments on the Consolidated Statements of Operations. The Company has various processes and controls in place to ensure that fair value is reasonably estimated. While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.
Fair Value Option	As permitted under the Financial Accounting Standards Board (“FASB”), Accounting Standards Codification (“ASC”) 825, Financial Instruments,
Accounting for Warrants at Fair Value	Accounting for Warrants at Fair Value The Company classifies as liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The fair value of warrants that include price protection reset provision features are deemed to be “down-round protection” and, therefore, do not meet the scope exception for treatment as a derivative under ASC 815, Derivatives and Hedging The Company assessed the classification of warrants issued, in connection with the Helocyte and Avenue convertible note financings in 2016 (the “ Helocyte and Avenue Warrants
Credit Facility With Detachable Warrant	The Company accounts for the Opus Credit Facility with detachable warrants in accordance with ASC 470, Debt The Company recorded the related issue costs and value ascribed to the warrants as a debt discount of the Opus Credit Facility. The discount is amortized utilizing the effective interest method over the term of the Opus Credit Facility. The unamortized discount, if any, upon repayment of the Opus Credit Facility will be expensed to interest expense. In accordance with ASC Subtopic 470-20, the Company determined the weighted average effective interest rate of the debt was approximately 39 Derivatives and Hedging
Issuance of Debt and Equity	The Company issues complex financial instruments which include both equity and debt features. The Company analyzes each instrument under ASC 480, Distinguishing Liabilities from Equity, Derivatives and Hedging Debt
Valuation of Warrants Related to NSC Note	Valuation of Warrants Related to NSC Note In accordance with ASC 815, the Company classified the fair value of the warrants granted in connection with the NSC Note transferred to Avenue effective February 2015 (the “Contingently Issuable Warrants”) as a derivative liability. The Company valued these Contingently Issuable Warrants using an option pricing model and used estimates for an expected dividend yield, a risk-free interest rate, and expected volatility together with management’s estimate of the probability of issuance of the Contingently Issuable Warrants. At each reporting period, as long as the Contingently Issuable Warrants are potentially issuable and there is a potential for an insufficient number of authorized shares available to settle the Contingently Issuable Warrants, these Contingently Issuable Warrants will be revalued, and any difference from the previous valuation date will be recognized as a change in fair value of derivative liabilities in the Consolidated Statements of Operations.
Recognizing Assets Acquired and Liabilities Assumed in a Business Combination	Acquired assets and assumed liabilities are recognized in a business combination on the basis of their fair values at the date of acquisition. The Company assesses fair value, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, using a variety of methods including income approaches such as present value techniques or cost approaches such as the estimation of current selling prices and replacement values. Fair value of the assets acquired and liabilities assumed, including intangible assets, are measured based on the assumptions and estimations with regards to the variable factors such as the amount and timing of future cash flows for the asset or liability being measured, appropriate risk-adjusted discount rates, nonperformance risk, or other factors that market participants would consider. Upon acquisition, the Company determines the estimated economic lives of the acquired intangible assets for amortization purposes, which are based on the underlying expected cash flows of such assets.
Goodwill, Intangible Assets and Long Lived Assets	Goodwill, Intangible Assets and Long Lived Assets Goodwill represents the excess acquisition cost over the fair value of net tangible and intangible assets acquired. Goodwill is not amortized and is subject to annual impairment testing on October 1st or between annual tests if an event or change in circumstance occurs that would more likely than not reduce the fair value of a reporting unit below its carrying value. In testing for goodwill impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances lead to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, the Company concludes that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is not required. If the Company concludes otherwise, it is required to perform the two-step impairment test. The goodwill impairment test is performed at the reporting unit level by comparing the estimated fair value of a reporting unit with its respective carrying value. If the estimated fair value exceeds the carrying value, goodwill at the reporting unit level is not impaired. If the estimated fair value is less than carrying value, further analysis is necessary to determine the amount of impairment, if any, by comparing the implied fair value of the reporting unit's goodwill to the carrying value of the reporting unit’s goodwill. The fair value of reporting units is based on widely accepted valuation techniques that the Company believes market participants would use, although the valuation process requires significant judgment and often involves the use of significant estimates and assumptions. The methodologies the Company utilizes in estimating the fair value of reporting units include market valuation methods that incorporate price-to-earnings and price-to-book multiples of comparable exchange traded companies and multiples of merger and acquisitions of similar businesses. The estimates and assumptions used in determining fair value could have a significant effect on whether or not an impairment charge is recorded and the magnitude of such a charge. Adverse market or economic events could result in impairment charges in future periods. Intangible assets deemed to have finite lives are amortized on a straight line basis over their estimated useful lives, where the useful life is the period over which the asset is expected to contribute directly, or indirectly, to its future cash flows. Intangible assets are reviewed for impairment on an interim basis when certain events or circumstances exist. For amortizable intangible assets, impairment exists when the carrying amount of the intangible asset exceeds its fair value. At least annually, the remaining useful life is evaluated. An intangible asset with an indefinite useful life is not amortized but assessed for impairment annually, or more frequently, when events or changes in circumstances occur indicating that it is more likely than not that the indefinite-lived asset is impaired. Impairment exists when the carrying amount exceeds its fair value. In testing for impairment, the Company has the option to first perform a qualitative assessment to determine whether it is more likely than not that an impairment exists. If it is determined that it is not more likely than not that an impairment exists, a quantitative impairment test is not necessary. If the Company concludes otherwise, it is required to perform a quantitative impairment test. To the extent an impairment loss is recognized, the loss establishes the new cost basis of the asset that is amortized over the remaining useful life of that asset, if any. Subsequent reversal of impairment losses is not permitted. Long-lived assets, primarily fixed assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.
Deferred Financing Costs	Deferred Financing Costs Financing costs incurred in connection with the note in favor of National Securities Corporation’s NSC Biotech Venture Fund I LLC (the “NSC Note”) are recorded as a reduction of principal balance due to ASU No. 2015-3 and are amortized over the appropriate expected life based on the term of the NSC Note using the effective interest rate method.
Revenue Recognition	Revenue Recognition The Company recognizes revenue for the performance of services or the shipment of products when each of the following four criteria is met: (i) persuasive evidence of an arrangement exists; (ii) products are delivered or as services are rendered; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured. Collaborative Arrangements Checkpoint is paid by TGTX, a related party, a share of the cost of the license and future milestone payments that are payable to Dana-Farber Cancer Institute pursuant to the license agreement (see Note 8). Checkpoint is also paid by TGTX for the Sponsored Research Agreement between Checkpoint and NeuPharma (see Note 8). The gross amounts of these payments are reported as revenue in the accompanying Statements of Operations. Checkpoint acts as a principal, bears credit risk and may perform part of the services required in the transactions. Consistent with ASC 605-45-15 Revenue Recognition - Principal Agent Considerations The Company follows ASC 605-25, Revenue Recognition - Multiple-Element Arrangements ASC 605-25 Collaborative Arrangements ASC 605-25 provides guidance relating to the separability of deliverables included in an arrangement into different units of accounting and the allocation of arrangement consideration to the units of accounting. The evaluation of multiple-element arrangements requires management to make judgments about (i) the identification of deliverables, (ii) whether such deliverables are separable from the other aspects of the contractual relationship, (iii) the estimated selling price of each deliverable, and (iv) the expected period of performance for each deliverable. To determine the units of accounting under a multiple-element arrangement, management evaluates certain separation criteria, including whether the deliverables have stand-alone value, based on the relevant facts and circumstances for each arrangement. Management then estimates the selling price for each unit of accounting and allocates the arrangement consideration to each unit utilizing the relative selling price method. The allocated consideration for each unit of accounting is recognized over the related obligation period in accordance with the applicable revenue recognition criteria. If there are deliverables in an arrangement that are not separable from other aspects of the contractual relationship, they are treated as a combined unit of accounting, with the allocated revenue for the combined unit recognized in a manner consistent with the revenue recognition applicable to the final deliverable in the combined unit. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as deferred revenue in the Consolidated Balance Sheets and recognized as revenue in the Consolidated Statements of Operations when the related revenue recognition criteria are met. Revenue Recognition – Milestone Method The Company follows ASC 605-28, Revenue Recognition-Milestone Method JMC Product Revenue JMC sells its products directly to wholesalers and specialty pharmacies. JMC recognizes product sales revenue when delivery has occurred, collectability is reasonably assured, and the price to the buyer is fixed or determinable, (in accordance with the specific contractual terms). Delivery occurs when title has transferred to the customer, and the customer has assumed the risks and rewards of ownership. Revenue from product sales is recognized net of provisions for estimated cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to certain of JMC’s wholesale customers. JMC establishes these provisions concurrently with the recognition of product sales revenue. JMC offers cash discounts for prompt payment and allowances are recorded at the time of sale. JMC allows customers to return product within a specified period of time before and after its expiration date. Provisions for returns are estimated based on historical levels for like products from external data sources, taking into account additional available information such as historical return and exchange levels, and inventory levels in the wholesale distribution channel through its partners. Although the company has limited history with these product sales, the Company believes based on its current level of sales that it can make reasonable estimates of returns based upon external data sources. JMC reviews its methodology and adequacy of the provision for returns on a quarterly basis, adjusting for changes in assumptions, historical internal and external results and business practices, as necessary. JMC’s co-promotion revenue for Dermasorb HC is based upon prescription volume over an established baseline.
Research and Development	Research and Development Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company’s behalf will be expensed as services are rendered or when the milestone is achieved. Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations for preclinical and clinical studies, investigative sites for clinical trials, consultants, the cost of acquiring and manufacturing clinical trial materials, and costs associated with regulatory filings, laboratory costs and other supplies. In accordance with ASC 730-10-25-1, Research and Development
Contingencies	Contingencies The Company records accruals for contingencies and legal proceedings expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated. If a loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.
Stock-Based Compensation	Stock-Based Compensation The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates. For stock-based compensation awards to non-employees, the Company remeasures the fair value of the non-employee awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of these non-employee awards are recognized as compensation expense in the period of change. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model or 409A valuations, as applicable. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.
Income Taxes	Income Taxes The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if management believes it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50
Non-Controlling Interests	Non-Controlling Interests Non-controlling interests in consolidated entities represent the component of equity in consolidated entities held by third parties. Any change in ownership of a subsidiary while the controlling financial interest is retained is accounted for as an equity transaction between the controlling and non-controlling interests.
Comprehensive Loss	Comprehensive Loss The Company’s comprehensive loss is equal to its net loss for all periods presented.
Reclassifications	Reclassifications Certain prior period amounts may have been reclassified to conform to the current year presentation.
National [Member]
Use of Estimates	Use of Estimates The preparation of these financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Revenue Recognition	Revenue Recognition Commission revenue represents commissions generated by National's financial advisors for their clients' purchases and sales of mutual funds, variable annuities, general securities and other financial products, most of which is paid to the advisors as commissions for initiating the transactions. Commission revenue is generated from front-end sales commissions that occur at the point of sale, as well as trailing commissions. National recognizes front-end sales commission revenue and related clearing and other expenses on transactions introduced to its clearing brokers on a trade date basis. National also recognizes front-end sales commissions and related expenses on transactions initiated directly between the financial advisors and product sponsors upon receipt of notification from sponsors of the commission earned. Commission revenue also includes 12b-1 fees, and variable product trailing fees, collectively considered as trailing fees, which are recurring in nature. These trailing fees are earned by National based on a percentage of the current market value of clients' investment holdings in trail eligible assets. Because trail commission revenues are generally paid in arrears, management estimates commission revenues earned during each period. These estimates are based on a number of factors including investment holdings and the applicable commission rate and the amount of trail commission revenue received in prior periods. Estimates are subsequently adjusted to actual based on notification from the sponsors of trail commissions earned. Net dealer inventory gains, which are recorded on a trade-date basis, include realized and unrealized net gains and losses resulting from the National's principal trading activities. Investment banking revenues consist of underwriting revenues, advisory revenues and private placement fees. Underwriting revenues arise from securities offerings in which National acts as an underwriter and include management fees, selling concessions and underwriting fees, net of related syndicate expenses. Underwriting revenues are recorded at the time the underwriting is completed and the income is reasonably determined. Management estimates National’s share of the transaction-related expenses incurred by the syndicate, and recognizes revenues net of such expense. On final settlement, typically within 90 days from the trade date of the transaction, these amounts are adjusted to reflect the actual transaction-related expenses and the resulting underwriting fee. Investment advisory fees are derived from account management and investment advisory services. These fees are determined based on a percentage of the customers assets under management, may be billed monthly or quarterly and are recognized when earned. Interest is recorded on an accrual basis and dividends are recorded on the ex-dividend date. Transfer fees and fees for clearing services, which are recorded on a trade date basis, are principally charged to the broker on customer security transactions. Tax preparation and accounting fees are recognized upon completion of the services.
Principals of Consolidation	Principals of Consolidation The consolidated financial statements include the accounts of National and its wholly owned and majority owned subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation. In addition, National may consolidate entities which meet the definition of a variable interest entity for which National is the primary beneficiary. The primary beneficiary is the party who has the power to direct the activities of a variable interest entity that most significantly impact the entity’s economic performance and who has an obligation to absorb losses of the entity or a right to receive benefits from the entity that could potentially be significant to the entity. As of December 31, 2016 and 2015, National did not consolidate any variable interest entities .
Securities	Securities Securities owned and securities sold, but not yet purchased, are recorded at fair value. Authoritative accounting guidance defines fair value, establishes a framework for measuring fair value, and establishes a fair value hierarchy which prioritizes the inputs to valuation techniques. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A fair value measurement assumes that the transaction to sell the asset or transfer the liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market. Valuation techniques that are consistent with the market, income or cost approach are used to measure fair value. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three categories: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 Inputs other than quoted market prices that are observable, either directly or indirectly, and reasonably available. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of National. Level 3 Unobservable inputs which reflect the assumptions that National develops based on available information about what market participants would use in valuing the asset or liability.
Deferred Clearing and Marketing Credits	Deferred Clearing and Marketing Credits Deferred clearing credit represents a clearing fee rebate from National Financial Services (“NFS”), one of National’s clearing brokers, which is being recognized pro rata as a reduction of clearing charges over the term of the clearing agreement which expires in 2022. At September 30, 2016, the deferred clearing credit amounted to approximately $ 0.7 Deferred marketing credit represents a marketing rebate from NFS, which is being recognized pro rata as a reduction of marketing expenses over the term of the clearing agreement which expires in 2022. At September 30, 2016, the deferred marketing credit amounted to approximately $ 0.3
Reimbursement of Expenses	Reimbursement of Expenses The Company incurs certain costs on behalf of its financial advisors including those for insurance, professional registration, technology and information services and legal services, amongst others, which are charged back to the advisors. It is National’s policy to record the reimbursement as a reduction of the respective operating expense.
Legal Reserves	Legal Reserves In the normal course of business, National has been named, from time to time, as a defendant in legal and regulatory proceedings. National is also involved, from time to time, in other exams, investigations and similar reviews (both formal and informal) by governmental and self-regulatory agencies regarding its businesses, certain of which may result in judgments, settlements, fines, penalties or other injunctions. National recognizes a liability for a contingency in accrued expenses and other liabilities when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company accrues the most likely amount of such loss, and if such amount is not determinable, then the Company accrues the minimum in the range as the loss accrual. The determination of the outcome and loss estimates requires significant judgment on the part of management. National believes that any other matters for which it has determined a loss to be probable and reasonably estimable are not material to the consolidated financial statements. In many instances, it is not possible to determine whether any loss is probable or even possible or to estimate the amount of any loss or the size of any range of loss. National believes that, in the aggregate, the pending legal actions or regulatory proceedings and any other exams, investigations or similar reviews (both formal and informal) should not have a material adverse effect on the consolidated results of operations, cash flows or financial condition. In addition, National believes that any amount that could be reasonably estimated of potential loss or range of potential loss in excess of what has been provided in the consolidated financial statements is not material.
Recently Issued Accounting Standards	Adoption of Recent Accounting Pronouncements In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-03, Simplifying the Presentation of Debt Issuance Costs In August 2015, the FASB issued ASU No. 2015-15, Interest - Imputation of Interest: Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements Interest - Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The new guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The FASB has subsequently issued ASU No. 2016-10, Revenue from Contracts with Customers In January 2016, FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Liabilities In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”) . Under ASU 2016-09, companies will no longer record excess tax benefits and certain tax deficiencies in additional paid-in capital (“APIC”). Instead, they will record all excess tax benefits and tax deficiencies as income tax expense or benefit in the income statement and the APIC pools will be eliminated. In addition, ASU 2016-09 eliminates the requirement that excess tax benefits be realized before companies can recognize them. ASU 2016-09 also requires companies to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. Furthermore, ASU 2016-09 will increase the amount an employer can withhold to cover income taxes on awards and still qualify for the exception to liability classification for shares used to satisfy the employer’s statutory income tax withholding obligation. An employer with a statutory income tax withholding obligation will now be allowed to withhold shares with a fair value up to the amount of taxes owed using the maximum statutory tax rate in the employee’s applicable jurisdiction(s). ASU 2016-09 requires a company to classify the cash paid to a tax authority when shares are withheld to satisfy its statutory income tax withholding obligation as a financing activity on the statement of cash flows. Under current GAAP, it was not specified how these cash flows should be classified. In addition, companies will now have to elect whether to account for forfeitures on share-based payments by (1) recognizing forfeitures of awards as they occur or (2) estimating the number of awards expected to be forfeited and adjusting the estimate when it is likely to change, as is currently required. These aspects of ASU 2016-09 are effective for reporting periods beginning after December 15, 2016, with early adoption permitted provided that all of the guidance is adopted in the same period. The Company is currently evaluating the impact of ASU 2016-09 on its consolidated financial statements and related disclosures. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments, In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230) Restricted Cash The Company is currently in the process of evaluating the impact of this new pronouncement on its consolidated statements of cash flows. In January 2017, the FASB issued an ASU 2017-01, Business Combinations (Topic 805) Clarifying the Definition of a Business In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350)

National Holdings Corporation (

National Holdings Corporation (Tables)	12 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Schedule fair value of assets acquired and liabilities assumed at the date of the acquisition	The following table summarizes the preliminary fair value of assets acquired and liabilities assumed at the date of the acquisition ($ in thousands): Assets Cash and cash equivalents $ 27,498 Accounts receivable 4,889 Cash deposits with clearing organizations 1,030 Receivable from brokers, dealers and clearing agencies 1,607 Securities owned, at fair value 2,178 Prepaid expenses and other current assets 1,985 Property and equipment 1,132 Restricted cash 353 Intangible assets - trademark 3,000 Intangible assets - customer list 13,500 Goodwill 18,645 Total assets 75,817 Liabilities Accrued compensation payable $ 14,029 Accounts payable and accrued expenses 6,079 Deferred clearing and marketing credits 1,007 Warrants issuable 13,406 Other current liabilities 707 Total liabilities assumed 35,228 Non-controlling interests 17,717 Net assets acquired $ 22,872 Cash and cash equivalents from National $ 27,498 Cash to NHLD Shareholders (Tender Offer) 22,872 Net cash acquired in acquisition of National $ 4,626
Schedule of Acquired Finite-Lived Intangible Assets by Major Class	Amortization is calculated using the straight-line and accelerated methods over the following estimated useful lives: Useful life Trademark 10 years Customer lists 10 years
Schedule of Finite-Lived Intangible Assets	The gross carrying amounts related to acquired intangible assets as of December 31, 2016 are as follows ($ in thousands): Intangible assets at September 9, 2016 $ 16,500 Amortization expense (509) Intangible assets at December 31, 2016 $ 15,991
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The future amortization of these intangible assets is as follows ($ in thousands): Trademark Customer List Total Year Ended December 31, 2017 $ 300 $ 1,350 $ 1,650 Year Ended December 31, 2018 300 1,349 1,649 Year Ended December 31, 2019 300 1,349 1,649 Year Ended December 31, 2020 301 1,353 1,654 Year Ended December 31, 2021 300 1,349 1,649 Thereafter 1,407 6,333 7,740 Total $ 2,908 $ 13,083 $ 15,991
Schedule of pro forma financial data assumes the acquisition	Year Ended December 31, 2016 2015 (Unaudited) (Unaudited) Total revenues $ 190,556 $ 163,909 Net loss attributable to common stockholders $ (59,027) $ (47,310) Los per share: Basic $ (1.48) $ (1.21) Diluted $ (1.48) $ (1.21)

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Components of Property and Equipment	As of December 31, ($ in thousands) Useful Life (Years) 2016 2015 Computer equipment 3 $ 440 $ 13 Furniture and fixtures 5 821 69 Leasehold improvements 5 - 15 5,396 21 Construction in progress (1) NA – 274 Total property and equipment 6,657 377 Less: Accumulated depreciation (445) (68) Property and equipment, net $ 6,212 $ 309 (1) For build-out of the Company's new office in New York, NY.
National Holdings Corporation [Member]
Property, Plant and Equipment [Line Items]
Components of Property and Equipment	National' s property and equipment as of September 30, 2016 consisted of the following ($ in thousands): September 30, Estimated Useful 2016 Lives (in years) Equipment $ 600 5 Furniture and fixtures 65 5 Leasehold improvements 259 Lesser of useful life or term of lease Capital Leases (Primarily composed of computer equipment) 276 5 Total property and equipment 1,200 Less: Accumulated depreciation (36) Property and equipment, net $ 1,164

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2016
Fair Value for Derivative Contingently Issuable Warrant Liabilities	Avenue’s Contingently Issuable ($ in thousands) Warrants Beginning balance at January 1, 2016 $ 114 Additions - Change in fair value 188 Ending balance at December 31, 2016 $ 302
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	Fair Value Measurement as of December 31, 2016 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Long-term investments, at fair value $ - $ - $ 1,414 $ 1,414 Total $ - $ - $ 1,414 $ 1,414 Liabilities Contingently Issuable Warrants $ - $ - $ 302 $ 302 Warrant liabilities - - 179 179 Helocyte Convertible Note, at fair value - - 4,487 4,487 Avenue Convertible Note, at fair value - - 200 200 Total $ - $ - $ 5,168 $ 5,168 Fair Value Measurement as of December 31, 2015 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Long-term investments, at fair value $ - $ - $ 2,485 $ 2,485 Liabilities Derivative warrant liability $ - $ - $ 114 $ 114
Schedule of changes in fair value of financial instruments	The table below provides a roll forward of the changes in fair value of Level 3 financial instruments for the years ended December 31, 2016 and 2015: Helocyte Contingently Convertible Avenue Investment in Investment in Issuable Note, at fair Convertible Note, Warrant ($ in thousands) Origo laser device Warrants value at fair value liabilities Total Balance at December 31, 2015 $ 2,235 $ 250 $ 114 $ - $ - $ - $ 2,599 Additions during the period - - 14,040 4,409 200 440 19,089 Issuance of warrants - - (793) - - - (793) Change in fair value of investments (1,071) - - - - - (1,071) Change in fair value of convertible notes - - - 78 - 78 Change in fair value of derivative liabilities - - 1,300 - (261) 1,039 Balance at December 31, 2016 $ 1,164 $ 250 $ 14,661 $ 4,487 $ 200 $ 179 $ 20,942 Contingently Investment in Investment in Issuable Warrant ($ in thousands) Origo laser device Warrants liabilities Total Balance at December 31, 2014 $ 3,910 $ 250 $ - $ - $ 4,160 Additions during the period - - 175 114 289 Change in fair value of investments (1,675) - - - (1,675) Change in fair value of derivative liabilities - - 438 - 438 Issuance of warrants (613) (613) Balance at December 31, 2015 $ 2,235 $ 250 $ - $ 114 $ 2,599
Warrants Issuable [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	Such valuation (using level 3 inputs) was determined by use of the Black-Scholes option pricing model using the following assumptions: September 30, 2016 Dividend yield 0.00 % Expected volatility 118.85 % Risk-free interest rate 1.14 % Life (in years) 5
Avenue [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	The fair value of Avenue’s Contingently Issuable Warrants was determined by applying management’s estimate of the probability of issuance of the Contingently Issuable Warrants together with an option pricing model, with the following key assumptions: December 31, December 31, 2016 2015 Risk-free interest rate 2.45 % 2.27 % Expected dividend yield - - Expected term in years 10.00 9.84 Expected volatility 87 % 83 % Probability of issuance of the warrant 50 % 25 %
Avenue [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the convertible debt that is categorized within Level 3 of the fair value hierarchy for the year ended December 31, 2016 is as follows: December 31, 2016 Risk-free interest rate 0.62% - 1.20 % Expected dividend yield -% Expected term in years 0.50 – 2.00 Expected volatility 63.1%
Avenue [Member] | Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	A summary of the weighted average (in aggregate) significant unobservable inputs (level 3 inputs) used in measuring the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy for the year ended December 31, 2016 is as follows: December 31, 2016 Risk-free interest rate 2.45 % Expected dividend yield - Expected term in years 10.00 Expected volatility 87 %
Checkpoint [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	The fair value of Checkpoint’s Contingently Issuable Warrants was determined at various issuance dates from March 19, 2015 to August 31, 2015 (“ Issuance Dates 0.2 0.6 October 30, Issuance Dates 2015 Risk-free interest rate 2.26 % 2.16 % Expected dividend yield - - Expected term in years 10.00 10.00 Expected volatility 83 % 100.86 % Probability of issuance of the warrant 25 % 100 %
Fair Value for Derivative Contingently Issuable Warrant Liabilities	Checkpoint’s Contingently Issuable ($ in thousands) Warrants Beginning balance at January 1, 2015 $ - Additions 175 Change in fair value 438 Issuance of Warrants (October 30, 2015) (613) Ending balance at December 31, 2015 $ -
Mustang [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	The fair value of Mustang’s Contingently Issuable Warrants was determined by applying management’s estimate of the probability of issuance of the Contingently Issuable Warrants together with an option-pricing model, with the following key assumptions: Issuance Dates Risk-free interest rate 1.37 % Expected dividend yield - Expected term in years 10.00 Expected volatility 76.70 % Probability of issuance of the warrant 100 %
Fair Value for Derivative Contingently Issuable Warrant Liabilities	Mustang’s Contingently Issuable ($ in thousands) Warrants Beginning balance at January 1, 2016 $ - Additions 634 Change in fair value 159 Issuance of Warrants (October 25, 2016) (793) Ending balance at December 31, 2016 $ -
Mustang [Member] | Warrant [Member]
Fair Value for Derivative Contingently Issuable Warrant Liabilities	Fair Value of Derivative Warrant ($ in thousands) Liability Beginning balance at January 1, 2016 $ - Additions 12 Change in fair value of derivative liabilities - Ending balance at December 31, 2016 $ 12
Helocyte [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the convertible debt that is categorized within Level 3 of the fair value hierarchy for the year ended December 31, 2016 is as follows: December 31, 2016 Risk-free interest rate 0.74% - 1.17 % Expected dividend yield -% Expected term in years 0.75 – 1.91 Expected volatility 61.7%
Helocyte [Member] | Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	A summary of the weighted average (in aggregate) significant unobservable inputs (level 3 inputs) used in measuring the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy for the year ended December 31, 2016 is as follows: December 31, 2016 Risk-free interest rate 1.82% - 1.91 % Expected dividend yield -% Expected term in years 4.50 – 4.92 Expected volatility 70.0% Strike price $0.44
Fair Value for Derivative Contingently Issuable Warrant Liabilities	($ in thousands) Fair Value of Beginning balance at January 1, 2016 $ - Additions 428 Change in fair value of derivative liabilities (261) Ending balance at December 31, 2016 $ 167
National Holdings Corporation [Member]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table shows the fair values hierarchy of National's financial instruments measured at fair value on a recurring basis on the Consolidated Balance Sheets as of September 30, 2016: Fair Value Measurement as of September 30, 2016 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Corporate stock 101 — 101 Municipal bonds — 2,111 — 2,111 Restricted stock — 145 — 145 Total $ 101 $ 2,256 $ — $ 2,357 Liabilities Corporate stock 298 — — 298 Warrants issuable 14,359 14,359 Total $ 298 $ — $ 14,359 $ 14,657

Licenses Acquired (Tables)

Licenses Acquired (Tables)	12 Months Ended
	Dec. 31, 2016
Research and Development [Abstract]
Research and Development Arrangement, Contract to Perform for Others	For the years ended December 31, 2016, 2015 and 2014, the Company’s research and development-licenses acquired are comprised of the following: For the Years Ended December 31, ($ in thousands) 2016 2015 2014 Fortress $ 325 $ - $ - Fortress Companies: Avenue - 3,000 - Checkpoint 3,160 3,159 - Coronado SO - 1,607 - Helocyte 53 200 - Mustang 1,682 2,147 - Escala - 1,295 - Cellvation 312 - - Total $ 5,532 $ 11,408 $ -

Debt and Interest (Tables)

Debt and Interest (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Schedule Of Interest Expenses	Total debt consists of the following as of December 31, 2016 and December 31, 2015: December 31, ($ in thousands) 2016 2015 Interest rate Maturity IDB Note $ 14,929 $ 14,009 2.25% Feb - 2018 NSC Note 3,608 10,000 8.00% Sep - 2018 Opus Credit Facility 7,000 - 12.00% Sep - 2018 Helocyte Convertible Note, at fair value 1,031 - 5.00% - 8.00% Dec - 2017 Helocyte Convertible Note, at fair value 2,051 - 5.00% - 8.00% March - 2018 Helocyte Convertible Note, at fair value 1,405 - 5.00% - 8.00% May - 2018 Avenue Convertible Note, at fair value 200 - 5.00% - 8.00% June - 2018 Total notes payable 30,224 24,009 Less: Discount on notes payable 2,009 835 Total notes payable, long-term $ 28,215 $ 23,174
Schedule Of Interest Expenses For Debt Arrangements	The following table shows the details of interest expense for all debt arrangements during the periods presented. Interest expense includes contractual interest and amortization of the debt discount and amortization of fees represents fees associated with loan transaction costs, amortized over the life of the loan: For the Years Ended December 31, ($ in thousands) 2016 2015 2014 IDB Note Interest $ 328 $ 314 $ 292 Amortization of fees 1 5 4 Total IDB Note 329 319 296 NSC Debt Interest 599 690 - Amortization of fees 1,270 309 - Total NSC Debt 1,869 999 - Opus Credit Facility Interest 192 - - Amortization of fees 195 - - Total Opus Note 387 - - Ovamed Interest - 166 154 Total Ovamed - 166 154 LOC Fees Interest 11 - - Total LOC 11 - - Helocyte Convertible Note Interest 61 - - Financing fee 962 - - Total Helocyte Convertible Note 1,023 - - Avenue Convertible Note Financing fee 70 - - Total Avenue Convertible Note 70 - - Hercules Debt Interest (1) - - 845 Amortization of fees - - 43 Total Hercules Debt - - 888 D&O Insurance Interest 1 - - Total D&O Insurance 1 - - Total Interest Expense and Financing Fee $ 3,690 $ 1,484 $ 1,338 (1) Interest expense related to the Company’s loan with Hercules was $ 0.8 0.4

Accrued Liabilities and other37

Accrued Liabilities and other Long-Term Liabilities (Tables)	12 Months Ended
	Dec. 31, 2016
Components of Accrued Expenses and Other Long-Term Liabilities	December 31, ($ in thousands) 2016 2015 Accrued expenses: Professional fees $ 1,253 $ 382 Salaries, bonuses and related benefits 2,846 2,492 Accrued Severance 53 Ovamed manufacturing rights - short term component 900 2,007 Research and development 394 303 Dr. Falk Pharma milestone 2,634 2,717 JMC accrued cost of goods sold 726 - Lease impairment 128 146 Other 1,148 523 Total accrued expenses $ 10,082 $ 8,570 Other long-term liabilities: Deferred rent and long-term lease abandonment charge 5,014 584 Total other long-term liabilities $ 5,014 $ 584
National Holdings Corporation [Member]
Components of Accrued Expenses and Other Long-Term Liabilities	September 30, 2016 Legal $ 1,346 Audit 198 Telecommunications 209 Data Services 425 Regulatory 444 Settlements 832 Deferred rent 65 Contingent consideration payable 424 Other 3,223 Total $ 7,166

Non-Controlling Interests (Tabl

Non-Controlling Interests (Tables)	12 Months Ended
	Dec. 31, 2016
Noncontrolling Interest [Abstract]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net	Non-controlling interests in consolidated entities are as follows: As of December 31, 2016 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Helocyte Cellvation National Holdings Total NCI equity share $ (494) $ (217) $ 12,376 $ 32,160 $ (192) $ (612) $ 4 $ 17,643 $ 60,668 Net loss attributed to non-controlling interests (349) (19) (1,805) (11,733) (355) (1,155) (158) (621) (16,195) Non-controlling interests in consolidated entities $ (843) $ (236) $ 10,571 $ 20,427 $ (547) $ (1,767) $ (154) $ 17,022 $ 44,473 ($ in thousands) As of December 31, 2015 Avenue Coronado SO Mustang Checkpoint JMC Total NCI equity share $ 6 $ 23 $ 14 $ 32,760 $ 79 $ 32,882 Net loss attributed to non-controlling interests (567) (240) (373) (3,855) (420) (5,455) Non-controlling in interests consolidated entities $ (561) $ (217) $ (359) $ 28,905 $ (341) $ 27,427
Components Of Non-Controlling Interests In Loss Of Consolidated Entities	The components of non-controlling interests in loss of consolidated entities are as follows: For the year ended December 31, 2016 ($ in thousands) Avenue Coronado SO Mustang Checkpoint (1) JMC Helocyte Cellvation National Holdings Total Non-controlling interests in loss of consolidated entities $ (349) $ (19) $ (1,805) $ (11,733) $ (355) $ (1,155) $ (158) $ (621) $ (16,195) Non-controlling ownership 10.2 % 13.0 % 26.7 % 62.9 % 7.0 % 20.5 % 22.0 % 43.4 % (1) Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights. ($ in thousands) For the year ended December 31, 2015 Avenue Coronado SO Mustang Checkpoint JMC Total Non-controlling interests in loss of consolidated entities $ (567) $ (240) $ (373) $ (3,855) $ (420) $ (5,455) Non-controlling ownership 11.5 % 13 % 10 % 62.3 %(1) 8.8 %

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Computations of Diluted Weighted Average Shares Outstanding	The following shares of potentially dilutive securities, weighted during the years ended December 31, 2016, 2015, and 2014 have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive: For the Years Ended December 31, 2016 2015 2014 Warrants to purchase Common Stock 456,150 685,061 693,636 Opus warrants to purchase Common Stock 1,780,000 - - Options to purchase Common Stock 1,604,214 1,960,443 2,276,813 Unvested Restricted Stock 8,749,052 6,816,321 6,087,717 Unvested Restricted Stock Units 1,087,563 427,627 - Total 13,676,979 9,889,452 9,058,166

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Share-based Compensation, Activity	The following table summarizes the stock-based compensation expense from stock option, employee stock purchase programs and restricted Common Stock awards and warrants for the years ended December 31, 2016, 2015 and 2014: For the Years Ended December 31, ($ in thousands) 2016 2015 2014 Employee awards $ 7,386 $ 8,130 $ 5,492 Executive awards of Fortress Companies' stock - 2,228 - Non-employee awards 33 33 54 Fortress Companies (1), (2) 4,709 3,900 - Total stock-based compensation expense $ 12,128 $ 14,291 $ 5,546 (1) Consists of approximately $ 28,000 3.9 0.5 0.3 7,000 42,000 (2) Consists of approximately $ 50,400 3.3 0.6
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable	The following table summarizes Fortress stock option activities excluding activities related to Fortress Companies: Total weighted Weighted average Weighted average average intrinsic remaining contractual Number of shares exercise price value life (years) Options vested and expected to vest at December 31, 2015 1,779,365 $ 4.37 $ 666,396 6.32 Forfeited (648,864) 0.51 - - Options vested and expected to vest at December 31, 2016 1,130,501 $ 3.73 $ 602,451 4.93 Exercisable as of December 31, 2016 1,105,501 $ 3.71 $ 602,451 4.91
Nonvested Restricted Stock Shares Activity	The following table summarizes Fortress restricted stock awards and restricted stock units activities, excluding activities related to Fortress Companies: Weighted average Number of shares grant price Unvested balance at December 31, 2015 8,757,935 $ 2.47 Restricted stock granted 1,240,868 2.77 Restricted stock cancelled (33,333) 2.69 Restricted stock vested (173,333) 2.73 Restricted stock units granted 641,000 2.93 Restricted stock units cancelled (111,750) 3.58 Restricted stock units vested (227,292) 3.56 Unvested balance at December 31, 2016 10,094,095 $ 2.49
Schedule of Warrant Activities	The following table summarizes Fortress warrant activities, excluding activities related to Fortress Companies: Total weighted Weighted average Weighted average average intrinsic remaining contractual Number of shares exercise price value life (years) Outstanding as of December 31, 2015 569,835 $ 6.31 $ 120,700 1.84 Granted 1,880,000 3.00 - 5.65 Expired (161,382) 6.30 - - Exercised (*) (25,000) 1.37 33,250 - Outstanding as of December 31, 2016 2,263,453 $ 3.62 $ 79,800 4.74 Exercisable as of December 31, 2016 483,453 $ 5.88 $ 79,800 2.13 (*) - cashless
Schedule of Fair Value of Separate Accounts by Major Category of Investment	On July 15, 2015 and on October 31, 2016, the following grants of 500,000 Exercise 2015 Warrant Shares Risk Free Rate Volatilty Life price Fair Value Mustang 1,000,000 2.36 % 106.11 % 10 $ 0.147 $ 135 Checkpoint 1,000,000 2.36 % 106.11 % 10 $ 0.129 $ 118 Avenue 1,000,000 2.36 % 106.11 % 10 $ 0.146 $ 134 CNDO SO 1,000,000 2.36 % 106.11 % 10 $ 1.190 $ 1,091 Helocyte 1,000,000 2.36 % 106.11 % 10 $ 0.097 $ 89 JMC 1,000,000 2.36 % 106.11 % 10 $ 0.650 $ 596 Escala 1,000,000 2.36 % 106.11 % 10 $ 0.071 $ 65 2016 Cellvation 1,000,000 2.86 % 70 % 9 $ 0.024 $ 18,075
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The fair value of options granted in 2016 was estimated using the following assumptions: For the year ended December 31, 2016 Risk-free interest rate 1.14% - 2.25 % Expected dividend yield - Expected term in years 5.05 - 6.95 Expected volatility 96.89% - 105.48 %
Schedule of Share-based Compensation, Restricted Stock Award Activity	Fair Value RSU Grant Vesting Term Vested Forfeited Unvested per Share President 1,500,000 4 250,000 (1,250,000) - $ 0.650 Sales Operations Staff 450,000 4 116,666 - 333,334 $ 0.650 1,950,000 366,666 (1,250,000) 333,334

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Schedule of Future Minimum Rental Payments for Operating Leases	Total future minimum lease payments under these leases are: ($ in thousands) 2017 $ 2,806 2018 2,692 2019 2,713 2020 2,754 2021 2,622 Beyond 27,261 Total minimum lease payments $ 40,848
National Holdings [Member]
Schedule of Future Minimum Rental Payments for Operating Leases	As of September 30, 2016, National leases office space in various states expiring at various dates through August 2025, and is committed under operating leases for future minimum lease payments as follows (dollars in thousands): Fiscal Year Ending Rental Expense Less, Sublease Income Net 2017 $ 2,774 $ 84 $ 2,690 2018 2,196 — 2,196 2019 1,524 — 1,524 2020 1,390 — 1,390 2021 1,092 — 1,092 Thereafter 2,232 — 2,232 Total $ 11,208 $ 84 $ 11,124

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities	The significant components of the Company’s deferred taxes consist of the following: As of December 31, 2016 2015 Deferred tax assets: Net operating loss carryforwards $ 76,486 $ 54,249 Amortization of up-front fees 7,277 4,442 Amortization of in-process R&D 742 599 Stock compensation 10,899 8,158 Accruals and reserves 4,025 210 Tax Credits 6,305 4,583 Start Up Costs 98 - Unrealized loss on investments 1,095 358 Total deferred tax assets 106,927 72,599 Less valuation allowance (94,688) (66,730) Net deferred tax assets $ 12,239 $ 5,869 Deferred tax liabilities: Intangibles $ (4,449) $ - Basis in subsidiary (7,790) (5,869) Total deferred tax assets, net $ - $ -
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the statutory tax rates and the effective tax rates is as follows: For the Year Ended December 31, 2016 2015 2014 Percentage of pre-tax income: U.S. federal statutory income tax rate 35 % 35 % 35 % State taxes, net of federal benefit 3 % 5 % 5 % Credits 2 % 1 % 6 % Non-deductible items (4) % - % (1) % Provision to return 2 % - % - % Stock based compensation shortfall (2) % (1) % - % Other - % 1 % - % Change in valuation allowance (33) % (44) % (45) % Change in subsidiary basis (3) % 3 % - % Effective income tax rate - % - % - %

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	Dermatology Pharmaceutical and Products Biotechnology Year Ended December 31, 2016 Sales Product Development National Consolidated Net Revenue $ 3,587 $ 2,570 $ 10,323 $ 16,480 Direct cost of goods (790) - - (790) Sales and marketing costs (5,774) - - (5,774) Research and development - (35,134) - (35,134) General and administrative (1,474) (26,755) - (28,229) National expenses (11,754) (11,754) Segment loss from operations $ (4,451) $ (59,319) $ (1,431) $ (65,201) Segment assets $ 4,469 $ 115,145 $ 38,220 $ 157,834 Dermatology Pharmaceutical and Products Biotechnology Year Ended December 31, 2015 Sales Product Development National Consolidated Net Revenue $ 273 $ 590 $ - $ 863 Direct cost of goods - ) - - - ) Sales and marketing costs (2,850) - - (2,850) Research and development - (29,810) - (29,810) General and administrative (1,682) (17,052) - (18,734) Segment loss from operations $ (4,259) $ (46,272) $ - $ (50,531) Segment assets $ 1,965 $ 116,542 $ - $ 118,610

Selected Quarterly Financial 44

Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	The following table contains quarterly financial information for fiscal years 2016 and 2015. The Company believes that the following information reflects all normal recurring adjustments necessary for a fair statement of the information for the periods presented. (in thousands, except per share data) First Quarter Second Quarter Third Quarter Fourth Quarter 2016 Total Revenue $ 660 $ 2,230 $ 975 $ 14,405 Operating expenses $ (15,571) $ (17,042) $ (17,180) $ (32,217) Other income/(expense) $ (1,552) $ (1,253) $ (710) $ (2,065) Non-controlling interests $ 4,438 $ 3,911 $ 3,975 $ 3,871 Net loss attributable to common stockholders $ (12,205) $ (12,478) $ (12,981) $ (17,431) Basic and diluted net loss per common share $ (0.31) $ (0.31) $ (0.32) $ (0.43) 2015 Total Revenue $ 500 $ - $ 25 $ 338 Operating expenses $ (12,571) $ (7,762) $ (18,097) $ (12,964) Other income/(expense) $ (464) $ 1,344 $ (1,783) $ (2,449) Non-controlling interests $ 479 $ 243 $ 1,694 $ 3,039 Net loss attributable to common stockholders $ (12,056) $ (6,175) $ (18,161) $ (12,036) Basic and diluted net loss per common share $ (0.31) $ (0.16) $ (0.46) $ (0.30)

Organization and Description 45

Organization and Description of Business - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Sep. 09, 2016	Dec. 31, 2016	Dec. 01, 2016	Jun. 01, 2016	Apr. 27, 2016	Dec. 31, 2015
Organization And Nature Of Business [Line Items]
Common Stock Par Or Stated Value Per Share		$ 0.001	$ 2.03	$ 2.40		$ 0.001
National Holdings Corporation [Member]
Organization And Nature Of Business [Line Items]
Merger Agreement Minimum Percentage Of Shares In Tender Offer To Completed Merger	56.60%
Merger Agreement Termination Fee	$ 22.9
Common Stock Par Or Stated Value Per Share	$ 0.02				$ 0.02
Business Acquisition, Share Price	$ 3.25				$ 3.25

Summary of Significant Accoun46

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2014	Sep. 30, 2016	Dec. 31, 2015
Accounting Policies [Line Items]
Percentage of tax benefit likely of being realized	50.00%
Restricted Cash and Cash Equivalents	$ 15,900,000			$ 14,600,000
Gain (Loss) on Sale of Assets and Asset Impairment Charges		$ 400,000
Allowance for Doubtful Accounts Receivable	$ 0			0
Debt Instrument, Interest Rate, Stated Percentage	39.00%
Deferred Revenue and Credits, Current	$ 995,000			0
Elimination Of Revenue	1,300,000
Pledged Assets Separately Reported, Loans Pledged as Collateral, at Fair Value	600,000			600,000
Deferred Clearing [Member]
Accounting Policies [Line Items]
Deferred Revenue and Credits, Current			$ 700,000
Marketing Credits [Member]
Accounting Policies [Line Items]
Deferred Revenue and Credits, Current			$ 300,000
Hercules Note Payble [Member]
Accounting Policies [Line Items]
Restricted Cash and Cash Equivalents	$ 14,900,000			$ 14,000,000

National Holdings Corporation -

National Holdings Corporation - Fair value of assets acquired and liabilities assumed at the date of the acquisition (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Assets
Cash and cash equivalents	$ 27,498
Accounts receivable	4,889
Cash deposits with clearing organizations	1,030
Receivable from brokers, dealers and clearing agencies	1,607
Securities owned, at fair value	2,178
Prepaid expenses and other current assets	1,985
Property and equipment	1,132
Restricted cash	353
Goodwill	18,645	$ 0
Total assets	75,817
Liabilities
Accrued compensation payable	14,029
Accounts payable and accrued expenses	6,079
Deferred clearing and marketing credits	1,007
Warrants issuable	13,406
Other current liabilities	707
Total liabilities assumed	35,228
Non-controlling interests	17,717
Net assets acquired	22,872
Cash and cash equivalents from National	27,498
Cash to NHLD Shareholders (Tender Offer)	22,872
Net cash acquired in acquisition of National	4,626
Trademarks [Member]
Assets
Intangible assets	3,000
Customer Lists [Member]
Assets
Intangible assets	$ 13,500

National Holdings Corporation48

National Holdings Corporation - Amortization is calculated using the straight-line method over the estimated useful lives (Detail)	12 Months Ended
	Dec. 31, 2016
Trademarks [Member]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years
Customer Lists [Member]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years

National Holdings Corporation49

National Holdings Corporation - gross carrying amounts related to acquired intangible assets (Detail) $ in Thousands	1 Months Ended
	Sep. 30, 2016USD ($)
Intangible assets at September 9, 2016	$ 16,500
Amortization expense	(509)
Intangible assets at December 31, 2016	$ 15,991

National Holdings Corporation50

National Holdings Corporation - future amortization of these intangible assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Year Ended December 31, 2017	$ 1,650
Year Ended December 31, 2018	1,649
Year Ended December 31, 2019	1,649
Year Ended December 31, 2020	1,654
Year Ended December 31, 2021	1,649
Thereafter	7,740
Total	17,408	$ 1,250
Customer Lists [Member]
Year Ended December 31, 2017	1,350
Year Ended December 31, 2018	1,349
Year Ended December 31, 2019	1,349
Year Ended December 31, 2020	1,353
Year Ended December 31, 2021	1,349
Thereafter	6,333
Total	13,083
Trademarks [Member]
Year Ended December 31, 2017	300
Year Ended December 31, 2018	300
Year Ended December 31, 2019	300
Year Ended December 31, 2020	301
Year Ended December 31, 2021	300
Thereafter	1,407
Total	$ 2,908

National Holdings Corporation51

National Holdings Corporation - Schedule of pro forma financial data assumes the acquisition (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Total revenues	$ 190,556	$ 163,909
Net loss attributable to common stockholders	$ (59,027)	$ (47,310)
Los per share:
Basic	$ (1.48)	$ (1.21)
Diluted	$ (1.48)	$ (1.21)

National Holdings Corporation52

National Holdings Corporation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	1 Months Ended		12 Months Ended
	Sep. 30, 2016	Apr. 27, 2016	Dec. 31, 2016	Dec. 01, 2016	Sep. 09, 2016	Jun. 01, 2016	Dec. 31, 2015
Business Combination, Consideration Transferred			$ 22,872
Common Stock Par Or Stated Value Per Share			$ 0.001	$ 2.03		$ 2.40	$ 0.001
Goodwill			$ 18,645				$ 0
National Holdings Corporation [Member]
Business Acquisition, Percentage of Voting Interests Acquired	56.10%	56.00%			56.60%
Business Acquisition, Share Price		$ 3.25			$ 3.25
Number Of Shares Tendered		7
Business Combination, Consideration Transferred	$ 22,900	$ 22,900
Common Stock Par Or Stated Value Per Share		$ 0.02			$ 0.02

Broker-Dealers and Clearing O53

Broker-Dealers and Clearing Organizations and Other Receivables - Additional Information (Detail) - USD ($)	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Brokers And Dealers [Line Items]
Receivables from Brokers-Dealers and Clearing Organizations	$ 3,357,000		$ 0
Allowance for Doubtful Accounts Receivable	0		$ 0
Accounts Receivable, Net, Total	$ 71,800
Broker -Dealers And clearing Organisation [Member]
Brokers And Dealers [Line Items]
Receivables from Brokers-Dealers and Clearing Organizations		$ 3,400,000
Allowance for Doubtful Accounts Receivable		700,000
Broker -Dealers And clearing Organisation [Member] | Other Receivable [Member]
Brokers And Dealers [Line Items]
Accounts Receivable, Net, Total		$ 5,400,000

Forgivable Loans Receivable - A

Forgivable Loans Receivable - Additional Information (Detail)	Dec. 31, 2016
Debt Instrument, Interest Rate, Stated Percentage	39.00%
Forgivable Loan Receivable [Member]
Debt Instrument, Interest Rate, Stated Percentage	9.00%

Property and Equipment - Compon

Property and Equipment - Components of Property and Equipment (Detail) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Total property and equipment			$ 1,200
Less: Accumulated depreciation			(36)
Property and equipment, net		$ 7,376	1,164	$ 309
Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		6,657		377
Less: Accumulated depreciation		(445)		(68)
Property and equipment, net		6,212		309
Computer Equipment [Member] | Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 440		13
Useful Life (Years)		3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment			65
Furniture and Fixtures [Member] | Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 821		69
Useful Life (Years)		5 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment			$ 259
Leasehold Improvements [Member] | Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 5,396		21
Leasehold Improvements [Member] | Fortress Biotech Inc [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Life (Years)		15 years
Leasehold Improvements [Member] | Fortress Biotech Inc [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful Life (Years)		5 years
Construction in progress [Member] | Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	[1]	$ 0		$ 274
[1]	For build-out of the Company's new office in New York, NY.

Property and Equipment - Schedu

Property and Equipment - Schedule Of Interest Expenses For Debt Arrangements (Detail) - USD ($) $ in Thousands	1 Months Ended
	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property Plant And Equipment Gross	$ 1,200
Less: Accumulated depreciation	(36)
Property Plant And Equipment Net	1,164	$ 7,376	$ 309
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property Plant And Equipment Gross	600
Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property Plant And Equipment Gross	65
Leaseholds And Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property Plant And Equipment Gross	259
Assets Held under Capital Leases [Member]
Property, Plant and Equipment [Line Items]
Property Plant And Equipment Gross	$ 276
National Holdings Corporation [Member] | Equipment [Member]
Property, Plant and Equipment [Line Items]
Property Plant And Equipment Useful Life	5 years
National Holdings Corporation [Member] | Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property Plant And Equipment Useful Life	5 years
National Holdings Corporation [Member] | Leaseholds And Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	Lesser of useful life or term of lease
National Holdings Corporation [Member] | Assets Held under Capital Leases [Member]
Property, Plant and Equipment [Line Items]
Property Plant And Equipment Useful Life	5 years

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Depreciation		$ 400,000	$ 26,000	$ 23,000
National Holdings Corporation [Member]
Property, Plant and Equipment [Line Items]
Depreciation	$ 36,000

Fair Value Measurements - Avenu

Fair Value Measurements - Avenue's Contingently Issuable Warrants with option pricing model (Detail)	1 Months Ended	5 Months Ended	12 Months Ended
	Oct. 30, 2015	Aug. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Avenue [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate			2.45%	2.27%
Expected dividend yield			0.00%	0.00%
Expected term in years			10 years	9 years 10 months 2 days
Expected volatility			87.00%	83.00%
Probability of issuance of the warrant			50.00%	25.00%
Mustang [Member] | Contingently Issuable Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate			1.37%
Expected dividend yield			0.00%
Expected term in years			10 years
Expected volatility			76.70%
Probability of issuance of the warrant			100.00%
Checkpoint [Member] | Contingently Issuable Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	2.16%	2.26%
Expected dividend yield	0.00%	0.00%
Expected term in years	10 years	10 years
Expected volatility	100.86%	83.00%
Probability of issuance of the warrant	100.00%	25.00%

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Fair Value of Financial Instruments (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	$ 2,599	$ 4,160
Additions during the period	19,089	289
Issuance of warrants	(793)	(613)
Change in fair value of investment	(1,071)	(1,675)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	78
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Derivative Liability Gain Loss Included In Earnings	1,039	438
Balance	20,942	2,599
Contingently Issuable Warrant [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	114	0
Additions during the period	14,040	175
Issuance of warrants	(793)	(613)
Change in fair value of investment	0	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	0
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Derivative Liability Gain Loss Included In Earnings	1,300	438
Balance	14,661	114
Helocyte Convertible Note At Fair Value [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	0
Additions during the period	4,409
Issuance of warrants	0
Change in fair value of investment	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	78
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Derivative Liability Gain Loss Included In Earnings	0
Balance	4,487	0
Avenue Convertible Note, at fair value [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	0
Additions during the period	200
Issuance of warrants	0
Change in fair value of investment	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Derivative Liability Gain Loss Included In Earnings
Balance	200	0
Warrant liabilities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	0	0
Additions during the period	440	114
Issuance of warrants	0
Change in fair value of investment	0	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	0
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Derivative Liability Gain Loss Included In Earnings	(261)	0
Balance	179	0
Investment In Laser Device [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	250	250
Additions during the period	0	0
Issuance of warrants	0
Change in fair value of investment	0	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	0
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Derivative Liability Gain Loss Included In Earnings	0	0
Balance	250	250
Investment In Origo [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	2,235	3,910
Additions during the period	0	0
Issuance of warrants	0
Change in fair value of investment	(1,071)	(1,675)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	0
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Derivative Liability Gain Loss Included In Earnings	0	0
Balance	$ 1,164	$ 2,235

Fair Value Measurements - Warra

Fair Value Measurements - Warrant Liabilities And Convertible Notes At Fair Value (Detail) - $ / shares	1 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2016
Warrants Issuable [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk free rate	1.14%
Expected dividend yield	0.00%
Expected term in years	5 years
Expected volatility	118.85%
Avenue [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected volatility		63.10%
Avenue [Member] | Minimum [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk free rate		0.62%
Expected term in years		6 months
Avenue [Member] | Maximum [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk free rate		1.20%
Expected term in years		2 years
Avenue [Member] | Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk free rate		2.45%
Expected dividend yield		0.00%
Expected term in years		10 years
Expected volatility		87.00%
Helocyte [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected dividend yield		0.00%
Expected volatility		61.70%
Helocyte [Member] | Minimum [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk free rate		0.74%
Expected term in years		9 months
Helocyte [Member] | Maximum [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk free rate		1.17%
Expected term in years		1 year 10 months 28 days
Helocyte [Member] | Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected dividend yield		0.00%
Expected volatility		70.00%
Strike price		$ 0.44
Helocyte [Member] | Warrant [Member] | Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk free rate		1.82%
Expected term in years		4 years 6 months
Helocyte [Member] | Warrant [Member] | Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk free rate		1.91%
Expected term in years		4 years 11 months 1 day

Fair Value Measurements - Deriv

Fair Value Measurements - Derivative Contingently Issuable Warrant liabilities (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Additions	$ 19,089	$ 289
Avenue [Member] | Contingently Issuable Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value at the beginning of period:	114
Additions	0
Change in fair value	188
Fair value at end of period:	302	114
Mustang [Member] | Contingently Issuable Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value at the beginning of period:	0
Additions	634
Change in fair value	159
Issuance of Warrants	(793)
Fair value at end of period:	0	0
Mustang [Member] | Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value at the beginning of period:	0
Additions	12
Change in fair value	0
Fair value at end of period:	12	0
Checkpoint [Member] | Contingently Issuable Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value at the beginning of period:	0	0
Additions		175
Change in fair value		438
Issuance of Warrants		(613)
Fair value at end of period:		0
Helocyte [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value at the beginning of period:	0
Additions	428
Change in fair value	(261)
Fair value at end of period:	$ 167	$ 0

Fair Value Measurements - Natio

Fair Value Measurements - National Financial Instruments Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Assets
Long-term investments, at fair value	$ 1,414		$ 2,485
Total	1,414
Liabilities
Liabilities	5,168
National Holdings Corporation [Member]
Assets
Total		$ 2,357
Liabilities
Liabilities		14,657
Contingently Issuable Warrant [Member]
Liabilities
Liabilities	302
Warrant [Member]
Liabilities
Liabilities	179		114
Helocyte Convertible Note One [Member]
Liabilities
Liabilities	4,487
Avenue Convertible Note [Member]
Liabilities
Liabilities	200
Corporate stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		101
Liabilities
Liabilities		298
Municipal bonds Assets [Member] | National Holdings Corporation [Member]
Assets
Total		2,111
Restricted stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		145
Warrants Issuable [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		14,359
Fair Value, Inputs, Level 1 [Member]
Assets
Long-term investments, at fair value	0		0
Total	0
Liabilities
Liabilities	0
Fair Value, Inputs, Level 1 [Member] | National Holdings Corporation [Member]
Assets
Total		101
Liabilities
Liabilities		298
Fair Value, Inputs, Level 1 [Member] | Contingently Issuable Warrant [Member]
Liabilities
Liabilities	0
Fair Value, Inputs, Level 1 [Member] | Warrant [Member]
Liabilities
Liabilities	0		0
Fair Value, Inputs, Level 1 [Member] | Helocyte Convertible Note One [Member]
Liabilities
Liabilities	0
Fair Value, Inputs, Level 1 [Member] | Avenue Convertible Note [Member]
Liabilities
Liabilities	0
Fair Value, Inputs, Level 1 [Member] | Corporate stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		101
Fair Value, Inputs, Level 1 [Member] | Municipal bonds Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0
Fair Value, Inputs, Level 1 [Member] | Restricted stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0
Fair Value, Inputs, Level 1 [Member] | Corporate stock Liabilities [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		298
Fair Value, Inputs, Level 1 [Member] | Warrants Issuable [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		0
Fair Value, Inputs, Level 2 [Member]
Assets
Long-term investments, at fair value	0		0
Total	0
Liabilities
Liabilities	0
Fair Value, Inputs, Level 2 [Member] | National Holdings Corporation [Member]
Assets
Total		2,256
Liabilities
Liabilities		0
Fair Value, Inputs, Level 2 [Member] | Contingently Issuable Warrant [Member]
Liabilities
Liabilities	0
Fair Value, Inputs, Level 2 [Member] | Warrant [Member]
Liabilities
Liabilities	0		0
Fair Value, Inputs, Level 2 [Member] | Helocyte Convertible Note One [Member]
Liabilities
Liabilities	0
Fair Value, Inputs, Level 2 [Member] | Avenue Convertible Note [Member]
Liabilities
Liabilities	0
Fair Value, Inputs, Level 2 [Member] | Corporate stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0
Fair Value, Inputs, Level 2 [Member] | Municipal bonds Assets [Member] | National Holdings Corporation [Member]
Assets
Total		2,111
Fair Value, Inputs, Level 2 [Member] | Restricted stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		145
Fair Value, Inputs, Level 2 [Member] | Corporate stock Liabilities [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		0
Fair Value, Inputs, Level 2 [Member] | Warrants Issuable [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		0
Fair Value, Inputs, Level 3 [Member]
Assets
Long-term investments, at fair value	1,414		2,485
Total	1,414
Liabilities
Liabilities	5,168
Fair Value, Inputs, Level 3 [Member] | National Holdings Corporation [Member]
Assets
Total		0
Liabilities
Liabilities		14,359
Fair Value, Inputs, Level 3 [Member] | Contingently Issuable Warrant [Member]
Liabilities
Liabilities	302
Fair Value, Inputs, Level 3 [Member] | Warrant [Member]
Liabilities
Liabilities	179		$ 114
Fair Value, Inputs, Level 3 [Member] | Helocyte Convertible Note One [Member]
Liabilities
Liabilities	4,487
Fair Value, Inputs, Level 3 [Member] | Avenue Convertible Note [Member]
Liabilities
Liabilities	$ 200
Fair Value, Inputs, Level 3 [Member] | Corporate stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0
Fair Value, Inputs, Level 3 [Member] | Municipal bonds Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0
Fair Value, Inputs, Level 3 [Member] | Restricted stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0
Fair Value, Inputs, Level 3 [Member] | Corporate stock Liabilities [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		0
Fair Value, Inputs, Level 3 [Member] | Warrants Issuable [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		$ 14,359

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)

1 Months Ended

5 Months Ended

12 Months Ended

Dec. 19, 2016

Oct. 31, 2016

Sep. 30, 2016

Oct. 30, 2015

Sep. 30, 2014

Aug. 31, 2014

Apr. 18, 2014

Mar. 17, 2014

Aug. 31, 2015

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Dec. 30, 2016

Dec. 01, 2016

Jun. 01, 2016

Sep. 18, 2015

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Equity Method Investments

$ 250,000

$ 300,000

Equity Method Investment, Ownership Percentage

35.00%

Short-term Investments, Total

$ 243,000

Share Price

$ 2.39

$ 2.82

Investments in and Advances to Affiliates, at Fair Value, Period Increase (Decrease), Total

1,100,000

Investment Owned, at Fair Value

2,357,000

$ 0

Fair Value Adjustment of Warrants

$ 1,039,000

$ 438,000

$ 0

Warrants Issued

139,592

Value of Warrants Issued

$ 600,000

$ 200,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 2,500

$ 7

Equity Securities Called by Warrant

$ 10,000

Private Placement [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Acquisition, Share Price

$ 4.20

Origo Acquisition Corporation [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Investment Owned, at Fair Value

$ 1,200,000

Investments In Subsidiary Number Of Shares Transferred To Subsidiary

1,050,000

Investments In Subsidiary Number Of Shares Outstanding

265,000

Fair Value Assumptions Probability Of Business Combination

51.53%

51.53%

Realized Investment Gains (Losses)

$ 25,000

Unrealized Gain (Loss) on Investments

1,000,000

Working Capital Note Convertible To Equity

$ 300,000

Business Acquisition, Equity Interest Issued or Issuable, Basis for Determining Value

Under the Merger, shareholders and warrant holders in Origo will receive 0.6 shares or warrants of Ainas common stock, respectively, for each share or warrant of Origo they hold.

National Holdings Corporation [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Percentage of Outstanding Stock To Be Issued Upon Exercise of Warrants

44.00%

Percentage of outstanding shares, Tendered

80.00%

Warrants Expiration period

5 years

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 3.25

$ 3.25

Warrants Not Settleable in Cash, Fair Value Disclosure

$ 5,400,000

Mustang Bio, Inc. [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Number of Warrants Issued

138,462

Contingently Issuance Warrants

$ 800,000

Non Redeemable warrants [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Acquisition, Share Price

0.42

Redeemable warrants [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Acquisition, Share Price

0.30

Binomial Lattice Model [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value Assumptions, Exercise Price

$ 11.50

Risk free rate

0.85%

Fair Value Assumptions, Expected Volatility Rate

25.60%

Binomial Lattice Model [Member] | Warrant [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Acquisition, Share Price

$ 0.82

Ghaidarov Model [Member] | Warrant [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Acquisition, Share Price

0.58

Private Units [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Share Price

$ 8.16

Argus Neurooptics Llc [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases

$ 50,000

Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net, Total

$ 300,000

$ 300,000

Argus Neurooptics Llc [Member] | Class A Preferred Stock [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Shares Received Under Purchase Agreement

$ 13,409,962

Percentage Of Shares Received Under Purchase Agreement

83.00%

Preferred Units, Issued

16,091,954

Licenses Acquired - Summary Of

Licenses Acquired - Summary Of Research and Development Arrangement Contract (Detail) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Apr. 28, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		$ 5,532	$ 11,408	$ 0
Fortress [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		325	0	0
Avenue Therapeutics, Inc. [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		0	3,000	0
Checkpoint Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		3,160	3,159	0
Coronado SO Co, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		0	1,607	0
Helocyte [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	$ 200	53	200	0
Mustang Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		1,682	2,147	0
Escala [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		0	1,295	0
Cellvation [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		$ 312	$ 0	$ 0

Licenses Acquired - Additional

Licenses Acquired - Additional Information (Detail) - USD ($)

May 11, 2015

Oct. 31, 2016

Sep. 30, 2016

May 31, 2016

Feb. 23, 2016

Dec. 31, 2015

Oct. 31, 2015

Sep. 30, 2015

Jul. 16, 2015

Jun. 17, 2015

Apr. 28, 2015

Mar. 31, 2015

Feb. 28, 2015

Dec. 31, 2016

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Dec. 01, 2016

Jul. 31, 2016

Jun. 01, 2016

Feb. 17, 2015

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payments to Acquire Intangible Assets

$ 350,000

$ 1,250,000

$ 0

Research And Development In Process

5,532,000

11,408,000

0

Stock Issued During Period, Shares, Issued for Services

10,000

Stock Issued During Period, Value, Issued for Services

2,000

1,000

4,000

Research And Development Expense

(35,134,000)

(29,810,000)

Payments to Acquire in Process Research and Development

200,000

Share Price

$ 2.39

$ 2.82

Stock Issued During Period, Value, Other

3,502,000

Proceeds From Issuance Of Common Stock

0

0

3,502,000

Share-based Compensation

$ 12,128,000

$ 14,291,000

5,546,000

Common Stock Shares Authorized

100,000,000

100,000,000

100,000,000

100,000,000

Common Stock [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Stock Issued During Period, Shares, Issued for Services

500,000

Development Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

$ 22,000,000

$ 10,700,000

Sale Millstone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

7,000,000

26,200,000

NeuPharma [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research And Development In Process

$ 1,000,000

$ 1,000,000

NeuPharma [Member] | Development Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

40,000,000

NeuPharma [Member] | Sale Millstone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

40,000,000

NeuPharma [Member] | Regulatory Approvals To Commercialize Products [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

$ 22,500,000

City Of Hope [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Marketability Percentage Of Invested Capital

44.80%

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent

30.00%

Share Price

$ 0.147

Stock Issued During Period, Value, Other

$ 100,000

City Of Hope [Member] | Development Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

$ 1,500,000

City Of Hope [Member] | Sale Millstone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

13,000,000

National Institutes of Health [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Milestone Fees

700,000

New Zealand Pharmaceuticals Ltd [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Reimbursement Revenue

600,000

Dana-Farber [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Shares Issued, Price Per Share

$ 0.065

Stock Issued During Period, Shares, Issued for Services

500,000

136,830

Stock Issued During Period, Value, Issued for Services

$ 32,500

$ 600,000

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

5.00%

5.00%

Proceeds From Issuance Of Common Stock

$ 10,000,000

Dana-Farber [Member] | First Commercial Sale Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

21,500,000

Dana-Farber [Member] | Additional Sales Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

60,000,000

Mustang Bio, Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Royalty Guarantees, Commitments, Amount

$ 1,000,000

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

10.00%

Minimum Annual Royalty Payable

$ 1,000,000

Mustang Bio, Inc [Member] | Development Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

14,500,000

Mustang Bio, Inc [Member] | Financial Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

2,000,000

Escala Therapeutics, Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Fees

$ 1,300,000

Reimbursement Revenue

$ 1,300,000

Gene Medicine, Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

19,300,000

Royalty Guarantees, Commitments, Amount

$ 100,000

$ 300,000

Effcon Laboratories, Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Fees

$ 200,000

Revenue Recognition Milestone Method Payments Due

5,300,000

Royalty Guarantees, Commitments, Amount

$ 1,600,000

Teva Pharmaceutical Industries Ltd [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payments for Fees

$ 500,000

Teva Pharmaceutical Industries Ltd [Member] | Regulatory Approvals To Commercialize Products [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

206,500,000

Teva Pharmaceutical Industries Ltd [Member] | Clinical Development and Regulatory Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

$ 220,000,000

Jubilant Biosys Ltd [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research And Development In Process

2,000,000

Revenue Recognition Milestone Method Payments Due

$ 87,500,000

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

50.00%

50.00%

Payment Of Upfront Licensing Fee

$ 2,000,000

Royalty Revenue

$ 1,500,000

Jubilant Biosys Ltd [Member] | Sale Millstone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Milestone Method Revenue Additional Payments Eligible To Receive

89,000,000

Jubilant Biosys Ltd [Member] | Regulatory Approvals To Commercialize Products [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

59,500,000

Jubilant Biosys Ltd [Member] | Successful Achievement Of One Preclinical Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

300,000

Jubilant Biosys Ltd [Member] | Completion Of Three Clinical Development Milestones For Two Licensed Products [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

25,500,000

Jubilant Biosys Ltd [Member] | Five Regulatory Approvals And First Commercial Sales [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

61,700,000

Jubilant Biosys Ltd [Member] | Three Sales Milestones Based On Aggregate Net Sales [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

89,000,000

Jubilant Biosys Ltd [Member] | Clinical Development and Regulatory Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

$ 89,000,000

Jubilant Biosys Ltd [Member] | TG Therapeutics, Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment Of Upfront Licensing Fee

1,000,000

Collaborative Agreements with TGTX [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payments for Fees

500,000

600,000

600,000

Collaborative Agreements with TGTX [Member] | NeuPharma [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payments for Fees

42,000

Agreement With City Of Hope [Member] | Mustang Bio, Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment Of Upfront Licensing Fee

2,000,000

Triplex [Member] | City Of Hope [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Minimum Annual Royalty Payable

750,000

Pentameter [Member] | City Of Hope [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Minimum Annual Royalty Payable

750,000

Pentameter [Member] | City Of Hope [Member] | Development Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

5,500,000

Pentameter [Member] | City Of Hope [Member] | Sale Millstone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

26,000,000

Coronado SO Co, Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research And Development In Process

$ 0

$ 1,607,000

0

Payments for Fees

$ 900,000

Stock Issued During Period, Shares, Other

150,000

Research And Development Expense

$ 500,000

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

13.00%

13.00%

13.00%

13.00%

Checkpoint Therapeutics, Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research And Development In Process

$ 3,160,000

$ 3,159,000

0

Stock Issued During Period, Value, Purchase of Assets

$ 22,000,000

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

[1]

62.30%

62.90%

62.90%

62.30%

Checkpoint Therapeutics, Inc [Member] | First Commercial Sale Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

21,500,000

Checkpoint Therapeutics, Inc [Member] | Additional Sales Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

60,000,000

Checkpoint Therapeutics, Inc [Member] | Clinical Development Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

7,000,000

Checkpoint Therapeutics, Inc [Member] | Commercial Sales In Specified Territories [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

$ 14,500,000

Checkpoint Therapeutics, Inc [Member] | Dana-Farber [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Stock Issued During Period, Value, Purchase of Assets

$ 5,500,000

Helocyte [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research And Development In Process

200,000

$ 53,000

$ 200,000

$ 0

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

20.50%

20.50%

Helocyte [Member] | Triplex [Member] | Development Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

9,000,000

Helocyte [Member] | Triplex [Member] | Sale Millstone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

26,000,000

Licensing Agreements [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payments to Acquire Intangible Assets

$ 45,000

$ 150,000

Licensing Agreements [Member] | City Of Hope [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Marketability Percentage Of Invested Capital

44.50%

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent

30.00%

Share Price

$ 0.097

$ 0.097

Stock Issued During Period, Value, Other

$ 48,500

Licensing Agreements [Member] | City Of Hope [Member] | Common Class A [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued

500,000

Licensing Agreements [Member] | Dana-Farber [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payments for Fees

$ 1,000,000

Licensing Agreements [Member] | Mustang Bio, Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Stock Issued During Period, Shares, Issued for Services

293,588

Stock Issued During Period, Value, Issued for Services

$ 1,700,000

Share Price

$ 5.73

$ 5.73

Proceeds from Third Party Investors

$ 10,000,000

Common Stock Shares Authorized

1,000,000

1,000,000

Licensing Agreements [Member] | Cellvation Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Marketability Percentage Of Invested Capital

40.20%

Stock Issued During Period, Shares, Issued for Services

500,000

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent

30.00%

Share Price

$ 0.024

Stock Issued During Period, Value, Other

$ 12,000

Payment of Upfront Fees

$ 300,000

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

5.00%

Licensing Agreements [Member] | Cellvation Inc [Member] | Development Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

$ 6,200,000

Licensing Agreements [Member] | Cellvation Inc [Member] | Sale Millstone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

6,000,000

Licensing Agreements [Member] | Cellvation Inc [Member] | Minimum [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Additional Minimum Annual Royalty Payable

50,000

Licensing Agreements [Member] | Cellvation Inc [Member] | Maximum [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Additional Minimum Annual Royalty Payable

200,000

Licensing Agreements [Member] | Cellvation Inc [Member] | Research and Development - Licenses Acquired [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Share-based Compensation

$ 12,000

Licensing Agreements [Member] | Coronado SO [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Marketability Percentage Of Invested Capital

44.80%

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent

30.00%

Share Price

$ 1.19

$ 1.19

Licensing Agreements [Member] | IV Tramadol [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payments to Acquire Intangible Assets

$ 1,000,000

Payments for Fees

$ 2,000,000

Licensing Agreements [Member] | Helocyte [Member] | Common Class A [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued

8,333

Avenue Therapeutics, Inc. [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Shares Issued, Price Per Share

$ 0.146

$ 0.146

Research And Development Expense

$ 14,000

$ 29,000

Debt Instrument, Fee Amount

$ 3,000,000

Secondary License [Member] | Cellvation Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Fees

50,000

Revenue Recognition Milestone Method Payments Due

300,000

Second TBI License [Member] | Cellvation Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Minimum Annual Royalty Payable

$ 100,000

[1]

Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.

Milestones and Sponsored Rese66

Milestones and Sponsored Research Agreements - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended			12 Months Ended
	Aug. 31, 2016	Mar. 31, 2016	Feb. 29, 2016	Dec. 31, 2016	Dec. 31, 2015	Oct. 31, 2016	Mar. 31, 2015
Research And Development Expense				$ (35,134)	$ (29,810)
Payments to Acquire in Process Research and Development				200
Checkpoint Therapeutics, Inc [Member]
Stock Issued During Period, Value, Purchase of Assets				22,000
Helocyte Inc [Member]
Payments For Research And Development Expenses	$ 2,000			4,400
Helocyte Inc [Member] | Pep Vax [Member]
Payments For Research And Development Expenses	1,000			2,000
Helocyte Inc [Member] | Triplex [Member]
Payments For Research And Development Expenses	$ 1,000			2,400
Mustang Bio, Inc [Member]
Research And Development Expense Payable Milestone Payment				2,000	$ 1,500		$ 2,000
UCLB [Member]
Payment of Upfront Fees				$ 100
Milestone Payments		$ 400
UCLB [Member] | Minimum [Member]
Royalty Percentage				3.00%
UCLB [Member] | Maximum [Member]
Royalty Percentage				5.00%
Cellvation [Member]
Research And Development Expense Payable Milestone Payment						$ 700
Research And Development Expense				$ 200
City Of Hope [Member]
Research And Development Expense Payable Milestone Payment		2,000	$ 3,400
Payments to Acquire in Process Research and Development		$ 1,000	$ 1,000

Intangibles - Additional Inform

Intangibles - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Jan. 31, 2016	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Indefinite-lived Intangible Assets [Line Items]
Payments to Acquire Intangible Assets			$ 350,000	$ 1,250,000	$ 0
Cost of Goods Sold, Amortization			183,000	$ 0	$ 0
Journey Medical Corporation [Member]
Indefinite-lived Intangible Assets [Line Items]
Payments to Acquire Intangible Assets	$ 50,000	$ 1,300,000	300,000
Cost of Goods Sold, Amortization			$ 200,000

Debt and Interest - Long-term d

Debt and Interest - Long-term debt (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Jul. 31, 2016	Dec. 31, 2015
Debt [Line Items]
Total notes payable, long-term	$ 30,224		$ 24,009
Less: Discount of notes payable	2,009		835
Total notes payable, long-term, net	$ 22,528		23,174
Interest Rate	39.00%
IDB Note [Member]
Debt [Line Items]
Total notes payable, long-term	$ 14,929		14,009
Interest Rate	2.25%
Maturity Date	Feb - 2018
NSC Note [Member]
Debt [Line Items]
Total notes payable, long-term	$ 3,608		10,000
Less: Discount of notes payable		$ 600
Interest Rate	8.00%
Maturity Date	Sep - 2018
Opus Credit Facility [Member]
Debt [Line Items]
Total notes payable, long-term	$ 7,000		0
Interest Rate	12.00%
Maturity Date	Sep - 2018
Helocyte Convertible Note One [Member]
Debt [Line Items]
Total notes payable, long-term	$ 1,031		0
Maturity Date	Dec - 2017
Helocyte Convertible Note One [Member] | Minimum [Member]
Debt [Line Items]
Interest Rate	5.00%
Helocyte Convertible Note One [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%
Debt Instrument Due [Member] | Minimum [Member]
Debt [Line Items]
Interest Rate	5.00%
Debt Instrument Due [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%
Avenue Convertible Note [Member]
Debt [Line Items]
Total notes payable, long-term	$ 200		0
Maturity Date	June - 2018
Avenue Convertible Note [Member] | Minimum [Member]
Debt [Line Items]
Interest Rate	5.00%
Avenue Convertible Note [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%
Helocyte Convertible Note Two [Member]
Debt [Line Items]
Total notes payable, long-term	$ 2,051		0
Maturity Date	March - 2018
Helocyte Convertible Note Three [Member]
Debt [Line Items]
Total notes payable, long-term	$ 1,405		$ 0
Maturity Date	May - 2018

Debt and Interest - Schedule of

Debt and Interest - Schedule of Interest Expenses for Debt Arrangements (Detail) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Debt [Line Items]
Financing fee		$ 1,032	$ 0	$ 0
Total Interest Expense and Financing Fee		3,690	1,484	1,338
LOC Fees [Member]
Debt [Line Items]
Interest		11	0	0
Interest and Debt Expense		11	0	0
IDB Note [Member]
Debt [Line Items]
Interest		328	314	292
Amortization of fees		1	5	4
Interest and Debt Expense		329	319	296
NSC Debt [Member]
Debt [Line Items]
Interest		599	690	0
Amortization of fees		1,270	309	0
Interest and Debt Expense		1,869	999	0
Ovamed [Member]
Debt [Line Items]
Interest		0	166	154
Interest and Debt Expense		0	166	154
Opus Credit Facility [Member]
Debt [Line Items]
Interest		192	0	0
Amortization of fees		195	0	0
Interest and Debt Expense		387	0	0
Helocyte Convertible Note [Member]
Debt [Line Items]
Interest		61	0	0
Financing fee		962	0	0
Interest and Debt Expense		1,023	0	0
Avenue Convertible Note [Member]
Debt [Line Items]
Financing fee		70	0	0
Interest and Debt Expense		70	0	0
Hercules Debt [Member]
Debt [Line Items]
Interest	[1]	0	0	845
Amortization of fees		0	0	43
Interest and Debt Expense		0	0	888
D&O Insurance [Member]
Debt [Line Items]
Interest		1	0	0
Interest and Debt Expense		$ 1	$ 0	$ 0
[1]	Interest expense related to the Company’s loan with Hercules was $0.8 million, including $0.4 million related to accretion of the debt discount for the year ended December 31, 2014.

Debt and Interest- Additional I

Debt and Interest- Additional Information (Detail) - USD ($)

Sep. 14, 2016

Feb. 13, 2014

Oct. 25, 2016

Sep. 30, 2016

Jun. 30, 2016

Feb. 29, 2016

Oct. 30, 2015

Aug. 31, 2012

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Jul. 31, 2016

Oct. 31, 2015

Sep. 18, 2015

Mar. 31, 2015

Debt [Line Items]

Term loan

$ 30,224,000

$ 24,009,000

Warrant to purchase common stock

7

Warrant exercise price

$ 2,500

$ 7

Debt Instrument, Interest Rate, Stated Percentage

39.00%

Debt Discount

$ 1,466,000

314,000

$ 0

Debt discount recorded

2,009,000

835,000

Debt Instrument, Unamortized Discount (Premium), Net, Total

$ 400,000

Percentage of Cash Flow Pursuant to ASC 470

10.00%

Fair Value Adjustment of Warrants

$ 1,039,000

438,000

0

Debt Related Commitment Fees and Debt Issuance Costs

1,032,000

0

0

Professional Fees

$ 0.2

Convertible Notes Payable, Current

$ 1,031,000

0

Letter of Credit [Member]

Debt [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

2.00%

Interest Expense, Debt

$ 11,000

0

0

Letters of Credit Outstanding, Amount

1,500,000

Warrant [Member]

Debt [Line Items]

Approximate fair value of the warrant

$ 300,000

Israel Discount Bank Of New York [Member]

Debt [Line Items]

Debt Instrument, Fee Amount

$ 15,000,000

Notes Payable

$ 14,900,000

14,000,000

IDB Promissory Note Payable [Member]

Debt [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

2.25%

Debt Instrument, Unused Borrowing Capacity, Amount

100,000

Debt Instrument, Periodic Payment

14,000,000

Debt Instrument, Fee Amount

15,000,000

Loan Agreement [Member]

Debt [Line Items]

Interest rate

The loan bore interest at a rate per annum equal to the greater of (i) 9.25% or (ii) 9.25% plus the sum of the prevailing prime rate minus 3.25%.

Maturity Date

Mar. 1, 2016

Interest payment term

The loan required interest-only payments for the initial 12 months and thereafter requires repayment of the principal balance with interest in 30 monthly installments.

Opus Credit Facility [Member]

Debt [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

12.00%

Maturity Date

Sep. 14, 2018

Class Of Warrant Or Right Value Of Securities Called By Warrants Or Rights

$ 1,500,000

Class Of Warrant Or Right Exercise Price Percentage Of Warrants Or Rights

3.00%

Legal Fees

$ 25,000,000

Class Of Warrant Or Right Discount On Warrant

$ 2,000,000

Warrants and Rights Outstanding

7,000,000

NSC Notes Payable [Member]

Debt [Line Items]

Term loan

$ 3,608,000

10,000,000

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt discount recorded

$ 600,000

Debt Instrument, Face Amount

900,000

Interest Expense, Debt

$ 599,000

$ 690,000

0

Long-term Debt, Gross

$ 3,600,000

Notes Payable

$ 10,000,000

Debt Instrument, Term

10 years

Debt Instrument, Interest Rate, Effective Percentage

17.83%

14.00%

Contingently Issuable Warrants Percentage

25.00%

25.00%

Hercules Note Payble [Member]

Debt [Line Items]

Interest Expense, Debt

[1]

$ 0

$ 0

845,000

Hercules Note Payble [Member] | Loan Agreement [Member]

Debt [Line Items]

Debt Instrument, Periodic Payment

14,000,000

Debt Instrument, Periodic Payment, Principal

13,200,000

Debt Instrument Term Charges

400,000

Debt Instrument, Fee Amount

300,000

Interest Expense, Debt

$ 100,000

Hercules Debt Agreement [Member]

Debt [Line Items]

Interest Expense, Debt

800,000

Accretion of debt discount

400,000

Hercules Debt Agreement [Member] | Warrant [Member]

Debt [Line Items]

Fair value of the warrant volatility

87.20%

Fair value of risk-free interest rate

1.10%

Hercules Debt Agreement [Member] | Loan Agreement [Member]

Debt [Line Items]

Term loan

$ 15,000,000

Received net proceeds

14,700,000

Subsequent private placement

$ 2,000,000

Warrant to purchase common stock

73,009

Warrant exercise price

$ 5.65

Charges on termination of the loan stated percentage

2.65%

Charges on termination of the loan, amount

$ 400,000

Debt Discount

$ 900,000

Interest rate for amortize loan discounts

12.30%

Fees Related To Loan Issuance Costs

$ 200,000

Helocyte Convertible Note One [Member]

Debt [Line Items]

Term loan

1,031,000

0

Debt Instrument, Term

18 months

Proceeds from Issuance or Sale of Equity

$ 10,000,000

Class Of Warrant Or Right Value Of Securities Called By Warrants Or Rights

$ 400,000

Class Of Warrant Or Right Exercise Price Percentage Of Warrants Or Rights

110.00%

Legal Fees

$ 100,000

Helocyte Convertible Note One [Member] | Conversion One [Member]

Debt [Line Items]

Debt Instrument, Convertible, Terms of Conversion Feature

(a) the lowest price per share at which equity securities of Helocyte are sold in such sale less a 33% discount and (b) a per share price based on a pre-offering valuation of $50.0 million divided by the number of common shares outstanding on a fully-diluted basis.

Helocyte Convertible Note One [Member] | Conversion Two [Member]

Debt [Line Items]

Debt Instrument, Convertible, Terms of Conversion Feature

(a) a discount to the price per share being paid in the Sale of Helocyte equal to 33% or (b) a conversion price per share based on a pre-sale valuation of $50.0 million divided by the fully-diluted common stock of Helocyte immediately prior to the Sale of Helocyte (excluding the notes).

Helocyte Convertible Note One [Member] | Minimum [Member]

Debt [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Helocyte Convertible Note One [Member] | Maximum [Member]

Debt [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Avenue Convertible Note [Member]

Debt [Line Items]

Term loan

$ 200,000

0

Subsequent private placement

$ 200,000

Debt Instrument, Term

18 months

Debt Related Commitment Fees and Debt Issuance Costs

$ 70,000

$ 0

$ 0

Debt Instrument, Convertible, Terms of Conversion Feature

(a) the lowest price per share at which equity securities of Avenue are sold in such sale less a 33% discount and (b) a per share price based on a pre-offering valuation of $30.0 million divided by the number of common shares outstanding on a fully-diluted basis.

Proceeds from Issuance or Sale of Equity

$ 10,000,000

Class Of Warrant Or Right Value Of Securities Called By Warrants Or Rights

10,000

Legal Fees

$ 44,000

Debt Instrument, Interest Rate, Stated Percentage,Current Year

5.00%

Debt Instrument, Interest Rate, Stated Percentage,After Twelve Month

8.00%

Net Proceeds From Issuance Of Private Placement After Paying Fees

$ 100,000

Payments for Other Fees

58,000

Paymens For Placement Fee

10,000

Professional Fees

4,000

Convertible Notes Payable, Current

$ 200,000

Placement Fee Percentage

10.00%

Avenue Convertible Note [Member] | Minimum [Member]

Debt [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Avenue Convertible Note [Member] | Maximum [Member]

Debt [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Helocyte Convertible Note [Member] | Maximum [Member]

Debt [Line Items]

Debt Instrument, Face Amount

$ 5,000,000

Checkpoint [Member]

Debt [Line Items]

Debt Instrument, Unamortized Discount (Premium), Net, Total

$ 300,000

Long-term Debt, Fair Value

200,000

Fees Related To Loan Issuance Costs

$ 2,800,000

Checkpoint [Member] | NSC Notes Payable [Member]

Debt [Line Items]

Debt Related Commitment Fees and Debt Issuance Costs

2,800,000

Avenue [Member] | NSC Notes Payable [Member]

Debt [Line Items]

Debt Related Commitment Fees and Debt Issuance Costs

3,000,000

Warrant to NSC [Member]

Debt [Line Items]

Approximate fair value of the warrant

$ 600,000

Debt discount recorded

$ 200,000

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

139,592

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price

$ 0.0001

$ 0.0001

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

10 years

10 years

Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term

10 years

10 years

Fair Value Adjustment of Warrants

$ 800,000

$ 400,000

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Issued

138,462

Contingently Issuable Warrants issued in connection with NSC Note Avenue [Member]

Debt [Line Items]

Debt Instrument, Unamortized Discount (Premium), Net, Total

100,000

$ 100,000

Mustang [Member] | NSC Notes Payable [Member]

Debt [Line Items]

Debt Related Commitment Fees and Debt Issuance Costs

$ 3,600,000

[1]

Interest expense related to the Company’s loan with Hercules was $0.8 million, including $0.4 million related to accretion of the debt discount for the year ended December 31, 2014.

Accrued Liabilities and other71

Accrued Liabilities and other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Accrued expenses:
Professional fees	$ 1,253	$ 382
Salaries, bonuses and related benefits	2,846	2,492
Accrued severance	53	0
Ovamed manufacturing rights - short term component	900	2,007
Research and development	394	303
Dr. Falk Pharma milestone	2,634	2,717
JMC Accrued Cost Of goods Sold	726	0
Lease impairment	128	146
Other	1,148	523
Total accrued expenses	10,082	8,570
Other long-term liabilities:
Deferred rent and long-term lease abandonment charge	5,014	584
Total other long-term liabilities	$ 5,014	$ 584

Accrued Expenses and Other Long

Accrued Expenses and Other Long-Term Liabilities- Accounts Payable and Other Accrued Expenses (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Sep. 30, 2016
Legal	$ 1,253	$ 382
Other	1,148	523
Total	24,295	10,438
Payments to Acquire Intangible Assets	350	$ 1,250	$ 0
Ovamed Manufacturing Rights [Member]
Other	900
Payments to Acquire Intangible Assets	$ 1,100
National Holdings Corporation [Member]
Legal				$ 1,346
Audit				198
Telecommunications				209
Data Services				425
Regulatory				444
Settlements				832
Deferred rent				65
Contingent consideration payable				424
Other				3,223
Total				$ 7,166

Accrued Liabilities and other73

Accrued Liabilities and other Long-Term Liabilities - Additional Information (Detail) $ in Thousands, € in Millions	12 Months Ended
	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2016EUR (€)	Dec. 12, 2014USD ($)	Dec. 31, 2012USD ($)
Schedule Accrued Expenses And Other Long-Term Liabilities [Line Items]
Other Liabilities	$ 2,600			€ 2.5
Other Accrued Liabilities, Current	1,148	$ 523
Asset Retirement Obligation, Accretion Expense	0	$ 200	$ 200
Capital Leases, Future Minimum Payments Receivable, Next Twelve Months					$ 500
Ovamed Manufacturing Rights [Member]
Schedule Accrued Expenses And Other Long-Term Liabilities [Line Items]
Other Liabilities						$ 1,500
Other Accrued Liabilities, Current	$ 900

Non-Controlling Interests - Sum

Non-Controlling Interests - Summary Of Non-controlling Interests in Consolidated Entities (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016		Dec. 31, 2015	Dec. 31, 2014
Noncontrolling Interest [Line Items]
NCI equity share									$ 60,668		$ 32,882
Net loss attributed to non-controlling interests	$ 3,871	$ 3,975	$ 3,911	$ 4,438	$ 3,039	$ 1,694	$ 243	$ 479	(16,195)		(5,455)	$ 0
Non-controlling interests in consolidated entities	44,473				27,427				44,473		27,427
Avenue [Member]
Noncontrolling Interest [Line Items]
NCI equity share									(494)		6
Net loss attributed to non-controlling interests									(349)		(567)
Non-controlling interests in consolidated entities	(843)				(561)				(843)		(561)
Coronado SO Co, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share									(217)		23
Net loss attributed to non-controlling interests									(19)		(240)
Non-controlling interests in consolidated entities	(236)				(217)				(236)		(217)
Mustang Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share									12,376		14
Net loss attributed to non-controlling interests									(1,805)		(373)
Non-controlling interests in consolidated entities	10,571				(359)				10,571		(359)
Checkpoint Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share									32,160		32,760
Net loss attributed to non-controlling interests									(11,733)	[1]	(3,855)
Non-controlling interests in consolidated entities	20,427				28,905				20,427		28,905
JMC [Member]
Noncontrolling Interest [Line Items]
NCI equity share									(192)		79
Net loss attributed to non-controlling interests									(355)		(420)
Non-controlling interests in consolidated entities	(547)				$ (341)				(547)		$ (341)
Helocyte [Member]
Noncontrolling Interest [Line Items]
NCI equity share									(612)
Net loss attributed to non-controlling interests									(1,155)
Non-controlling interests in consolidated entities	(1,767)								(1,767)
Cellvation [Member]
Noncontrolling Interest [Line Items]
NCI equity share									4
Net loss attributed to non-controlling interests									(158)
Non-controlling interests in consolidated entities	(154)								(154)
National Holdings [Member]
Noncontrolling Interest [Line Items]
NCI equity share									17,643
Net loss attributed to non-controlling interests									(621)
Non-controlling interests in consolidated entities	$ 17,022								$ 17,022
[1]	Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.

Non-Controlling Interests - S75

Non-Controlling Interests - Summary Of Components of Non-Controlling Interests in Loss of Consolidated Entities (Detail) - USD ($) $ in Thousands		3 Months Ended								12 Months Ended
		Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016		Dec. 31, 2015	Dec. 31, 2014
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities		$ 3,871	$ 3,975	$ 3,911	$ 4,438	$ 3,039	$ 1,694	$ 243	$ 479	$ (16,195)		$ (5,455)	$ 0
Avenue [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities										$ (349)		$ (567)
Non-controlling ownership		10.20%				11.50%				10.20%		11.50%
Coronado SO Co, Inc [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities										$ (19)		$ (240)
Non-controlling ownership		13.00%				13.00%				13.00%		13.00%
Mustang Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities										$ (1,805)		$ (373)
Non-controlling ownership		26.70%				10.00%				26.70%		10.00%
Checkpoint Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities										$ (11,733)	[1]	$ (3,855)
Non-controlling ownership	[1]	62.90%				62.30%				62.90%		62.30%
JMC [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities										$ (355)		$ (420)
Non-controlling ownership		7.00%				8.80%				7.00%		8.80%
Helocyte [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities										$ (1,155)
Non-controlling ownership		20.50%								20.50%
Cellvation [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities										$ (158)
Non-controlling ownership		22.00%								22.00%
National Holdings [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities										$ (621)
Non-controlling ownership		43.40%								43.40%
[1]	Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.

Net Loss per Common Share - Com

Net Loss per Common Share - Computations of Diluted Weighted Average Shares Outstanding (Detail) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	13,676,979	9,889,452	9,058,166
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	456,150	685,061	693,636
Opus warrants to purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	1,780,000	0	0
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	1,604,214	1,960,443	2,276,813
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	8,749,052	6,816,321	6,087,717
Unvested Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	1,087,563	427,627	0

Net Loss per Common Share - Add

Net Loss per Common Share - Additional Information (Detail) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount	13,676,979	9,889,452	9,058,166
Restricted Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount	8,749,052	6,816,321	6,087,717

Stockholders' Equity - Employee

Stockholders' Equity - Employee Stock Purchase Programs (Detail) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 12,128	$ 14,291	$ 5,546
Fortress Companies [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	[1],[2]	4,709	3,900	0
Employee Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		7,386	8,130	5,492
Executive Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		0	2,228	0
Non-Employee Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 33	$ 33	$ 54
[1]	Consists of approximately $28,000 of Avenue's compensation expenses, approximately $3.9 million of Checkpoint's compensation expense, approximately $0.5 million of JMC's compensation expenses, approximately $0.3 million of Helocyte's compensation expenses, approximately $7,000 of Cellvation's compensation expenses and approximately $42,000 of National Holdings' compensation expenses on stock and option grants for the year ended December 31, 2016
[2]	Consists of approximately $50,400 of Avenue's compensation expenses, approximately $3.3 million of Checkpoint's compensation expense, and approximately $0.6 million of JMC's compensation expenses on stock grants for the year ended December 31, 2015.

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Options vested and expected to vest	1,779,365
Number of shares, Forfeited	(648,864)
Number of shares, Options vested and expected to vest	1,130,501	1,779,365
Number of shares, Exercisable as of December 31, 2016	1,105,501
Weighted average exercise price, Options vested and expected to vest	$ 4.37
Weighted average exercise price, Forfeited	0.51
Weighted average exercise price, Options vested and expected to vest	3.73	$ 4.37
Weighted average exercise price, Exercisable as of December 31, 2016	$ 3.71
Total Weighted average intrinsic value, Options vested and expected to vest	$ 666,396
Total Weighted average intrinsic value, Options vested and expected to vest	602,451	$ 666,396
Total weighted average intrinsic value, Exercisable as of December 31, 2016	$ 602,451
Weighted average remaining contractual life (years), Options vested and expected to vest	4 years 11 months 5 days	6 years 3 months 25 days
Weighted average remaining contractual life (years), Exercisable as of December 31, 2016	4 years 10 months 28 days

Stockholders' Equity - Restrict

Stockholders' Equity - Restricted Stock Activity (Detail)	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Restricted stock granted	1,950,000
Number of shares, Restricted stock vested	(366,666)
Number of shares, Restricted units cancelled	(1,250,000)
Number of shares, Unvested balance	333,334
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Unvested balance	8,757,935
Number of shares, Restricted stock granted	1,240,868
Number of shares, Restricted stock cancelled	(33,333)
Number of shares, Restricted stock vested	(173,333)
Number of shares, Restricted stock units granted	641,000
Number of shares, Restricted units cancelled	(111,750)
Restricted stock units vested	(227,292)
Number of shares, Unvested balance	10,094,095
Weighted average grant price, Unvested balance | $ / shares	$ 2.47
Weighted average grant price, Restricted stock granted | $ / shares	2.77
Weighted average grant price, Restricted stock cancelled | $ / shares	2.69
Weighted average grant price, Restricted stock vested | $ / shares	2.73
Weighted average grant price, Restricted stock units granted | $ / shares	2.93
Weighted average grant price, Restricted stock units cancelled | $ / shares	3.58
Weighted average grant price, Restricted stock units vested | $ / shares	3.56
Weighted average grant price, Unvested balance | $ / shares	$ 2.49

Stockholders' Equity - Summariz

Stockholders' Equity - Summarizes Fortress warrant activities (Detail) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015
Subsidiary or Equity Method Investee [Line Items]
Number of shares, Granted		1,950,000
Warrant [Member]
Subsidiary or Equity Method Investee [Line Items]
Number of shares, Outstanding		569,835
Number of shares, Granted		1,880,000
Number of shares, Expired		(161,382)
Number of shares, Exercised	[1]	(25,000)
Number of shares, Outstanding		2,263,453	569,835
Number of shares, Exercisable		483,453
Weighted average exercise price, Outstanding		$ 6.31
Weighted average exercise price, Granted		3
Weighted average exercise price, Expired		6.30
Weighted average exercise price, Exercised	[1]	1.37
Weighted average exercise price, Outstanding		3.62	$ 6.31
Weighted average exercise price, Exercisable		$ 5.88
Total weighted average instrinsic value, Outstanding		$ 120,700
Total weighted average intrinsic value, Granted		0
Total weighted average intrinsic value, Exercised	[1]	33,250
Total weighted average intrinsic value, Cancelled		79,800
Total weighted average intrinsic value, Exercisable		$ 79,800
Weighted average remaining contractual life (years), Outstanding		4 years 8 months 26 days	1 year 10 months 2 days
Weighted average remaining contractual life, Exercisable (years)		2 years 1 month 17 days
[1]	cashless

Stockholders' Equity - Warrants

Stockholders' Equity - Warrants (Detail) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares
Mustang [Member]
Warrant Shares | shares	1,000,000
Risk Free Rate	2.36%
Volatilty	106.11%
Life	10 years
Exercise price | $ / shares	$ 0.147
Fair Value | $	$ 135
Checkpoint [Member]
Warrant Shares | shares	1,000,000
Risk Free Rate	2.36%
Volatilty	106.11%
Life	10 years
Exercise price | $ / shares	$ 0.129
Fair Value | $	$ 118
Avenue [Member]
Warrant Shares | shares	1,000,000
Risk Free Rate	2.36%
Volatilty	106.11%
Life	10 years
Exercise price | $ / shares	$ 0.146
Fair Value | $	$ 134
CNDO SO [Member]
Warrant Shares | shares	1,000,000
Risk Free Rate	2.36%
Volatilty	106.11%
Life	10 years
Exercise price | $ / shares	$ 1.190
Fair Value | $	$ 1,091
Helocyte [Member]
Warrant Shares | shares	1,000,000
Risk Free Rate	2.36%
Volatilty	106.11%
Life	10 years
Exercise price | $ / shares	$ 0.097
Fair Value | $	$ 89
JMC [Member]
Warrant Shares | shares	1,000,000
Risk Free Rate	2.36%
Volatilty	106.11%
Life	10 years
Exercise price | $ / shares	$ 0.650
Fair Value | $	$ 596
Escala [Member]
Warrant Shares | shares	1,000,000
Risk Free Rate	2.36%
Volatilty	106.11%
Life	10 years
Exercise price | $ / shares	$ 0.071
Fair Value | $	$ 65

Stockholders' Equity - Fair val

Stockholders' Equity - Fair value of options (Detail) - Journey Medical Corporation [Member]	12 Months Ended
	Dec. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, Minimum	1.14%
Risk-free interest rate, Maximum	2.25%
Expected dividend yield	0.00%
Expected volatility, Minimum	96.89%
Expected volatility, Maximum	105.48%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	5 years 18 days
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	6 years 11 months 12 days

Stockholders' Equity - Restri84

Stockholders' Equity - Restricted Stock Unit (Detail)	12 Months Ended
	Dec. 31, 2016$ / sharesshares
RSU Grant	1,950,000
Vested	366,666
Forfeited	(1,250,000)
Unvested	333,334
President [Member]
RSU Grant	1,500,000
Vesting Term	4 years
Vested	250,000
Forfeited	(1,250,000)
Unvested	0
Fair value per Share | $ / shares	$ 0.650
Sales Operations Staff [Member]
RSU Grant	450,000
Vesting Term	4 years
Vested	116,666
Forfeited	0
Unvested	333,334
Fair value per Share | $ / shares	$ 0.650

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	Jul. 15, 2015	Jun. 01, 2015	Jun. 02, 2014	Dec. 01, 2016	Oct. 31, 2016	Jun. 01, 2016	May 31, 2016	Mar. 31, 2016	Mar. 30, 2016	Feb. 29, 2016	Feb. 23, 2016	Jan. 02, 2016	Dec. 02, 2015	Oct. 30, 2015	Sep. 18, 2015	Jul. 28, 2015	Dec. 01, 2014	Feb. 28, 2014	Jun. 30, 2013	Dec. 31, 2016	Sep. 30, 2016	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Oct. 19, 2015	Jun. 02, 2015	Dec. 02, 2014	Mar. 17, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Based compensation, Options Contractual term																							10 years
Stock-based compensation weighted-average vesting period																							2 years 2 months 12 days
Employee Stock Purchase Plan to eligible employees, Reckoning fair value percentage during offering period				85.00%		85.00%														85.00%			85.00%
Employee Stock Purchase Plan to eligible employees, compensation expense recognized																							$ 0.1	$ 45,000	$ 25,000
Common Stock issued in connection with the first ESPP offering				52,769		33,958
Share Based Compensation Restricted Stock Units																							$ 9,900,000	$ 6,900,000	4,000,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition																							2 years 2 months 12 days
Common Stock Par Or Stated Value Per Share				$ 2.03		$ 2.40														$ 0.001			$ 0.001	$ 0.001
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value																									11,600,000
Share Price				$ 2.39		$ 2.82
Research And Development Expense																							$ (35,134,000)	$ (29,810,000)
General and Administrative Expense																							$ (28,229,000)	(18,734,000)
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																				9,978,201			9,978,201
Proceeds from Stock Options Exercised																							$ 0	216,000	596,000
Class of Warrant or Right, Exercise Price of Warrants or Rights															$ 7					$ 2,500			$ 2,500
Stock Issued During Period, Shares, Issued for Services											10,000
Stock Issued During Period, Value, Issued for Services																							$ 2,000	1,000	4,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	50,000																					1,500,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																				7			7
Proceeds from issuance of Common stock																							$ 0	0	3,502,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options																				$ 4,100,000			$ 4,100,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized																							7,700,000
Share-based Compensation																							$ 12,128,000	14,291,000	5,546,000
Percentage Of Placement Agent Fee																							10.00%
Proceeds from Issuance of Warrants																							$ (793,000)	(613,000)
Net Proceeds From Issuance Of Warrants																							$ 51,500,000
Stock Issued For Exercise Of Warrants																							10,000
Warrant Purchase Price Per Unit																							$ 50,000
Stock Issued During Period Shares warrants Exercised															2,500
Stock Issued During Period, Shares, New Issues															10,000
Stock Issued During Period, Value of Warrants Excercised															$ 50,000
Equity Method Investment, Ownership Percentage																													35.00%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period																							1,950,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period																							366,666
Warrants Issued														139,592
Stock Issued During Period, Value, New Issues																							$ 53,000,000
Payments of Stock Issuance Costs																							0	0	32,000
Stock Repurchased and Retired During Period, Shares					100,000
Treasury Stock Acquired, Average Cost Per Share					$ 0.176
Stock Repurchased and Retired During Period, Value					$ 17,600
Adjustments To Additional Paid In Capital At Market Offering Costs																							$ (79,000)
Market Offering [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares Issued, Price Per Share							$ 2.89
Proceeds from issuance of Common stock							$ 400,000
Issuance of Common Stock for At the Market Offering in shares							150,556
Adjustments To Additional Paid In Capital At Market Offering Costs							$ 79,000
Plan 2013 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Based compensation, shares available for issuance																				6,021,799			6,021,799
Plan 2007 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																				6,000,000			6,000,000
Longterm Incentive Program [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Class of Warrant or Right, Outstanding	500,000
Weighted Market Value Percentage of Invested Capital	44.80%
Weighted Average Cost Percentage of Capital	30.00%
Capital Units, Authorized												100
Share-based Compensation																							$ 300,000
Sharebased Compensation Arrangement By Sharebased Payment Award Percentage Of Shares Granted												1.00%
Checkpoint S2015 Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																							1.50%
After Amendment [Member] | Convertible Preferred Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Price																				$ 0.001			$ 0.001
Capital Units, Authorized																				15,000,000			15,000,000
After Amendment [Member] | Convertible Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Price																				$ 0.001			$ 0.001
Capital Units, Authorized																				100,000,000			100,000,000
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																				10,000,000			10,000,000
Checkpoint [Member] | Private Placement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 7
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total											$ 126,640
Class of Warrant or Right, Number of Securities Called by Warrants or Rights											3,500
Warrant Purchase Price Per Unit											$ 45,000
Proceeds from Issuance of Private Placement											$ 600,000
Warrants Issued											44,324
Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross										1,900,000								3,900,000
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost										$ 400,000
Former Board Of Director [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Restricted Stock Units	$ 133,000
Dr. Rosenwald [Member] | Longterm Incentive Program [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period												510,434
Mr. Weiss [Member] | Longterm Incentive Program [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value												$ 2,800,000
Senior Vice President [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Stock Issued During Period, Value, Issued for Services																							$ 1,900,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																			200,000
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost	$ 3,700,000
Director [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%
Avenue Therapeutics, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Research And Development Expense																							14,000	29,000
General and Administrative Expense																							14,000	21,000
Allocated Share-based Compensation Expense																							$ 28,000	$ 50,400,000,000
Weighted Market Value Percentage of Invested Capital																								44.80%
Weighted Average Cost Percentage of Capital																								30.00%
Shares Issued, Price Per Share																								$ 0.146
Avenue Therapeutics, Inc. [Member] | Consultants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Issued During Period, Shares, Issued for Services																								150,000
Avenue Therapeutics, Inc. [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Issued During Period, Shares, Issued for Services																								1,000,000
Avenue Therapeutics, Inc. [Member] | Share-based Compensation Award, Tranche One [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage																								50.00%
Avenue Therapeutics, Inc. [Member] | Share-based Compensation Award, Tranche Two [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage																								12.50%
Avenue Therapeutics, Inc. [Member] | Share-based Compensation Award, Tranche Three [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage																								50.00%
Mustang Bio, Inc [Member] | Private Placement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights																				$ 8.50			$ 8.50
Stock Issued During Period Shares warrants Exercised																				2,500
Stock Issued During Period, Value of Warrants Excercised																				$ 65,000
Stock Issued During Period, Value, New Issues																					$ 39,100,000
Warrant Expiration Term																							5 years
Warrants Issued During Period																							1.5
Journey Medical Corporation [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Price																$ 0.65
Weighted Market Value Percentage of Invested Capital																44.50%
Weighted Average Cost Percentage of Capital																30.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																1,950,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance																										1,250,000
Unamortized Debt Issuance Expense																										$ 800,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																							0.00%
Journey Medical Corporation [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																							6 years 11 months 12 days
Journey Medical Corporation [Member] | Employee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted Market Value Percentage of Invested Capital																							42.70%	44.20%
Weighted Average Cost Percentage of Capital																							21.10%	25.10%
Shares Issued, Price Per Share																				$ 0.68			$ 0.68	$ 0.53
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures																							440,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																							0.00%
Checkpoint Therapeutics, Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate																							80.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																							2.10%
Share Price																				$ 4.39		$ 0.065	$ 4.39
Allocated Share-based Compensation Expense																							$ 3,900,000
Fair Value Assumptions, Weighted Average Volatility Rate																						30.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage																						25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																						48 months
Weighted Average Cost Percentage of Capital																						44.80%
Risk free rate																							83.00%
Equity Method Investment, Ownership Percentage																				37.70%			37.70%
JMC [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense																							$ 0.5	$ 600,000
Helocyte Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense																							$ 0.3
Helocyte Inc [Member] | Consultants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate							68.00%																70.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate							1.30%																1.47%
Share Price							$ 0.46													$ 0.59			$ 0.59
Stock Issued During Period, Shares, Issued for Services							508,333	150,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period																							127,084
Helocyte Inc [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Price																				0.097			$ 0.097
Stock Issued During Period, Shares, Issued for Services									1,000,000
Share-based Compensation																							$ 55,000
Helocyte Inc [Member] | Non-employee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation																							200,000
Cellvation Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense																							7,000
Cellvation Inc [Member] | Consultants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate					70.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate					1.10%
Share Price					$ 0.024
Stock Issued During Period, Shares, Issued for Services					700,000
Share-based Compensation					$ 2,500
Cellvation Inc [Member] | Employee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Issued During Period, Shares, Issued for Services					1,000,000
Share-based Compensation					$ 4,000
National Holdings Corporation [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense																							$ 42,000
Class of Warrant or Right, Exercise Price of Warrants or Rights																				$ 3.25	$ 3.25		$ 3.25
National Holdings Corporation [Member] | Private Placement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage Of Placement Agent Fee																				10.00%
Payments of Stock Issuance Costs																				$ 3,900,000
Private Placement Stock Units Shares To Be Issued																				10,000			10,000
Warrants Issued During Period																							601,486
Research and Development Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense																							$ 4,700,000	5,800,000	1,100,000
General and Administrative Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense																							$ 7,400,000	8,500,000	4,400,000
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Restricted Stock Units																								400,000	$ 4,343,692
Deferred Compensation Arrangement with Individual, Shares Issued																							230,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted in Period, Fair Value																							$ 3.4
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period																							1,240,868
Restricted Stock [Member] | Journey Medical Corporation [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation																							$ 85,000
Restricted Stock [Member] | Checkpoint Therapeutics, Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate																							100.65%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																							10 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																							2.60%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																							60,000
Share-based Compensation																							$ 1,400,000	$ 300,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price																							$ 5.43
Restricted Stock [Member] | General and Administrative Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation																							$ 600,000
Restricted Stock Units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	40,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted in Period, Fair Value																							$ 1,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period																							641,000
Restricted Stock Units (RSUs) [Member] | Senior Vice President [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares																							150,000	300,000
New Award [Member] | Senior Vice President [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost	$ 3,300,000
Old Award [Member] | Senior Vice President [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost	$ 400,000
Employee Stock Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Stock Purchase Plan to eligible employees, Reckoning fair value percentage during offering period			85.00%										85.00%														85.00%	85.00%
Common Stock issued in connection with the first ESPP offering		14,681	7,139										13,317				6,841						177,919
Common Stock Par Or Stated Value Per Share			$ 1.45										$ 2.41														$ 1.80	$ 1.80
Share Price			$ 1.71										$ 2.84				$ 2.12										$ 2.12
Proceeds from Stock Options Exercised																								$ 200,000
Common Stock, Capital Shares Reserved for Future Issuance																				22,081			22,081
Employee Stock Option [Member] | Journey Medical Corporation [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation																							$ 400,000
Unvested Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation weighted-average vesting period																							2 years
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition																							2 years

Commitments and Contingencies -

Commitments and Contingencies - Total future minimum lease payments (Detail) $ in Thousands	Dec. 31, 2016USD ($)
Operating Leased Assets [Line Items]
2,017	$ 2,806
2,018	2,692
2,019	2,713
2,020	2,754
2,021	2,622
Thereafter	27,261
Total minimum lease payments	40,848
National Holdings [Member]
Operating Leased Assets [Line Items]
2,017	2,774
2,018	2,196
2,019	1,524
2,020	1,390
2,021	1,092
Thereafter	2,232
Total minimum lease payments	11,208
Less, Sublease Income 2017	84
Less, Sublease Income 2018	0
Less, Sublease Income 2019	0
Less, Sublease Income 2020	0
Less, Sublease Income 2021	0
Less, Sublease Income Thereafter	0
Less, Sublease Income Total	84
Net, 2017	2,690
Net, 2018	2,196
Net, 2019	1,524
Net, 2020	1,390
Net, 2021	1,092
Net, Thereafter	2,232
Net, Total	$ 11,124

Commitments and Contingencies87

Commitments and Contingencies - Additional Information (Detail)

Jan. 15, 2016

Oct. 03, 2014USD ($)

Sep. 30, 2016USD ($)

Sep. 30, 2016USD ($)

Jul. 31, 2016USD ($)a

Oct. 31, 2015USD ($)ft²

Apr. 30, 2013USD ($)ft²

Sep. 30, 2016USD ($)

Dec. 31, 2016USD ($)

Dec. 31, 2015USD ($)

Dec. 31, 2014USD ($)

Dec. 31, 2013USD ($)

Dec. 31, 2012USD ($)ft²

Aug. 01, 2016USD ($)

Operating Leased Assets [Line Items]

Land Subject to Ground Leases

2,295

6,100

8,700

Operating Leases, Rent Expense

$ 2,700,000

$ 53,000

$ 200,000

$ 0.1

Operating Leases, Rent Expense, Net, Total

$ 1,800,000

$ 0.4

$ 0.3

$ 0.6

Lease Expiration Period

5 years

Professional Fees

$ 0.2

Ovamed GmbH [Member] | Settlement and Forbearance Agreement [Member]

Operating Leased Assets [Line Items]

Contractual Obligation

$ 1,900,000

Payments for Legal Settlements

$ 1,100,000

Settlement Liabilities, Current

$ 800,000

800,000

800,000

Letter of Credit [Member]

Operating Leased Assets [Line Items]

Collateralized Agreements

0.4

$ 0.4

$ 0.4

New York, NY office space [Member]

Operating Leased Assets [Line Items]

Operating Leases, Rent Expense

0

Lease Expiration Period

15 years

Opus Point Partners Management, LLC [Member]

Operating Leased Assets [Line Items]

Operating Leases, Rent Expense

$ 300,000

Percentage of Rentable Area

10.00%

Prepaid Rent

$ 1.3

TG Therapeutics, Inc [Member]

Operating Leased Assets [Line Items]

Operating Leases, Rent Expense

$ 1,100,000

Percentage of Rentable Area

45.00%

TSO Laboratories, Inc [Member]

Operating Leased Assets [Line Items]

Operating Leases, Rent Expense

0.2

Operating Leases, Income Statement, Sublease Revenue

$ 8,200

Lease Expiration Date

Feb. 28, 2018

City Of Hope [Member]

Operating Leased Assets [Line Items]

Loss Contingency Damages Awarded Percentage

15.00%

Lease Agreements [Member]

Operating Leased Assets [Line Items]

Land Subject to Ground Leases | ft²

1,500

8,700

Operating Leases, Rent Expense

$ 0.1

$ 0.1

Contracted Build Out Costs Associated With Lease

$ 0.4

Employee Benefit Plan - Additio

Employee Benefit Plan - Additional Information (Detail) - USD ($)	Jan. 01, 2008	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plan Disclosure [Line Items]
Employee contribution percentage	4.00%
Employer matching contribution		$ 0.2	$ 0.1	$ 83,000
National Holdings [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent		75.00%

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)

Mar. 13, 2015

Oct. 03, 2014

Oct. 31, 2016

Sep. 30, 2016

Jul. 31, 2016

Jul. 26, 2016

May 31, 2016

Apr. 27, 2016

Oct. 31, 2015

May 31, 2015

Mar. 20, 2015

Mar. 17, 2015

Feb. 17, 2015

Sep. 30, 2014

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2012

Sep. 09, 2016

Jul. 05, 2016

Mar. 17, 2014

Related Party Transaction [Line Items]

Costs and Expenses, Related Party

$ 84,000

$ 24,000

$ 100,000

Accounts Receivable, Net, Total

71,800

Agreement Description Terms

(i) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Mustang or any of its respective subsidiaries that occurs after the effective date of the Mustang Founders Agreement and ending on the date when the Company no longer has majority voting control in Mustang’s voting equity, equal to two and one-half (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one-half percent (4.5%) of Mustang’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a Change in Control, Mustang will pay a one-time change in control fee equal to five (5x) times the product of (A) net sales for the twelve (12) months immediately preceding the change in control and (B) four and one-half percent (4.5%).

(i) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Cellvation or any of its respective subsidiaries that occurs after the effective date of the Cellvation Founders Agreement and ending on the date when the Company no longer has majority voting control in Cellvations voting equity, equal to two and one-half (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one-half percent (4.5%) of Cellvations annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a Change in Control, Cellvation will pay a one-time change in control fee equal to five (5x) times the product of (A) net sales for the twelve (12) months immediately preceding the change in control and (B) four and one-half percent (4.5%).

(i) pay an equity fee in shares of Helocyte common stock, payable within five (5) business days of the closing of any equity or debt financing for Helocyte or any of its respective subsidiaries that occurs after the effective date of the Helocyte Founders Agreement and ending on the date when Fortress no longer has majority voting control in Helocyte’s voting equity, equal to two and one half percent (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one half percent (4.5%) of Helocyte’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a Change in Control, the Company will pay a one-time change in control fee equal to five (5x) times the product of (i) net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%).

(i) issue annually to the Company, on the anniversary date of the Checkpoint Founders Agreement, shares of common stock equal to 2.5% of the fully-diluted outstanding equity of Checkpoint at the time of issuance; (ii) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Checkpoint or any of its subsidiaries that occurs after the effective date of the Checkpoint Founders Agreement and ending on the date when the Company no longer has majority voting control in Checkpoint’s voting equity, equal to 2.5% of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to 4.5% of Checkpoint’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control (as it is defined in the Checkpoint Founders Agreement), Checkpoint will pay a one-time change in control fee equal to five times (5x) the product of (i) net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%).

(i) pay an equity fee in shares of Avenue common stock, payable within five (5) business days of the closing of any equity or debt financing for Avenue or any of its respective subsidiaries that occurs after the effective date of the Avenue Founders Agreement and ending on the date when Fortress no longer has majority voting control in Avenue’s voting equity, equal to two and one half percent (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one half percent (4.5%) of Avenue’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a Change in Control, the Company will pay a one-time change in control fee equal to five (5x) times the product of (i) net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%).

Operating Leases, Rent Expense

$ 2,700,000

$ 53,000

$ 200,000

$ 0.1

Lease Sharing Agreements Contributions To Property Under Lease

4,800,000

Business Combination, Consideration Transferred

$ 22,872,000

Equity Method Investment, Ownership Percentage

35.00%

National Holdings Corporation [Member]

Related Party Transaction [Line Items]

Business Acquisition, Percentage of Voting Interests Acquired

56.10%

56.00%

56.60%

Business Combination, Consideration Transferred

$ 22,900,000

$ 22,900,000

Proceeds from Fees Received

$ 1,300,000

NSC Note [Member]

Related Party Transaction [Line Items]

Long-term Debt, Gross

$ 3,600,000

Chief Executive Officer [Member]

Related Party Transaction [Line Items]

Interest own in percent by principal stockholder or director

12.30%

12.20%

12.40%

Chord Advisors, LLC [Member]

Related Party Transaction [Line Items]

Related Party Transaction, Expenses from Transactions with Related Party

$ 10,000

Board of Directors Chairman [Member] | National Holdings Corporation [Member]

Related Party Transaction [Line Items]

Equity Method Investment, Ownership Percentage

4.60%

TG Therapeutics, Inc [Member]

Related Party Transaction [Line Items]

Percentage of Rentable Area

45.00%

40.00%

Operating Leases, Rent Expense

$ 1,100,000

Lease Improvement Cost Associate With Lease

$ 5,100,000

Due from Related Parties, Current

2,100,000

Prepaid Rent

400,000

OPPM [Member]

Related Party Transaction [Line Items]

Percentage of Rentable Area

10.00%

20.00%

Operating Leases, Rent Expense

$ 500,000

Lease Improvement Cost Associate With Lease

5,100,000

Due from Related Parties, Current

500,000

Prepaid Rent

95,000

Executives Vice Chairman [Member]

Related Party Transaction [Line Items]

Interest own in percent by family members of principal stockholder or director

14.90%

Mustang [Member] | Chord Advisors, LLC [Member]

Related Party Transaction [Line Items]

Related Party Transaction, Expenses from Transactions with Related Party

$ 7,500

Founder [Member] | Founders Agreement [Member]

Related Party Transaction [Line Items]

Lessee Leasing Arrangements, Operating Leases, Term of Contract

15 years

Management Services Agreement [Member]

Related Party Transaction [Line Items]

Annual Consulting Fee

$ 500,000

$ 500,000

$ 500,000

$ 500,000

Increase in Annual Consulting Fee

1,000,000

1,000,000

1,000,000

1,000,000

Excess In Net Assets Value

$ 100,000,000

$ 100,000,000

100,000,000

$ 100,000,000

Management Services Agreement [Member] | Checkpoint [Member]

Related Party Transaction [Line Items]

Long-term Debt, Gross

$ 2,800,000

Avenue [Member] | Chord Advisors, LLC [Member]

Related Party Transaction [Line Items]

Related Party Transaction, Expenses from Transactions with Related Party

$ 5,000

Avenue [Member] | Founders Agreement [Member]

Related Party Transaction [Line Items]

Agreement Description Terms

Company entered into an Exchange Agreement whereby the Company exchanged its 7.0 million Class B Common shares for 6.75 million common shares and 250,000 Class A Preferred shares. Class A Preferred Stock is identical to common stock other than as to voting rights, conversion rights and the PIK Dividend right (as described below). Each share of Class A Preferred Stock will be entitled to vote the number of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A) the shares of outstanding Helocyte common stock and (B) the whole shares of Helocyte common stock into which the shares of outstanding Class A Common Stock and Class A Preferred Stock are convertible and the denominator of which is the number of shares of outstanding Class A Preferred Stock. Thus, the Class A Preferred Stock will at all times constitute a voting majority. Each share of Class A Preferred Stock is convertible, at its option, into one fully paid and nonassessable share of Helocyte common stock, subject to certain adjustments. As the sole holder of Class A Preferred Stock, the Company will receive on each March 20 (each a “PIK Dividend Payment Date”) until the date all outstanding Class A Preferred Stock is converted into common stock or redeemed (and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and nonassessable shares of common stock (“PIK Dividends”) such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to two and one-half percent (2.5%) of Helocyte’s fully-diluted outstanding capitalization on the date that is one (1) business day prior to any PIK Dividend Payment Date.

Company entered into a Founders Agreement with Avenue, which was amended and restated on September 13, 2016 (the “Avenue Founders Agreement”), pursuant to which the Company assigned to Avenue all of its rights and interest under the Company’s license agreement with Revogenex for IV Tramadol. As consideration for the Avenue Founders Agreement, Avenue assumed $3.0 million in debt that the Company accumulated under the NSC Note (see Note 11) for expenses and costs of forming Avenue and obtaining IV Tramadol license, of which $3.0 million represents the acquisition of the License Agreement. The Avenue Founders Agreement has a term of 15 years, which upon expiration automatically renews for successive one-year periods unless terminated by the Company or a Change in Control (as defined in the Avenue Founders Agreement) occurs. Concurrently with the amendment and restatement of the Avenue Founders Agreement, the Company entered into an Exchange Agreement whereby the Company exchanged its 7.0 million Class A Common shares for approximately 7.5 million common shares and 250,000 Class A Preferred shares. Class A Preferred Stock is identical to common stock other than as to voting rights, conversion rights, election of directors and the PIK Dividend right (as described below). Each share of Class A Preferred Stock will be entitled to vote the number of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A) the shares of outstanding Avenue common stock and (B) the whole shares of Avenue common stock into which the shares of outstanding Class A Preferred Stock are convertible and the denominator of which is the number of shares of outstanding Class A Preferred Stock. Thus, the Class A Preferred Stock will at all times constitute a voting majority. Each share of Class A Preferred Stock is convertible, at its option, into one fully paid and nonassessable share of Avenue common stock, subject to certain adjustments. For a period of 10 years from the date of the first issuance of Class A Preferred Stock, the holders of record of shares of Class A Preferred Stock, exclusively and as a separate class, are entitled to appoint or elect the majority of Avenue’s Board of Directors. As holders of Class A Preferred Stock, the Company will receive on each February 17 (each a “PIK Dividend Payment Date”) until the date all outstanding Class A Preferred Stock is converted into common stock or redeemed (and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and nonassessable shares of common stock (“PIK Dividends”) such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to two and one-half percent (2.5%) of Avenue’s fully-diluted outstanding capitalization on the date that is one (1) business day prior to any PIK Dividend Payment Date.

Desk Share Agreements [Member]

Related Party Transaction [Line Items]

Payments for Rent

1,000,000

Mustang Bio, Inc [Member] | Founders Agreement [Member]

Related Party Transaction [Line Items]

Lessee Leasing Arrangements, Operating Leases, Term of Contract

15 years

Agreement Description Terms

Concurrently with the second amendment to the Mustang Founders Agreement, the Company entered into an Exchange Agreement whereby the Company exchanged its 7.25 million Class B Common shares for 7.0 million common shares and 250,000 Class A Preferred shares. Class A Preferred Stock is identical to common stock other than as to voting rights, conversion rights and the PIK Dividend right (as described below). Each share of Class A Preferred Stock will be entitled to vote the number of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A) the shares of outstanding Mustang common stock and (B) the whole shares of Mustang common stock into which the shares of outstanding Class A Common Stock and Class A Preferred Stock are convertible and the denominator of which is the number of shares of outstanding Class A Preferred Stock. Thus, the Class A Preferred Stock will at all times constitute a voting majority. Each share of Class A Preferred Stock is convertible, at the Company’s option, into one fully paid and nonassessable share of Mustang common stock, subject to certain adjustments. As holders of Class A Preferred Stock, the Company will receive on each March 13 (each a “PIK Dividend Payment Date”) until the date all outstanding Class A Preferred Stock is converted into common stock or redeemed (and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and nonassessable shares of common stock (“PIK Dividends”) such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to two and one-half percent (2.5%) of Mustang’s fully-diluted outstanding capitalization on the date that is one (1) business day prior to any PIK Dividend Payment Date.

Cellvation [Member] | Founders Agreement [Member]

Related Party Transaction [Line Items]

Agreement Description Terms

Company entered into a Founders Agreement with Cellvation (the “Cellvation Founders Agreement”). The Cellvation Founders Agreement provides that, in exchange for the time and capital expended in the formation of Cellvation and the identification of specific assets the acquisition of which result in the formation of a viable emerging growth life science company, the Company will loan Cellvation $0.2 million, representing the up-front fee required to acquire Cellvation’s license agreement and continue to fund Cellvation’s working capital needs. The Cellvation Founders Agreement has a term of 15 years, which, upon expiration, automatically renews for successive one-year periods unless terminated by the Company or a Change in Control (as defined in the Cellvation Founders Agreement) occurs. Pursuant to the Cellvation Founders Agreement, the Company received 7.6 million common shares and 250,000 Class A Preferred shares. Class A Preferred Stock is identical to common stock other than as to voting rights, conversion rights and the PIK Dividend right (as described below). Each share of Class A Preferred Stock will be entitled to vote the number of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A) the shares of outstanding Cellvation common stock and (B) the whole shares of Cellvation common stock into which the shares of outstanding Class A Preferred Stock are convertible and the denominator of which is the number of shares of outstanding Class A Preferred Stock. Thus, the Class A Preferred Stock will at all times constitute a voting majority. Each share of Class A Preferred Stock is convertible, at the Company’s option, into one fully paid and nonassessable share of Cellvation common stock, subject to certain adjustments. As holders of Class A Preferred Stock, the Company will receive on each October 31 (each a “PIK Dividend Payment Date”) until the date all outstanding Class A Preferred Stock is converted into common stock or redeemed (and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and nonassessable shares of common stock (“PIK Dividends”) such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to two and one-half percent (2.5%) of Cellvation’s fully-diluted outstanding capitalization on the date that is one (1) business day prior to any PIK Dividend Payment Date.

Shared Services Agreement [Member] | TG Therapeutics, Inc [Member]

Related Party Transaction [Line Items]

Proceeds from Related Party Agreement

$ 800,000

Income Taxes - Significant Comp

Income Taxes - Significant Components of Company's Deferred Taxes Consist (Detail) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Net operating loss carryforwards	$ 76,486	$ 54,249
Amortization of up-front fees	7,277	4,442
Amortization of in-process R&D	742	599
Stock compensation	10,899	8,158
Accruals and reserves	4,025	210
Tax Credits	6,305	4,583
Start Up Costs	98	0
Unrealized loss on investments	1,095	358
Total deferred tax assets	106,927	72,599
Less valuation allowance	(94,688)	(66,730)
Net deferred tax assets	12,239	5,869
Deferred tax liabilities:
Intangibles	(4,449)	0
Basis in subsidiary	(7,790)	(5,869)
Total deferred tax assets, net	$ 0	$ 0

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Statutory Tax Rates and Effective Tax Rates (Detail)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Percentage of pre-tax income:
U.S. federal statutory income tax rate	35.00%	35.00%	35.00%
State taxes, net of federal benefit	3.00%	5.00%	5.00%
Credits	2.00%	1.00%	6.00%
Non-deductible items	(4.00%)	0.00%	(1.00%)
Provision to return	2.00%	0.00%	0.00%
Stock based compensation shortfall	(2.00%)	(1.00%)	0.00%
Other	0.00%	1.00%	0.00%
Change in valuation allowance	(33.00%)	(44.00%)	(45.00%)
Change in subsidiary basis	(3.00%)	3.00%	0.00%
Effective income tax rate	0.00%	0.00%	0.00%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Valuation Allowance	$ 94,688	$ 66,730
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	28,000,000
National Holdings Corporation [Member]
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Valuation Allowance	8,800,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Income Tax Payable, Current	400,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets, Current	8,800,000
Deferred Tax Liabilities, Net, Current	3,200,000
Domestic Tax Authority [Member]
Income Tax Disclosure [Line Items]
Operating Loss Carryforwards	197,500,000
Effective Income Tax Rate Reconciliation, Tax Credit, Amount	6,300,000
State and Local Jurisdiction [Member]
Income Tax Disclosure [Line Items]
Operating Loss Carryforwards	$ 189,500,000

Net Capital Requirements of B93

Net Capital Requirements of Broker-Dealer Subsidiaries - Additional Information (Detail)	Dec. 31, 2016USD ($)	Sep. 30, 2016USD ($)
National Securities [Member]
Net Capital		$ 6,200,000
Excess Net Capital at 1000 Percent		6,000,000
Minimum Net Capital Required for Broker-Dealer Subsidiary		$ 250,000
Vfinance Investments [Member]
Net Capital	$ 2,200,000
Excess Net Capital at 1000 Percent	1,200,000
Minimum Net Capital Required for Broker-Dealer Subsidiary	$ 1,000,000
Vfinance Investments [Member] | Minimum [Member]
Ratio of Indebtedness to Net Capital	0.8
Vfinance Investments [Member] | Maximum [Member]
Ratio of Indebtedness to Net Capital	1

Segment Information - Operating

Segment Information - Operating Results by Reportable Segment (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Net Revenue									$ 16,480	$ 863
Direct cost of goods									(790)	0
Sales and marketing costs									(5,774)	(2,850)
Research and development									(35,134)	(29,810)
General and administrative									(28,229)	(18,734)
National expenses									82,190	51,394	$ 20,652
Segment loss from operations	$ (32,217)	$ (17,180)	$ (17,042)	$ (15,571)	$ (12,964)	$ (18,097)	$ (7,762)	$ (12,571)	(65,710)	(50,531)	$ (20,652)
Segment assets	170,731				118,610				170,731	118,610
Dermatology Products Sales [Member]
Segment Reporting Information [Line Items]
Net Revenue									3,587	273
Direct cost of goods									(790)	0
Sales and marketing costs									(5,774)	(2,850)
Research and development									0	0
General and administrative									(1,474)	(1,682)
National expenses
Segment loss from operations									(4,451)	(4,259)
Segment assets	4,469				1,965				4,469	1,965
Pharmaceutical And Biotechnology Product Development [Member]
Segment Reporting Information [Line Items]
Net Revenue									2,570	590
Direct cost of goods									0	0
Sales and marketing costs									0	0
Research and development									(35,134)	(29,810)
General and administrative									(26,755)	(17,052)
National expenses
Segment loss from operations									(59,319)	(46,272)
Segment assets	115,145				116,542				115,145	116,542
Financial Service Activities [Member]
Segment Reporting Information [Line Items]
Net Revenue									10,323	0
Direct cost of goods									0	0
Sales and marketing costs									0	0
Research and development									0	0
General and administrative									0	0
National expenses									(11,754)
Segment loss from operations									(1,431)	0
Segment assets	$ 38,220				$ 0				$ 38,220	$ 0

Segment Information - Additiona

Segment Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2016USD ($)
Segment Reporting Information [Line Items]
Accounts Receivable, Net	$ 71,800
Customer One [Member]
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Gross	1,900,000
Accounts Receivable, Net	1,100,000
Customer Two [Member]
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Gross	1,100,000
Accounts Receivable, Net	500,000
Customer Three [Member]
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Gross	$ 700,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($)

Jan. 02, 2017

Mar. 16, 2017

Feb. 28, 2017

Feb. 17, 2017

Jan. 31, 2017

Oct. 30, 2015

Dec. 31, 2016

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Sep. 30, 2016

Sep. 18, 2015

Mar. 17, 2014

Subsequent Event [Line Items]

Stock Issued During Period, Value, New Issues

$ 53,000,000

Payments of Stock Issuance Costs

$ 0

$ 0

$ 32,000

Percentage Of Placement Agent Fee

10.00%

Warrants Issued

139,592

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

7

7

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 2,500

$ 2,500

$ 7

Warrant Purchase Price Per Unit

$ 50,000

Equity Method Investment, Ownership Percentage

35.00%

National Holdings Corporation [Member]

Subsequent Event [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 3.25

$ 3.25

$ 3.25

Private Placement [Member] | National Holdings Corporation [Member]

Subsequent Event [Line Items]

Payments of Stock Issuance Costs

$ 3,900,000

Percentage Of Placement Agent Fee

10.00%

Subsequent Event [Member] | Mustang Bio, Inc [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Value, New Issues

$ 1,700,000

Shares Issued, Price Per Share

$ 5.73

Equity Method Investment, Ownership Percentage

40.00%

Subsequent Event [Member] | National Holdings Corporation [Member] | Mustang Bio, Inc [Member]

Subsequent Event [Line Items]

Warrants Issued

2,134,193

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

2,500

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 8.50

Warrant Expiration Term

5 years

Warrant Purchase Price Per Unit

$ 65,000

Subsequent Event [Member] | Caribe BioAdvisors LLC [Member]

Subsequent Event [Line Items]

Payments for Fees

$ 60,000

Subsequent Event [Member] | Private Placement [Member] | National Holdings Corporation [Member]

Subsequent Event [Line Items]

Payments of Stock Issuance Costs

5,500,000

Proceeds from Issuance of Private Placement

$ 55,500,000

Percentage Of Placement Agent Fee

10.00%

Warrants Issued

853,667

Percentage Of Shares Issued To Placement Agent

10.00%

Subsequent Event [Member] | City Of Hope [Member]

Subsequent Event [Line Items]

Payments for Fees

$ 100,000

Revenue Recognition Milestone Method Payments Due

$ 100,000

Subsequent Event [Member] | Opus Credit Facility [Member]

Subsequent Event [Line Items]

Proceeds from Lines of Credit

$ 2,000,000

Selected Quarterly Financial 97

Selected Quarterly Financial Data (Unaudited) (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Quarterly Financial Information [Line Items]
Total Revenue	$ 14,405	$ 975	$ 2,230	$ 660	$ 338	$ 25	$ 0	$ 500	$ 16,480	$ 863	$ 0
Operating expenses	(32,217)	(17,180)	(17,042)	(15,571)	(12,964)	(18,097)	(7,762)	(12,571)	(65,710)	(50,531)	(20,652)
Other income/(expense)	(2,065)	(710)	(1,253)	(1,552)	(2,449)	(1,783)	1,344	(464)
Non controlling interests	3,871	3,975	3,911	4,438	3,039	1,694	243	479	(16,195)	(5,455)	0
Net loss attributable to common stockholders	$ (17,431)	$ (12,981)	$ (12,478)	$ (12,205)	$ (12,036)	$ (18,161)	$ (6,175)	$ (12,056)	$ (55,095)	$ (48,428)	$ (20,386)
Basic and diluted net loss per common share	$ (0.43)	$ (0.32)	$ (0.31)	$ (0.31)	$ (0.30)	$ (0.46)	$ (0.16)	$ (0.31)	$ (1.38)	$ (1.24)	$ (0.56)